

GenCore version 5.1.4_p5_4578
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: March 13, 2003, 14:39:14 ; Search time 417 Seconds

(without alignments)

9245.614 Million cell updates/sec

Title: US-10-036-041-1

Perfect score: 1712

Sequence: 1 ggcactgcgcgagagacc.....ttgttaagataaaaaaaa 1712

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 1.0

Searched: 2185239 seqs; 1125999159 residues

Total number of hits satisfying chosen parameters: 4370478

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : N_Geneseq_101002.*

- 1: /SID22/gcgdata/geneseq/geneseq-emb1/NA1980.DAT.*
- 2: /SID22/gcgdata/geneseq/geneseq-emb1/NA1981.DAT.*
- 3: /SID22/gcgdata/geneseq/geneseq-emb1/NA1982.DAT.*
- 4: /SID22/gcgdata/geneseq/geneseq-emb1/NA1983.DAT.*
- 5: /SID22/gcgdata/geneseq/geneseq-emb1/NA1984.DAT.*
- 6: /SID22/gcgdata/geneseq/geneseq-emb1/NA1985.DAT.*
- 7: /SID22/gcgdata/geneseq/geneseq-emb1/NA1986.DAT.*
- 8: /SID22/gcgdata/geneseq/geneseq-emb1/NA1987.DAT.*
- 9: /SID22/gcgdata/geneseq/geneseq-emb1/NA1988.DAT.*
- 10: /SID22/gcgdata/geneseq/geneseq-emb1/NA1989.DAT.*
- 11: /SID22/gcgdata/geneseq/geneseq-emb1/NA1990.DAT.*
- 12: /SID22/gcgdata/geneseq/geneseq-emb1/NA1991.DAT.*
- 13: /SID22/gcgdata/geneseq/geneseq-emb1/NA1992.DAT.*
- 14: /SID22/gcgdata/geneseq/geneseq-emb1/NA1993.DAT.*
- 15: /SID22/gcgdata/geneseq/geneseq-emb1/NA1994.DAT.*
- 16: /SID22/gcgdata/geneseq/geneseq-emb1/NA1995.DAT.*
- 17: /SID22/gcgdata/geneseq/geneseq-emb1/NA1996.DAT.*
- 18: /SID22/gcgdata/geneseq/geneseq-emb1/NA1997.DAT.*
- 19: /SID22/gcgdata/geneseq/geneseq-emb1/NA1998.DAT.*
- 20: /SID22/gcgdata/geneseq/geneseq-emb1/NA1999.DAT.*
- 21: /SID22/gcgdata/geneseq/geneseq-emb1/NA2000.DAT.*
- 22: /SID22/gcgdata/geneseq/geneseq-emb1/NA2001A.DAT.*
- 23: /SID22/gcgdata/geneseq/geneseq-emb1/NA2001B.DAT.*
- 24: /SID22/gcgdata/geneseq/geneseq-emb1/NA2002.DAT.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1710.4	99.9	1712	21	AAA96336 cDNA encoding a no
2	1710.4	99.9	1760	21	AAA95787 Human immune syste
3	1696	99.1	1696	21	AA64058 Human znacp3 cDNA,
4	1695.4	99.0	1709	22	AA693874 Human cDNA encodin
5	1549.6	90.5	1620	22	AA199523 Human polynucleoti
6	1549.6	90.5	1792	22	AA159230 Human polynucleoti
7	1527	89.2	1927	22	AAAD12584 Human protein havi
8	1363.2	79.6	1608	24	ABK35221 Human cDNA encodin
9	1295.4	75.7	1799	22	AA161016 Human polynucleoti

c

10	766.6	44.8	810	22	AAF94076	Primer specific fo
11	741	43.3	741	24	ABK35591	Gene encoding nove
12	696.2	40.7	1035	22	AAC99776	Skin cell cDNA, SE
13	696.2	40.7	1035	24	ABL34928	cDNA encoding rat
14	696.2	40.7	1123	21	AAZ61633	cDNA encoding rat
15	696.2	40.7	1123	21	AAZ61730	Skin cell cDNA, SE
16	696.2	40.7	1123	22	AAC99566	Skin cell cDNA, SE
17	696.2	40.7	1123	22	AAC99663	Skin cell cDNA, SE
18	696.2	40.7	1123	24	ABL34718	Rat cDNA isolated
19	696.2	40.7	1123	24	ABL34815	Rat cDNA isolated
20	695.8	40.6	1117	21	AAC64064	Mouse znacrp2 DNA,
21	659	38.5	960	24	ABK35590	Gene encoding nove
22	544.2	31.8	738	21	AAC64063	Human znacrp3 degen
23	498.6	29.1	552	22	AAF94215	Primer specific fo
24	452	26.4	471	21	AAC02874	Human secreted pro
25	452	26.4	472	20	AAX39551	Human secreted pro
26	345.6	20.2	472	23	ABV56781	Human prostate exp
27	208	12.1	546	22	AAF93419	cDNA encoding SRT
28	136.2	8.0	548	22	ABA60188	Human foetal liver
29	136.2	8.0	548	22	AAK08465	Human brain expres
30	136.2	8.0	548	22	AAK34347	Human bone marrow
31	136.2	8.0	548	22	AAI40069	Probe #8755 used t
32	136.2	8.0	548	24	ABS09051	Human genome-deriv
33	130	7.6	130	22	ABA72727	Human foetal liver
34	130	7.6	130	22	AAK21157	Human brain expres
35	130	7.6	130	22	AAK47313	Human bone marrow
36	130	7.6	130	22	AAI53148	Probe #21834 used
37	130	7.6	130	24	ABS21483	Human genome-deriv
38	121.2	7.1	900	22	AAF45100	Human secreted pro
39	80.8	4.7	909	22	AAC89872	Human znacrp7 degen
40	78.8	4.6	435	24	ABL38127	Human colon tumour
41	78.8	4.6	1280	22	AAI99525	Human polynucleoti
42	78.8	4.6	2257	24	AAI44063	Human genseq metab
43	78.8	4.6	2727	22	AAAD16945	Novel human protei
44	78.8	4.6	2730	22	AAAD16951	Novel human protei
45	78.8	4.6	2874	22	AAAD16947	Novel human protei

ALIGNMENTS

RESULT 1
AAA96336
ID AAA96336 standard; cDNA; 1712 BP.

XX AC AAA96336;

XX DT 08-FEB-2001 (first entry)

XX DE cDNA encoding a novel polypeptide designated PRO1484.

XX KW Secreted protein; transmembrane protein; PRO1484; PRO4334; PRO1122;
KW PRO1889; PRO1890; PRO1887; PRO1785; PRO4353; PRO4357; PRO4405; PRO4356;
KW PRO4352; PRO4380; PRO4408; PRO5737; PRO4425; PRO5990; PRO6030;
KW PRO4424; PRO4422; PRO4430; PRO4499; tumour; obesity; diabetes;
KW insulinemia; kidney disorder; Bergers disease; nephropathy;
KW Schönlain-Henoch purpura; celiac disease; dermatitis herpetiformis;
KW Crohns disease; ss.

XX OS Homo sapiens.

XX FH Key Location/Qualifiers

XX FT CDS 77..817

XX FT sig_peptide /tag= a

XX FT sig_peptide /tag= b

XX PN WO200056889-A2.

XX XX 28-SEP-2000.

XX PF 01-MAR-2000; 2000WO-US05601.

c

PR	23-MAR-1999;	99US-0125774.
PR	23-MAR-1999;	99US-0125778.
PR	24-MAR-1999;	99US-0125826.
PR	31-MAR-1999;	99US-0127035.
PR	05-APR-1999;	99US-0127706.
PR	21-APR-1999;	99US-0130359.
PR	27-APR-1999;	99US-0131270.
PR	27-APR-1999;	99US-0131272.
PR	27-APR-1999;	99US-0131291.
PR	04-MAY-1999;	99US-0132371.
PR	04-MAY-1999;	99US-0132379.
PR	04-MAY-1999;	99US-0132383.
PR	25-MAY-1999;	99US-0135750.
PR	08-JUN-1999;	99US-0138166.
PR	20-JUL-1999;	99US-0144791.
PR	03-AUG-1999;	99US-0146970.
PR	09-DEC-1999;	99US-0170262.
XX		
PA	(GETH) GENENTECH INC.	
XX		
PI	Desnoyers L, Eaton DL, Goddard A, Godowski PJ, Gurney AL, Pan J;	
PI	Stewart TA, Watanabe CK, Wood WI, Zhang Z;	
XX		
DR	WPI; 2000-628263/60.	
DR	P-FSDB; AAB18909.	
XX		
PT	Novel secreted and transmembrane polypeptides useful for diagnosing	
PT	tumour in a mammal, for identifying agonists and antagonists of the	
PT	polypeptide and for therapeutic use	
XX		
PS	Claim 2; Fig 1; 222pp; English.	
XX		
CC	The present sequence encodes a secreted or transmembrane polypeptide.	
CC	The specification describes polypeptides designated PRO1484, PRO4334,	
CC	PRO1122, PRO1889, PRO1890, PRO1897, PRO1785, PRO4353, PRO4357, PRO4405,	
CC	PRO4356, PRO4352, PRO4380, PRO4354, PRO4406, PRO5737, PRO4425, PRO5990,	
CC	PRO6030, PRO4424, PRO4422, PRO4430 and PRO4499. PRO1889 polypeptide is	
CC	useful for diagnosing tumour in a mammal. The polypeptides, their	
CC	agonists and antagonists are useful treating a condition associated with	
CC	expression or activity of the polypeptide. Conditions treated include	
CC	obesity, diabetes or hyper- or hypo-insulinemia. The polypeptides are	
CC	capable of inducing proliferation of mammalian kidney mesangial cells	
CC	and are therefore useful for treating kidney disorders associated with	
CC	decreased mesangial cell function such as Bergers disease or other	
CC	nephropathies associated with Schonlein-Henoch purpura, celiac disease,	
CC	dermatitis herpetiformis or Crohn's disease. The nucleic acids may be used	
CC	to generate transgenic animals for use in development and screening of	
CC	therapeutically useful reagents and also for chromosome identification	
CC	and tissue typing.	
XX		
SQ	Sequence 1712 BP; 491 A; 358 C; 388 G; 475 T; 0 other;	
	Query Match 99.98; Score 1710.4; DB 21; Length 1712;	
	Best Local Similarity 99.9%; Pred. No. 0;	
	Matches 1711; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
OY	1 GGCACTCTGCCCGAGGACACCGCTCCTGGAGCTCTGCTGTCTTCAGGAGACTCTGA 60	
Db	1 GGCACTCTGCCCGAGGACACCGCTCCTGGAGCTCTGCTGTCTTCAGGAGACTCTGA 60	
OY	61 GGCTCTCTTGAGAATCATGCTTTGGAGCGAGCTCATCTATTGGCAACTGCTGGCTTGT 120	
Db	61 GGCTCTCTTGAGAATCATGCTTTGGAGCGAGCTCATCTATTGGCAACTGCTGGCTTGT 120	
OY	121 TTTCCTCCCTTTTGGCTGTGTCAAGATGAATACATGAGTCTCACAAACCGGAGGACT 180	
Db	121 TTTCCTCCCTTTTGGCTGTGTCAAGATGAATACATGAGTCTCACAAACCGGAGGACT 180	
OY	181 ACCCCCAGACTGCAGTAAGTGTGTGTCATGTAGACTACAGCTTTCAGGCTACCAGGCC 240	
Db	181 ACCCCCAGACTGCAGTAAGTGTGTGTCATGTAGACTACAGCTTTCAGGCTACCAGGCC 240	
OY	241 CCCTTGGGCCACCGGGGCCCTCTGTGCATCTCCAGGAAACCATGGAAACAATGGCAACAATGG 300	

708 TGAARTGAGGGCAATCAGATACATCCAGCAATCATGCTGTGCTAGCTAGCCAAAGG 767
 721 GGATGAGGTTGGCTGGCAATGCGCTCTCATGGGACCAACCAACGCTTCTC 780
 768 GGATGAGGTTGGCTGGCAATGCGCTCTCATGGGACCAACCAACGCTTCTC 827
 781 CACCTTTGCAGGATCTGCTCTTTGAAACTAGTAATATATGACTAGTAATAGCTCCAC 840
 828 CACCTTTGCAGGATCTGCTCTTTGAAACTAGTAATATATGACTAGTAATAGCTCCAC 887
 841 TTTGGGGAAGACTTGTAGCTAGCTGATTTGCTTACGATCTGAGCAACATTAAGTTGAGG 900
 888 TTTGGGGAAGACTTGTAGCTAGCTGATTTGCTTACGATCTGAGCAACATTAAGTTGAGG 947
 901 GTTTTACATTTGCTGATTTCAAAAAATTTATGTTGCAATGTTGTTACGCTACAGGTACA 960
 948 GTTTTACATTTGCTGATTTCAAAAAATTTATGTTGCAATGTTGTTACGCTACAGGTACA 1007
 961 CCAATAATGTTGGCAATTTGAGGGCTCAGAGAATCAACCAAAAATAGTCTTCTCAGA 1020
 1008 CCAATAATGTTGGCAATTTGAGGGCTCAGAGAATCAACCAAAAATAGTCTTCTCAGA 1067
 1021 TGACCTTTGACTAATATACGATCTTTATCACTCTTTTCCCTGGCACCTAAAGATAT 1080
 1068 TGACCTTTGACTAATATACGATCTTTATCACTCTTTTCCCTGGCACCTAAAGATAT 1127
 1081 TCTCTCTGACGAGGTTGGAATATTTTCTTATCACAAGAGTCAATTTGCAAAAGATT 1140
 1128 TCTCTCTGACGAGGTTGGAATATTTTCTTATCACAAGAGTCAATTTGCAAAAGATT 1187
 1141 TTGACTACTGCTGCTTTAATTTATACAGTTTTCAGGAACCCCTGAAAGTTTAAAGTTCA 1200
 1188 TTGACTACTGCTGCTTTAATTTAATACAGTTTTCAGGAACCCCTGAAAGTTTAAAGTTCA 1247
 1201 TTATTTCTTATAACATTTGAGAGAATCGGATGATGATGATGATGATGATGATGATGATGAT 1260
 1248 TTATTTCTTATAACATTTGAGAGAATCGGATGATGATGATGATGATGATGATGATGATGAT 1307
 1261 CAGGGGCACCTAGCTGCTTTATAGCTAATTTAGTGCCTCCGCTGCTGCTGCTGCTGCTGCTGCT 1320
 1308 CAGGGGCACCTAGCTGCTTTATAGCTAATTTAGTGCCTCCGCTGCTGCTGCTGCTGCTGCTGCT 1367
 1321 ACCCTTTCTTTTGTATCCCAAAATACATTAACCTCTGAAATTCACATCAATGCTATTT 1380
 1368 ACCCTTTCTTTTGTATCCCAAAATACATTAACCTCTGAAATTCACATCAATGCTATTT 1427
 1381 TAAAGTCAATAGATTTTATAGCTAATTTAGTGCCTCCGCTGCTGCTGCTGCTGCTGCTGCTGCT 1440
 1428 TAAAGTCAATAGATTTTATAGCTAATTTAGTGCCTCCGCTGCTGCTGCTGCTGCTGCTGCTGCT 1487
 1441 ATGTTCCCCCAATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1500
 1488 ATGTTCCCCCAATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1547
 1501 ACAAAATGTCATAATATCTCATAGGTTACAGTTGCGGATGAGTGAATTAATTAATTAATTAAT 1560
 1548 ACAAAATGTCATAATATCTCATAGGTTACAGTTGCGGATGAGTGAATTAATTAATTAATTAAT 1607
 1561 TTGACCAAGAGGATTTTATCTGAGGAACATACATTAATTAATTAATTAATTAATTAATTAATTAAT 1620
 1608 TTGACCAAGAGGATTTTATCTGAGGAACATACATTAATTAATTAATTAATTAATTAATTAATTAAT 1667
 1621 ATTTTACCTGGCTTTAGATAAACTGTGGCAAGAAAATGTAATGAGCAATATATGGA 1680
 1668 ATTTTACCTGGCTTTAGATAAACTGTGGCAAGAAAATGTAATGAGCAATATATGGA 1727
 1681 ATAACACACCTTTGTTAAAGATAAAAAA 1712
 1728 ATAACACACCTTTGTTAAAGATAAAAAA 1759

RESULT 3

AAC64058
 ID AAC64058 standard; cDNA; 1696 BP.
 AC AAC64058;
 XX
 XX 19-FEB-2001 (first entry)
 DE Human zacr3p3 cDNA, SEQ ID NO:1.
 XX
 XX Human zacr3p3; adipocyte complement related protein homologue;
 KW ACRP30; C1q domain; collagen-like domain; energy balance modulation;
 KW cellular metabolism; metabolic disorder; obesity; anorexia;
 KW antimicrobial agent; infection; platelet aggregation inhibition;
 KW adhesion; activation; vascular injury; antibacterial; antiviral; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO2000063377-A1.
 XX 26-OCT-2000.
 XX
 XX 19-APR-2000; 2000WO-US10454.
 XX
 XX 20-APR-1999; 99US-0294943.
 PR (ZYMO) ZYMOGENETICS INC.
 XX
 XX Piddington CS, Bishop PD;
 PI
 XX WPI: 2000-665243/64.
 DR P-PSDB; AAB29580.
 XX
 XX Novel zacr3p3 polypeptides used to treat or prevent bacterial or viral
 PT infections, for wound healing, improving blood flow, and to analyze
 PT energy efficiency in mammals.
 XX
 PS Claim 31; Page 107-109; 123pp; English.
 XX
 CC The invention relates to the human zacr3p3 protein (AAB29580) and to
 CC nucleic acids which encode it (AAC64058, AAC64063). zacr3p3 is a homologue
 CC of adipocyte complement related protein (ACRP30) and contains a
 CC collagen-like domain comprising Gly-Xaa-Xaa or Gly-Xaa-Pro repeats, and a
 CC C-terminal C1q domain comprising 10 beta-strands. The zacr3p3 gene is
 CC located on chromosome 5p12. The invention also relates to zacr3p3
 CC fragments, fusion proteins containing zacr3p3 polypeptides,
 CC zacr3p3-specific antibodies, expression constructs and host cells
 CC comprising zacr3p3 nucleic acids, and methods of recombinant production of
 CC zacr3p3. Human zacr3p3, and its agonists and antagonists may be used in the
 CC study and modulation of cellular metabolism and energy balance in
 CC mammals, and may therefore be used to treat disorders such as obesity and
 CC anorexia, and conditions associated with these disorders. Due to its C1q
 CC like domain, zacr3p3 and zacr3p3-containing fusion proteins may be useful
 CC as antimicrobial agents, promoting lysis or phagocytosis of infectious
 CC organisms such as bacteria or viruses. zacr3p3, its fragments, fusion
 CC proteins, antibodies and activity modulators may also be used to inhibit
 CC collagen-induced platelet aggregation, adhesion, or activation, and may
 CC therefore have potential for promoting blood flow within the vasculature
 CC of a mammal e.g., to treat injury to the vasculature or other collagenous
 CC tissue. Human zacr3p3 and its antibodies may additionally be used to study
 CC dimerisation and oligomerisation. The present sequence represents cDNA
 CC encoding human zacr3p3.
 XX
 SQ Sequence 1696 BP; 482 A; 355 C; 386 G; 473 T; 0 other;

Query Match 99.1%; Score 1696; DB 21; Length 1696;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 1696; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 9 CCCGAGGAGACACCGCTCCTGGAGCTCTGCTCTCTTCAGGGAGACTCTGAGGCTCTGT 58
 DB 1 CCCGAGGAGACACCGCTCCTGGAGCTCTGCTCTCTTCAGGGAGACTCTGAGGCTCTGT 60
 QY 69 TGAGATATCATGCTTTTGGAGGACGCTCATCTATTGGCAACTGCTGGCTGTTGTTTCTCTCC 128

Db 61 TCGAGATCATCTTTGGAGGAGCTCATCTATTGGCACTCTGGCTTTGTTTTTCCCTCC 120
 Qy 129 CTTTTTGCTGTGTCAGATGAATACATGGAGTCTCCCAACACCGGAGGACTACCCCGAG 188
 Db 121 CTTTTTGCTGTGTCAGATGAATACATGGAGTCTCCCAACACCGGAGGACTACCCCGAG 180
 Qy 189 ACTGAGTAAGTGTGTCATGAGACTACAGCTTTCAGAGGCTACCAAGCCGCCCTGGGC 248
 Db 181 ACTGAGTAAGTGTGTCATGAGACTACAGCTTTCAGAGGCTACCAAGCCGCCCTGGGC 240
 Qy 249 CACGGGCCCTCTCGGATTCAGGAACACCATGGAACAAATGGCAACATGGAGCCACTG 308
 Db 241 CACGGGCCCTCTCGGATTCAGGAACACCATGGAACAAATGGCAACATGGAGCCACTG 300
 Qy 309 GTCATGAAGGAGCCAAAGGTGAGAGGCGGACAAAGGTGACCTGGGGGCTCGAGGGAGC 368
 Db 301 GTCATGAAGGAGCCAAAGGTGAGAGGCGGACAAAGGTGACCTGGGGGCTCGAGGGAGC 360
 Qy 369 GGGGCGACATGGCCCAAGAGAGAGAGGCTACCCGGGATTCACACCAAGACTTCAGA 428
 Db 361 GGGGCGACATGGCCCAAGAGAGAGAGGCTACCCGGGATTCACACCAAGACTTCAGA 420
 Qy 429 TTGCATTTCATGGCTTCTCTGCAACCCACTTCAGCAATCAGAACAGTGGGATTATCTCA 488
 Db 421 TTGCATTTCATGGCTTCTCTGCAACCCACTTCAGCAATCAGAACAGTGGGATTATCTCA 480
 Qy 489 GCAGTGTGAGACCAACATGGAACCTCTTTGATGTCATGACTGGTAGATTTGGGGGCC 548
 Db 481 GCAGTGTGAGACCAACATGGAACCTCTTTGATGTCATGACTGGTAGATTTGGGGGCC 540
 Qy 549 CAGTATCAGGTGTGATTTCTTCCACTTCAGCATGATGAAGCATGAGGATTTGAGGAAG 608
 Db 541 CAGTATCAGGTGTGATTTCTTCCACTTCAGCATGATGAAGCATGAGGATTTGAGGAAG 600
 Qy 609 TGTATGTACTTCTTATGCAACATGCAACAGCTCTTCAGCATGTACAGCTATGAATGA 668
 Db 601 TGTATGTACTTCTTATGCAACATGCAACAGCTCTTCAGCATGTACAGCTATGAATGA 660
 Qy 669 AGGCAATCAGATACATCCAGCAATATGCTGTGCTGAAGCTACGCCAAAGGGATGAGG 728
 Db 661 AGGCAATCAGATACATCCAGCAATATGCTGTGCTGAAGCTACGCCAAAGGGATGAGG 720
 Qy 729 TTTGGCTGCGAATGCGCAATGCGCTCTCCATGGGACCAACAGCTTCTCCACCTTG 788
 Db 721 TTTGGCTGCGAATGCGCAATGCGCTCTCCATGGGACCAACAGCTTCTCCACCTTG 780
 Qy 789 CAGGATTCCTGCTCTTTGAACTAAGTAATATATGACTAGAAATAGCTTCCACTTTGGGA 848
 Db 781 CAGGATTCCTGCTCTTTGAACTAAGTAATATATGACTAGAAATAGCTTCCACTTTGGGA 840
 Qy 849 AGACTTGTAGCTGAGCTGATTTGTAGCATCTGAGGACATTAAGTTGAGGGTTTACA 908
 Db 841 AGACTTGTAGCTGAGCTGATTTGTAGCATCTGAGGACATTAAGTTGAGGGTTTACA 900
 Qy 909 TTGCTGTATTCAAAAATTTGCTTCAATGTTTTCACGCTACAGGTACACCAATAT 968
 Db 901 TTGCTGTATTCAAAAATTTGCTTCAATGTTTTCACGCTACAGGTACACCAATAT 960
 Qy 969 GTTGGCAATTCAGGGCTCAGAGAATCAACCAACAAATAGCTTCTCAGATGACCTTG 1028
 Db 961 GTTGGCAATTCAGGGCTCAGAGAATCAACCAACAAATAGCTTCTCAGATGACCTTG 1020
 Qy 1029 ACTAATATCTACGACTCTTTATCAGCTTTTCCCTTGGCACTTAAAGATAATTCCTCT 1088
 Db 1021 ACTAATATCTACGACTCTTTATCAGCTTTTCCCTTGGCACTTAAAGATAATTCCTCT 1080
 Qy 1089 GAGCAGGTTGGAATATTTTTTCTATCAGAGTCAATTTGCAAGAAATTTTGACTAC 1148
 Db 1081 GAGCAGGTTGGAATATTTTTTCTATCAGAGTCAATTTGCAAGAAATTTTGACTAC 1140
 Qy 1149 TCTGCTTTTAAATTAACAGTTTTTCAGGAAACCCCTGAAGTTTTTAAGTTCAATTTCTT 1208
 Db 1141 TCTGCTTTTAAATTAACAGTTTTTCAGGAAACCCCTGAAGTTTTTAAGTTCAATTTCTT 1200

Qy 1209 TATAACATTTGAGAGAATCGGATGTAGTATGACAGGCTGGGCAAGAACAGGGCA 1268
 Db 1201 TATAACATTTGAGAGAATCGGATGTAGTATGACAGGCTGGGCAAGAACAGGGCA 1260
 Qy 1269 CTAGCTGCTTATTAAGCTAATTTAGTGGCTCCGTTGTCAGCTTAGCCCTTTGACCCCTTC 1328
 Db 1261 CTAGCTGCTTATTAAGCTAATTTAGTGGCTCCGTTGTCAGCTTAGCCCTTTGACCCCTTC 1320
 Qy 1329 CTTTTTGATCCCAAAATACATTAATAAATCTGAATTCACATACATCTATTTAAAGTCA 1388
 Db 1321 CTTTTTGATCCCAAAATACATTAATAAATCTGAATTCACATACATCTATTTAAAGTCA 1380
 Qy 1389 ATAGATTTTAGCTATAAAGTCTTGACCAAGTATGTTGTTGTAATTTTGTATGTTCC 1448
 Db 1381 ATAGATTTTAGCTATAAAGTCTTGACCAAGTATGTTGTTGTAATTTTGTATGTTCC 1440
 Qy 1449 CCACATCCGCCCAACTTCGGATGTTGGGTCAGGAGTTGAGGTTTCACATTAACAAATG 1508
 Db 1441 CCACATCCGCCCAACTTCGGATGTTGGGTCAGGAGTTGAGGTTTCACATTAACAAATG 1500
 Qy 1509 TCATAAATATCTCATAGAGGTACACTGCAATAGATATTCAAATGTTGCATGTTGACCA 1568
 Db 1501 TCATAAATATCTCATAGAGGTACACTGCAATAGATATTCAAATGTTGCATGTTGACCA 1560
 Qy 1569 AGGATTTTATATCTGAAGACATACACTATTAATAAATACCTTAGAGAAAGATTTTGAC 1628
 Db 1561 AGGATTTTATATCTGAAGACATACACTATTAATAAATACCTTAGAGAAAGATTTTGAC 1620
 Qy 1629 CTGGCTTTAGATAAAGTGTGGCAAGAAAATGTAATGAGCAATATATGGAATAAACAC 1688
 Db 1621 CTGGCTTTAGATAAAGTGTGGCAAGAAAATGTAATGAGCAATATATGGAATAAACAC 1680
 Qy 1689 ACCTTTGTTAAAGATA 1704
 Db 1681 ACCTTTGTTAAAGATA 1696

RESULT 4
 AAF93874
 ID AAF93874 standard; cDNA; 1709 BP.
 XX AAF93874;
 XX 23-MAY-2001 (first entry)
 XX Human cDNA encoding a membrane or secretory protein clone PSEC0232.
 DE Human; secretory protein; membrane protein; vaccine; gene therapy;
 KW rheumatoid arthritis; diabetes; ss.
 XX Homo sapiens.
 OS
 XX
 PN EPI067182-A2.
 XX
 PD 10-JAN-2001.
 XX
 PF 07-JUL-2000; 2000EP-0114090.
 XX
 PR 08-JUL-1999; 99JP-0194179.
 PR 11-JAN-2000; 2000JP-0118775.
 PR 02-MAY-2000; 2000JP-0183766.
 XX
 PA (HELI-) HELIX RES INST.
 XX
 PI Ota T, Isogai T, Nishikawa T, Kawai Y, Sugiyama T, Hayashi K;
 XX WPI; 2001-093989/11.
 DR P-PSDB; AAB8847.
 XX
 PT Nucleic acids encoding secretory proteins/membrane proteins, useful in gene therapy or as candidate target molecules in drug development -

XX

Claim 1; SEQ ID 261; 609pp + CD ROM; English.

This invention relates to nucleic acid sequences AAF93744 - AAF93916 which encode human secretory or membrane proteins represented by AAB88317 - AAB88419. Included in the invention are primers AAF93317 - AAF94295 and AAF62232 - AAF62235 which are used to isolate the cDNA sequences of the invention. The invention also includes methods for the production of antibodies directed against the proteins, and cDNA sequences, which can be used in vaccines. The polynucleotide sequences can be used in gene therapy. The polynucleotide sequences and the proteins they encode may be used in the prevention, treatment and diagnosis of diseases associated with inappropriate secretory protein/membrane protein expression. The nucleic acids and complementary sequences may also be used as DNA probes in diagnostic assays (e.g. polymerase chain reactions (PCR)) to detect and quantitate the presence of similar nucleic acid sequences in samples. They may also be used to study the expression and function of secretory proteins/membrane polypeptides and their role in metabolism. The polypeptides may be used as antigens in the production of antibodies against them and in assays to identify modulators (agonists and antagonists) of expression and activity. The antibodies and antagonists may also be used as therapeutic agents to down regulate expression and activity. The antibodies may also be used as diagnostic agents for detecting the presence of the polypeptides in samples (e.g. by enzyme linked immunosorbant assay (ELISA). Examples of diseases which may be treated include rheumatoid arthritis and diabetes.

Sequence 1709 BP; 480 A; 363 C; 390 G; 476 T; 0 other;

```
Query Match          99.0%; Score 1695.4; DB 22; Length 1709;
Best Local Similarity 99.9%; Pred. No. 0;
Matches 1696; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

QY	1	GGCATCTGCCCGCAGGAGACACACGCTCCTGGAGCTCTGCTGTCTTCTCAGGGAGACTCTGA	60
Db	13	GGCATCTGCCCGCAGGAGACACACGCTCCCGAGCTCTGCTGTCTTCTCAGGGAGACTCTGA	72
QY	61	GGCTCTCTTCAGAAATCATGCTTTGGAGGAGCTCATCTATTGGCAACTCCTGGCTTTGTT	120
Db	73	GGCTCTCTTGAGAAATCATGCTTTGGAGGAGCTCATCTATTGGCAACTCCTGGCTTTGTT	132
QY	121	TTTCTCTCCCTTTTGGCTGTGTCGAAGATGAATACATGGAGTCTCCACAACCGGAGGACT	180
Db	133	TTTCTCTCCCTTTTGGCTGTGTCGAAGATGAATACATGGAGTCTCCACAACCGGAGGACT	192
QY	181	ACCCCCAGACTGCAGTAAGTGTGTGCATGGAGACTACAGCTTTCGAGGCTACCAAGGCC	240
Db	193	ACCCCCAGACTGCAGTAAGTGTGTGCATGGAGACTACAGCTTTCGAGGCTACCAAGGCC	252
QY	241	CCCTGGGCCACCGGGCCCTCTGGCATTTCCAGGAACCATGGAAACAATGGCAACAATGG	300
Db	253	CCCTGGGCCACCGGGCCCTCTGGCATTTCCAGGAACCATGGAAACAATGGCAACAATGG	312
QY	301	AGCCACTGTGTCATGAAGAGGCCAAAGGTGAGAAAGGCGACAAGGTGACCTGGGCGCTCG	360
Db	313	AGCCACTGTGTCATGAAGAGGCCAAAGGTGAGAAAGGCGACAAGGTGACCTGGGCGCTCG	372
QY	361	AGGGAGCGGGGGCAGCATGGCCCCAAAGAGAGAAAGGCTACCCGGGGATTCCACCCAGA	420
Db	373	AGGGAGCGGGGGCAGCATGGCCCCAAAGAGAGAAAGGCTACCCGGGGATTCCACCCAGA	432
QY	421	ACTTCAGATGTCATTCATGCTCTCTGGCAACCCACTTTCAGCAATCAGAAACAGTGGGAT	480
Db	433	ACTTCAGATGTCATTCATGCTCTCTGGCAACCCACTTTCAGCAATCAGAAACAGTGGGAT	492
QY	481	TATCTTTCAGCAGTGTTCAGACCAACAATTTGGAACCTTCTTTGATGTGTCATGCTGGTAGATT	540
Db	493	TATCTTTCAGCAGTGTTCAGACCAACAATTTGGAACCTTCTTTGATGTGTCATGCTGGTAGATT	552
QY	541	TGGGGCCCCAGTATACAGGTGTGTATTTCTTTCACCTTCAGCATGTATGAAGCATGAGGATGT	600
Db	553	TGGGGCCCCAGTATACAGGTGTGTATTTCTTTCACCTTCAGCATGTATGAAGCATGAGGATGT	612

QY 1681 ATACACACCTTTGTT 1697
Db 1693 ATAAACACACCTTTGTT 1709
RESULT 5
AAI99523
ID AAI99523 standard; cDNA; 1620 BP.
XX AAI99523;
XX 07-JAN-2002 (first entry)
XX Human polynucleotide SEQ ID NO 21.
XX Cytostatic; immunosuppressive; nootropic; neuroprotective; antiviral;
KW antiallergic; hepatotropic; antidiabetic; antiinflammatory; antiulcer;
KW vulnary; anticonvulsant; antibacterial; antifungal; antiparasitic;
KW cardiant; gene therapy; cancer; immune disorder; cardiovascular disorder;
KW neurological disease; infection; human; secreted protein; ss.
XX
OS Homo sapiens.
XX
PN WO20015173-A2.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01356.
XX
PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 14-JUL-2000; 2000US-0217496.
PR 26-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225477.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 23-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231113.
PR 08-SEP-2000; 2000US-0231114.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231988.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.

PR 17-NOV-2000; 2000US-0249245.
 PR 17-NOV-2000; 2000US-0249264.
 PR 17-NOV-2000; 2000US-0249265.
 PR 17-NOV-2000; 2000US-0249297.
 PR 17-NOV-2000; 2000US-0249299.
 PR 17-NOV-2000; 2000US-0249300.
 PR 01-DEC-2000; 2000US-0250160.
 PR 01-DEC-2000; 2000US-0250391.
 PR 05-DEC-2000; 2000US-0251030.
 PR 05-DEC-2000; 2000US-0251988.
 PR 05-DEC-2000; 2000US-0256719.
 PR 06-DEC-2000; 2000US-0251479.
 PR 08-DEC-2000; 2000US-0251856.
 PR 08-DEC-2000; 2000US-0251868.
 PR 08-DEC-2000; 2000US-0251869.
 PR 08-DEC-2000; 2000US-0251989.
 PR 08-DEC-2000; 2000US-0251990.
 PR 11-DEC-2000; 2000US-0254097.
 PR 05-JAN-2001; 2001US-0259678.
 XX
 PA (HUMA-) HUMAN GENOME SCI INC.
 XX
 PI Rosen CA, Barash SC, Ruben SM;
 XX
 DR WPI; 2001-451924/48.
 DR P-PSDB; AAM99925.
 XX
 DR
 DR
 XX
 PT New nucleic acids and polypeptides, useful for treating, preventing or
 PT ameliorating human disorders and diseases -
 XX
 PS Claim 1; SEQ ID NO 21; 465pp + Sequence Listing; English.
 XX
 CC The invention relates to novel human polynucleotides (AAI99513-AAI99538)
 CC and the encoded proteins (AAM9915-AAM9934) which are useful for
 CC preventing, treating or ameliorating medical conditions e.g. by protein
 CC or gene therapy. The genes are isolated from a range of human tissues
 CC disclosed in the specification. The nucleic acids, proteins, antibodies
 CC and (ant)agonists are useful in the diagnosis, treatment and prevention
 CC of: (a) cancer, e.g. breast and ovarian cancer and other cancers of the
 CC adrenal gland, bone, bone marrow, breast, gastrointestinal tract, liver,
 CC lung, or urogenital; (b) immune disorders e.g. Addison's disease,
 CC allergies, autoimmune haemolytic anaemia, autoimmune thyroiditis,
 CC diabetes mellitus, Crohn's disease, multiple sclerosis, rheumatoid
 CC arthritis and ulcerative colitis; (c) cardiovascular disorders such as
 CC myocardial ischaemia; (d) wound healing; (e) neurological diseases
 CC e.g. cerebral anoxia and epilepsy; and (f) infectious diseases such as
 CC viral, bacterial, fungal and parasitic infections.
 CC Note: The sequence data for this patent did not form part of the
 CC printed specification, but was obtained in electronic format directly
 CC from WIPO at ftp.wipo.int/pub/published_pct_sequences.
 XX
 SQ Sequence 1620 BP; 485 A; 332 C; 360 G; 440 T; 3 other;

Query Match 90.5%; Score 1549.6; DB 22; Length 1620;
 Best Local Similarity 99.7%; Pred. No. 0;
 Matches 1549; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 159 AGTCTCCACAACCGGAGGACTACCCAGACTGCAGTAAAGTGTGTCATGGAGACTACA 218
 DB 22 AGTCTCCACAACCGGAGGACTACCCAGACTGCAGTAAAGTGTGTCATGGAGACTACA 81
 QY 219 GCTTTCCAGGCTACCAAGGCCCTGGGCCACCGGGCCCTCCCTGGCAATTCAGGAACCC 278
 DB 82 GCTTTCCAGGCTACCAAGGCCCTGGGCCACCGGGCCCTCCCTGGCAATTCAGGAACCC 141
 QY 279 ATGGAACAATGGCAACAATGGAGCCACTGTGTCATGAAGAGCCAAAGGTGAGAGGCGC 338
 DB 142 ATGGAACAATGGCAACAATGGAGCCACTGTGTCATGAAGAGCCAAAGGTGAGAGGCGC 201
 QY 339 ACAAGGTGACCTGGGGCTCGAGGGAGCGGGGCGAGCATGGCCCCAAAGAGAGAGG 398
 DB 202 ACAAGGTGACCTGGGGCTCGAGGGAGCGGGGCGAGCATGGCCCCAAAGAGAGAGG 261

QY 399 GCTACCCGGGGAATTCACAGAACTTCAGATTGCATTTCATGGCTTCTCTGGCAACCCACT 458
 DB 262 GCTACCCGGGGAATTCACAGAACTTCAGATTGCATTTCATGGCTTCTCTGGCAACCCACT 321
 QY 459 TCAGCAATCAGACAGTGGGATTAATCTTCAGCAGTGTGTAGACCAACAATTCGAACTTCT 518
 DB 322 TCAGCAATCAGACAGTGGGATTAATCTTCAGCAGTGTGTAGACCAACAATTCGAACTTCT 381
 QY 519 TTGATGTCAGTGGTAGATTGGGGCCCAAGTATCAGGTGTGTATTTCTTCCACTTCA 578
 DB 382 TTGATGTCAGTGGTAGATTGGGGCCCAAGTATCAGGTGTGTATTTCTTCCACTTCA 441
 QY 579 GCATGATGAACATGAGATGTTGAGGAAGTGTGTGTACCTTTATGACAAATGGCAACA 638
 DB 442 GCATGATGAACATGAGATGTTGAGGAAGTGTGTGTACCTTTATGACAAATGGCAACA 501
 QY 639 CAGTCTTCAGCATGTACAGCTATGAAATGAAGGCAAAATCAGATACATCCAGCAATCATG 698
 DB 502 CAGTCTTCAGCATGTACAGCTATGAAATGAAGGCAAAATCAGATACATCCAGCAATCATG 561
 QY 699 CTGTGCTGAAGCTAGCCAAAGGGGATGAGGTTTGGCTCGGAATGGCAATGGCGCTCTCC 758
 DB 562 CTGTGCTGAAGCTAGCCAAAGGGGATGAGGTTTGGCTCGGAATGGCAATGGCGCTCTCC 621
 QY 759 ATGGGGACCACCAACGGCTTCTCCACCTTTGAGGATTCCTGCTCTTTGAAACTAAGTAAA 818
 DB 622 ATGGGGACCACCAACGGCTTCTCCACCTTTGAGGATTCCTGCTCTTTGAAACTAAGTAAA 681
 QY 819 TATATGACTAGAATGAGTCCACTTTGGGGAAGACTTGTAGCTGAGCTGATTTGATGAT 878
 DB 682 TATATGACTAGAATGAGTCCACTTTGGGGAAGACTTGTAGCTGAGCTGATTTGATGAT 741
 QY 879 CTGAGGAACATTAAGTTGAGGTTTACATTTGCTGATTTCAAAAATTTATTTGCTGCA 938
 DB 742 CTGAGGAACATTAAGTTGAGGTTTACATTTGCTGATTTCAAAAATTTATTTGCTGCA 801
 QY 939 TGTGTTGCTCACCTACAGTACACCAATAATGTTGGACAATTCAGGGGCTCAGAGAATCA 998
 DB 802 TGTGTTGCTCACCTACAGTACACCAATAATGTTGGACAATTCAGGGGCTCAGAGAATCA 861
 QY 999 ACCAATAATGCTTCTCAGATGACCTTGACTAATATATCTACAGCACTTTATCACCTT 1058
 DB 862 ACCAATAATGCTTCTCAGATGACCTTGACTAATATATCTACAGCACTTTATCACCTT 921
 QY 1059 TCCTTGGCACCTAAAAGATAATCTCTCTGACGAGCTTGGAAATATTTTTTCTATCA 1118
 DB 922 TCCTTGGCACCTAAAAGATAATCTCTCTGACGAGCTTGGAAATATTTTTTCTATCA 981
 QY 1119 CAGAAGTCATTTGCAAGAATTTTACCTCTGCTCTGCTCTGCTCTGCTCTGCTCTGCT 1178
 DB 982 CAGAAGTCATTTGCAAGAATTTTACCTCTGCTCTGCTCTGCTCTGCTCTGCTCTGCT 1041
 QY 1179 AACCCCTGAAGTTTAAAGTTCATTTATTAACATTTGAGAGAAATCGGATGATGTA 1238
 DB 1042 AACCCCTGAAGTTTAAAGTTCATTTATTAACATTTGAGAGAAATCGGATGATGTA 1101
 QY 1239 TATCAGAGGCTGGGCAAGAACAGGGGCACTAGCTGCTCTTATAGCTAAATTTAGTGCC 1298
 DB 1102 TATCAGAGGCTGGGCAAGAACAGGGGCACTAGCTGCTCTTATAGCTAAATTTAGTGCC 1161
 QY 1299 TCCGTGTTGAGCTTTGAGCTTTGACCTTTTCCCTTTGATCCACAAAATACATTAAGCTCT 1358
 DB 1162 TCCGTGTTGAGCTTTGAGCTTTGACCTTTTCCCTTTGATCCACAAAATACATTAAGCTCT 1221
 QY 1359 GAATTCACATACATGCTATTTTAAAGTCAATAGATTTTAGCTATTAAGTCTTGACGAG 1418
 DB 1222 GAATTCACATACATGCTATTTTAAAGTCAATAGATTTTAGCTATTAAGTCTTGACGAG 1281
 QY 1419 TAATGCTGTTGATTTTGTGTATGTTCCCAACATCGCCCCCACTTCGATGCTGGGGT 1478
 DB 1282 TAATGCTGTTGATTTTGTGTATGTTCCCAACATCGCCCCCACTTCGATGCTGGGGT 1341
 QY 1479 CAGGAGGTTGAGTTCACTATTAAACAAATGCTATAAATATCTCATAGAGGTACAGTGCCA 1538

Db 1342 CAGAGGTTGAGTTCACATATTAACAATGTCATAAATATCTCATAGAGGTACAGTGCCA 1401
 Qy 1539 ATAGATATTCAAATGTTGTCATGTTGACACAGAGGATTTTATATCTTGAAGAATACACTA 1598
 Db 1402 ATAGATATTCAAATGTTGTCATGTTGACACAGAGGATTTTATATCTTGAAGAATACACTA 1461
 Qy 1599 TTAATAATACCTTAGAGAAAGATTTTGACCTGGCTTTAGATAAATCTGTGGCAAGAAA 1658
 Db 1462 TTAATAATACCTTAGAGAAAGATTTTGACCTGGCTTTAGATAAATCTGTGGCAAGAAA 1521
 Qy 1659 ATGTAATCAGCAATATATGGAATAAACAACACACCTTTTGTAAAGATAAATAAAAAA 1712
 Db 1522 ATGTAATCAGCAATATATGGAATAAACAACACACCTTTTGTAAARAWAAAAA 1575
 RESULT 6
 AAI59230
 ID AAI59230 standard; cDNA; 1792 BP.
 XX
 AC AAI59230;
 XX
 DT 22-OCT-2001 (first entry)
 XX
 DE Human polynucleotide SEQ ID NO 1433.
 XX
 KW Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;
 KW peripheral nervous system; neuropathy; central nervous system; CNS;
 KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
 KW amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
 KW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
 KW leukaemia; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200153312-A1.
 XX
 PD 26-JUL-2001.
 XX
 PF 26-DEC-2000; 2000WO-US34263.
 XX
 PR 21-JAN-2000; 2000US-0488725.
 PR 25-APR-2000; 2000US-0552317.
 PR 09-JUL-2000; 2000US-0598042.
 PR 19-JUL-2000; 2000US-0620312.
 PR 03-AUG-2000; 2000US-0653450.
 PR 14-SEP-2000; 2000US-0662191.
 PR 19-OCT-2000; 2000US-0693036.
 PR 29-NOV-2000; 2000US-0727344.
 XX
 PA (HYSE-) HYSEQ INC.
 XX
 PI Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;
 PI Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J;
 PI Zhao QA, Zhou P, Goodrich R, Drmanac RT;
 XX
 DR WPI; 2001-442253/47.
 DR P-PSDB; AAM40074.
 XX
 PT Novel nucleic acids and polypeptides, useful for treating disorders
 PT such as central nervous system injuries -
 XX
 PS Claim 1; SEQ ID NO 1433; 10078pp; English.
 XX
 CC The invention relates to human nucleic acids (AAI57798-AAI61369) and
 CC the encoded polypeptides (AAM38642-AAM42213) with nootropic,
 CC immunosuppressant and cytostatic activity. The polynucleotides are useful
 CC in gene therapy. A composition containing a polypeptide or polynucleotide
 CC of the invention may be used to treat diseases of the peripheral nervous
 CC system, such as peripheral nervous injuries, peripheral neuropathy and
 CC localised neuropathies and central nervous system diseases, such as
 CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
 CC lateral sclerosis, and Shy-Drager Syndrome. Other uses include the

CC utilisation of the activities such as: Immune system suppression,
 CC Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
 CC and thrombolytic activity, cancer diagnosis and therapy, drug screening,
 CC assays for receptor activity, arthritis and inflammation, leukaemias and
 CC C.N.S disorders.
 CC Note: The sequence data for this patent did not form part of the printed
 CC specification.
 XX
 SO Sequence 1792 BP; 541 A; 352 C; 393 G; 506 T; 0 other:
 Query Match 90.5%; Score 1548.6; DB 22; Length 1792;
 Best Local Similarity 99.7%; Pred. No. 0;
 Matches 1551; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
 Qy 155 ATGAGAGTCTCCACAAACCGGAGGACTACCCAGAGCTGAGTGAAGTGTGATGAGAC 214
 Db 238 AGGGAGTCTCCACAAACCGGAGGACTACCCAGAGCTGAGTGAAGTGTGATGAGAC 297
 Qy 215 TACAGCTTTTCGAGGCTACCAAGGCCCTGGGCCACCGGCCCTCTGGCATTCACGA 274
 Db 298 TACAGCTTTTCGAGGCTACCAAGGCCCTGGGCCACCGGCCCTCTGGCATTCACGA 357
 Qy 275 AACCATGGAACAATGGAACAATGGAACAATGGAACAATGGAACAATGGAACAATGGAACA 334
 Db 358 AACCATGGAACAATGGAACAATGGAACAATGGAACAATGGAACAATGGAACAATGGAACA 417
 Qy 335 GGCACAAAGGTGACCTGGGCCCTCGAGGGAGCGGGGAGCAGTGGCCCCCAAGAGAG 394
 Db 418 GGCACAAAGGTGACCTGGGCCCTCGAGGGAGCGGGGAGCAGTGGCCCCCAAGAGAG 477
 Qy 395 AAGGCTACCGGGGATTCACAGCACTTCCAGATTTGAGTGAAGTGTGATGAGTGTGATGAGT 454
 Db 478 AAGGCTACCGGGGATTCACAGCACTTCCAGCACTTCCAGCACTTCCAGCACTTCCAGCACT 537
 Qy 455 CACTTCAGCAATCAGAACAGTGGGATTTATCTTCAGCAGTGTGAGACCAACAATGGAACA 514
 Db 538 CACTTCAGCAATCAGAACAGTGGGATTTATCTTCAGCAGTGTGAGACCAACAATGGAACA 597
 Qy 515 TTCTTTGATGTGATGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGT 574
 Db 598 TTCTTTGATGTGATGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGT 657
 Qy 575 TTCAGCATGATGAGCATGAGGATGTTGAGGAAGTGTGATGATGATGATGATGATGATGATGAT 634
 Db 658 TTCAGCATGATGAGCATGAGGATGTTGAGGAAGTGTGATGATGATGATGATGATGATGATGAT 717
 Qy 635 AACACAGTCTTCAGCATGATGAGTGTGAGGAAGTGTGAGGAAGTGTGAGGAAGTGTGAGGA 694
 Db 718 AACACAGTCTTCAGCATGATGAGTGTGAGGAAGTGTGAGGAAGTGTGAGGAAGTGTGAGGA 777
 Qy 695 CATGCTGTGCTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGA 754
 Db 778 CATGCTGTGCTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGA 837
 Qy 755 CTCCATGGGGACCAACAGCTTCTCCAGGATTCCTGCTCTCTTCAAACTAAG 814
 Db 838 CTCCATGGGGACCAACAGCTTCTCCAGGATTCCTGCTCTCTTCAAACTAAG 897
 Qy 815 TAAATATATGACTAGCAATAGCTTCCACTTTGGGGAAGAGCTTGTAGCTGAGCTGATTTGTTA 874
 Db 898 TAAATATATGACTAGCAATAGCTTCCACTTTGGGGAAGAGCTTGTAGCTGAGCTGATTTGTTA 957
 Qy 875 CGATCTGAGGAACATTAAGTGTGAGGTTTACATTTGCTGTATTCACAAAATTTATGGTT 934
 Db 958 CGATCTGAGGAACATTAAGTGTGAGGTTTACATTTGCTGTATTCACAAAATTTATGGTT 1017
 Qy 935 GCAATGTTGTTCAAGCTACAGTACCAATTAATTTGAGCAATTTCAAGGGGCTCAGAGA 994
 Db 1018 GCAATGTTGTTCAAGCTACAGTACCAATTAATTTGAGCAATTTCAAGGGGCTCAGAGA 1077
 Qy 995 ATCAACCAACAAATAGTCTTCTCAGATGACCTTTGACTATATATATATATATATATATATAT 1054
 Db 1078 ATCAACCAACAAATAGTCTTCTCAGATGACCTTTGACTATATATATATATATATATATATAT 1137

QY 1055 TCCTTCCTTGGCACCTAAAGATAATCTCTCTGACGAGCTGGAATATTTTCT 1114
 Db 1138 TCCTTCCTTGGCACCTAAAGATAATCTCTCTGACGAGCTGGAATATTTTCT 1197
 QY 1115 ATCAGAGAGTCATTGCAAGAAATTTGACCTACTCTGCTTTAAATTAATACCACTTTT 1174
 Db 1198 ATCAGAGAGTCATTGCAAGAAATTTGACCTACTCTGCTTTAAATTAATACCACTTTT 1257
 QY 1175 CAGGAACCCCTGAAGTTTAACTTATCTTTTATACATTTGAGAGATCCGATGTA 1234
 Db 1258 CAGGAACCCCTGAAGTTTAACTTATCTTTTATACATTTGAGAGATCCGATGTA 1317
 QY 1235 GTGATATGACAGGCTGGGGCAAGAACAGGCGACTAGCTGCTTATTAGCTAATTTAGT 1294
 Db 1318 GTGATATGACAGGCTGGGGCAAGAACAGGCGACTAGCTGCTTATTAGCTAATTTAGT 1377
 QY 1295 GCGCTCCGTTGACGCTTAGGCTTTGACCCCTTTCCCTTTGATPCCACAAAATACATTA 1354
 Db 1378 GCGCTCCGTTGACGCTTAGGCTTTGACCCCTTTCCCTTTGATPCCACAAAATACATTA 1437
 QY 1355 CTCTCAATTCACATCAATGCTATTTTAAAGTCAATAGATTTAGCTATTAAGTCTTGA 1414
 Db 1438 CTCTCAATTCACATCAATGCTATTTTAAAGTCAATAGATTTAGCTATTAAGTCTTGA 1497
 QY 1415 CCAGTAATGTGCTGTAATTTGCTATGTTCCCTCCACATCGCCCAACTTCGGATGTG 1474
 Db 1498 CCAGTAATGTGCTGTAATTTGCTATGTTCCCTCCACATCGCCCAACTTCGGATGTG 1557
 QY 1475 GGGTCAGGAGTTGAGTTCATTAACAAATGTCATTAATATCTATAGAGGTACAGT 1534
 Db 1558 GGGTCAGGAGTTGAGTTCATTAACAAATGTCATTAATATCTATAGAGGTACAGT 1617
 QY 1535 GCCATATATTCATTAATGTCATGTTGACAGGAGGATTTATATCTGAGACATAC 1594
 Db 1618 GCCATATATTCATTAATGTCATGTTGACAGGAGGATTTATATCTGAGACATAC 1677
 QY 1595 ACTATTAATAATACCTTAGAGAAAGATTTTGACCTGCTTTAGATAAACTGTGCAAG 1654
 Db 1678 ACTATTAATAATACCTTAGAGAAAGATTTTGACCTGCTTTAGATAAACTGTGCAAG 1737
 QY 1655 AAAATGTAAAGAGCAATATATGGAATAAACACACCTTTGTTAAAGATAAAAA 1709
 Db 1738 AAAATGTAAAGAGCAATATATGGAATAAACACACCTTTGTTAAAGATAAAAA 1792

RESULT 7
 AAD12584
 ID AAD12584 standard; cDNA; 1927 BP.
 XX
 AC AAD12584;
 XX
 DT 25-SEP-2001 (first entry)
 DE Human protein having hydrophobic domain encoding cDNA clone HP10781.
 DE Human; hydrophobic domain; gene therapy; nutritional supplement;
 KW cell proliferation; immunomodulatory; autoimmune disorder; antimicrobial;
 KW multiple sclerosis; rheumatoid arthritis; insulin-dependent diabetes;
 KW haematopoiesis; tissue growth activity; Parkinson's disease; cytostatic;
 KW Huntington's disease; Alzheimer's disease; chemotactic; chemokinetic;
 KW haemostatic; thrombolytic; tumour growth inhibitor; anabolic;
 KW contraceptive; antiinfertility; antiinflammatory; ss.
 OS Homo sapiens.
 XX
 FH Key
 FT CDS
 FT Location/Qualifiers
 FT 89..760
 FT /*tag= a
 FT /product= "Human protein having hydrophobic domain"
 FT /note= "CDS is specifically is claimed in claim 3"
 FT 89..157
 FT sig_peptide
 FT /*tag= b

mat_peptide 158..757
 /*tag= c
 /product= "Mature human protein with hydrophobic domain"
 WO200149728-A2.
 12-JUL-2001.
 28-DEC-2000; 2000WO-JP09359.
 06-JAN-2000; 2000JP-0000585.
 11-JAN-2000; 2000JP-0000588.
 03-FEB-2000; 2000JP-0026862.
 03-MAR-2000; 2000JP-0058367.
 (PROT-) PROTEGENE INC.
 (SAGA) SAGAMI CHEM RES CENT.
 Kato S, Kimura T;
 WPI; 2001-418355/44.
 P-PSDB; AAE06589.
 Human proteins with hydrophobic domains and the nucleic acids encoding them, useful for preventing diagnosing and treating e.g. cancer, Alzheimer's and inflammation -
 Claim 4; Page 352-354; 563pp; English.
 The present sequence is human protein with hydrophobic domain encoding cDNA clone HP10781. The polynucleotide and polypeptide of the invention may be used in the prevention, diagnosis and treatment of diseases associated with inappropriate polypeptide expression. The polynucleotides may be used to produce the polypeptide, by inserting the nucleic acids into a host cell and culturing the cell to express the protein. The polynucleotides and its complementary sequences may also be used as DNA probes in diagnostic assays and also used in gene therapy. The polypeptides may also be used as antigens in the production of antibodies and in assays to identify modulators of polypeptide expression and activity. The polypeptides and nucleic acids may be used as nutritional supplements, to modulate cytokine and cell proliferation activity, to modulate immune stimulation or suppression (e.g. for the treatment of microbial infections and autoimmune disorders such as multiple sclerosis, rheumatoid arthritis and insulin-dependent diabetes), to modulate haematopoiesis, to modulate tissue growth activity (e.g. for the treatment of Parkinson's disease, Huntington's disease and Alzheimer's disease), to modulate actin and inhibit activity (e.g. for controlling fertility), to modulate chemotactic and chemokinetic activity, to modulate haemostatic and thrombolytic activity, to modulate receptor ligand activity, to modulate inflammation and to inhibit tumour growth.

Query Match 89.2%; Score 1527; DB 22; Length 1927;
 Best Local Similarity 99.9%; Pred. No. 0;
 Matches 1538; Conservative 0; Mismatches 0; Indels 1; Gaps 1;
 QY 159 AGTCTCCACAAACCGGAGGACTACCCCGAGACTGCAGTAAGTGTGTGTCATGGAGACTACA 218
 Db 390 AGTCTCCACAAACCGGAGGACTACCCCGAGACTGCAGTAAGTGTGTGTCATGGAGACTACA 449
 QY 219 GCTTTCAGGCTACCAAGGCCCCCTTGGCCACCGGGCCCTCTCGGCAATCCAGGAAC 278
 Db 450 GCTTTCAGGCTACCAAGGCCCCCTTGGCCACCGGGCCCTCTCGGCAATCCAGGAAC 509
 QY 279 ATGGAACAATGGCAACAATGGAGCCACTGTCATGAAGGAGCCAAAGGTGAGAGGCG 338
 Db 510 ATGGAACAATGGCAACAATGGAGCCACTGTCATGAAGGAGCCAAAGGTGAGAGGCG 569
 QY 339 ACAAGGTGACCTGGGGCTCTGAGGGAGGGGGGCGGAGCATGGCCCCCAAGAGGAGAAGG 398
 Db 570 ACAAGGTGACCTGGGGCTCTGAGGGAGGGGGGCGGAGCATGGCCCCCAAGAGGAGAAGG 629

QY 399 GCTACCCGGGATTCACACAGAACTTCAGATTGCAATTCATGGCTTCTCTGSCAACCCACT 458
 Db 630 GCTACCCGGGATTCACACAGAACTTCAGATTGCAATTCATGGCTTCTCTGSCAACCCACT 689
 QY 459 TCAGCAATCAGACAGTGGGATTAATCTTCAGCAGTGTGAGACCAACATTCGAACCTCT 518
 Db 690 TCAGCAATCAGACAGTGGGATTAATCTTCAGCAGTGTGAGACCAACATTCGAACCTCT 748
 QY 519 TTGATGTCATGACATGGTAGATTTCGGGCCCCAGATATCAGGTGTGATTTCTTCCACCTTCA 578
 Db 749 TTGATGTCATGACATGGTAGATTTCGGGCCCCAGATATCAGGTGTGATTTCTTCCACCTTCA 808
 QY 579 GCATGATGAACATGAGATGTTGAGGAAGTGTATGTGTACCTTATGCACATGGCAACA 638
 Db 809 GCATGATGAACATGAGATGTTGAGGAAGTGTATGTGTACCTTATGCACATGGCAACA 868
 QY 639 CAGTCTTCAGCATCTACAGCTATCAATGAAGGCAATCAGATACATCCAGCAATCATG 698
 Db 869 CAGTCTTCAGCATCTACAGCTATCAATGAAGGCAATCAGATACATCCAGCAATCATG 928
 QY 699 CTGTGCTGAAGCTAGCCAAAGGGATGAGGTTTGGCTGCGAATGGCAATGGCGCTCTCC 758
 Db 929 CTGTGCTGAAGCTAGCCAAAGGGATGAGGTTTGGCTGCGAATGGCGCTCTCC 988
 QY 759 ATGGGGACCAACGCTTCTCCACCTTTGAGGATTCCTGCTCTTTGAACTAAGTAAA 818
 Db 989 ATGGGGACCAACGCTTCTCCACCTTTGAGGATTCCTGCTCTTTGAACTAAGTAAA 1048
 QY 819 TATATGACTAGAATAGCTCCACTTTGGGGAAGACTTCTAGCTGAGCTGATTGTTACGAT 878
 Db 1049 TATATGACTAGAATAGCTCCACTTTGGGGAAGACTTCTAGCTGAGCTGATTGTTACGAT 1108
 QY 879 CTGAGGAACATTAAGTTGAGGTTTACATGCTGTATCAAAAAATATTGCTGCAAA 938
 Db 1109 CTGAGGAACATTAAGTTGAGGTTTACATGCTGTATCAAAAAATATTGCTGCAAA 1168
 QY 939 TGTGTTACGCTACAGTACACCAATTAATGTTGGCAATTCAGGGGCTCAGAGAATCA 998
 Db 1169 TGTGTTACGCTACAGTACACCAATTAATGTTGGCAATTCAGGGGCTCAGAGAATCA 1228
 QY 999 ACCACAAATAGTCTCTCAGATGACCTTGACTAATATACCTCAGCATCTTTATCAGCTTT 1058
 Db 1229 ACCACAAATAGTCTCTCAGATGACCTTGACTAATATACCTCAGCATCTTTATCAGCTTT 1298
 QY 1059 TCCTTGGCACCTAAAGATAATCTCCTCTGACGAGGTTGGAAATATTTTTTCTATCA 1118
 Db 1289 TCCTTGGCACCTAAAGATAATCTCCTCTGACGAGGTTGGAAATATTTTTTCTATCA 1348
 QY 1119 CAGAAGTCATTTGCAAGAAATTTTGACTACTCTGCTTTTAAATTAATACCAAGTTTTCAGG 1178
 Db 1349 CAGAAGTCATTTGCAAGAAATTTTGACTACTCTGCTTTTAAATTAATACCAAGTTTTCAGG 1408
 QY 1179 AACCCCTGAAGCTTTAAGTTTCAATTAATTTTATAACATTTGAGAGAAATCGGATGAGTGA 1238
 Db 1409 AACCCCTGAAGCTTTAAGTTTCAATTAATTTTATAACATTTGAGAGAAATCGGATGAGTGA 1468
 QY 1239 TATGACAGGGCTGGGGCAAGAACAGGGGCACTAGCTGCTTATTTAGTAAATTTAGTGCCC 1298
 Db 1469 TATGACAGGGCTGGGGCAAGAACAGGGGCACTAGCTGCTTATTTAGTAAATTTAGTGCCC 1528
 QY 1299 TCCGTGTTACGCTTAGCCTTTGACCCCTTCTCTTTTGATCCACAAATACATTAACACTCT 1358
 Db 1529 TCCGTGTTACGCTTAGCCTTTGACCCCTTCTCTTTTGATCCACAAATACATTAACACTCT 1588
 QY 1359 GAATTCACATCAATGCTATTTTAAAGTCAATAGATTTTACCTATAAAGTCTTTGACCAAG 1418
 Db 1589 GAATTCACATCAATGCTATTTTAAAGTCAATAGATTTTACCTATAAAGTCTTTGACCAAG 1648
 QY 1419 TAATGTGGTGAATTTTGTATGTTCCCCACATCGCCCCAACCTTCGGGATGCGGGT 1478
 Db 1649 TAATGTGGTGAATTTTGTATGTTCCCCACATCGCCCCAACCTTCGGGATGCGGGT 1708

QY 1479 CAGCAGGTTGAGGTTCACTATTACAAATGTCATAAATCTCATAGAGGTACAGTGCCA 1538
 Db 1709 CAGCAGGTTGAGGTTCACTATTACAAATGTCATAAATCTCATAGAGGTACAGTGCCA 1768
 QY 1539 ATAGATATTCAAAATGTTGCTGTTGACAGAGGATTTTATATCTGAAGACATACACTA 1598
 Db 1769 ATAGATATTCAAAATGTTGCTGTTGACAGAGGATTTTATATCTGAAGACATACACTA 1828
 QY 1599 TTAATAATACCTTAGAGAAAGATTTTGACCTGCTTTAGATAAACTGTGGCAAGAAA 1658
 Db 1829 TTAATAATACCTTAGAGAAAGATTTTGACCTGCTTTAGATAAACTGTGGCAAGAAA 1888
 QY 1659 ATGTAATGAGCAATATATGGAATAAACAACACCTTTGTT 1697
 Db 1889 ATGTAATGAGCAATATATGGAATAAACAACACCTTTGTT 1927

RESULT 8
 ABK35221
 ID -ABK35221 standard; cDNA; 1608 BP.
 XX
 AC ABK35221;
 XX
 AC
 DT 08-MAY-2002 (first entry)
 XX
 DE Human cDNA encoding secreted protein #359.
 XX
 KW Human; secreted protein; gene; ss; nutritional supplement; haemophilia;
 KW viral infection; bacterial infection; fungal infection; diabetes; asthma;
 KW autoimmune disorder; rheumatoid arthritis; multiple sclerosis; tumour;
 KW autoimmune thyroiditis; allergic reaction; neurodegenerative disease;
 KW Alzheimer's disease; Parkinson's disease; liver fibrosis; cancer; ulcer;
 KW coagulation disorder; inflammatory disorder; Crohn's disease; incision;
 KW tissue regeneration; wound healing; burn; haematopoiesis;
 KW myeloid cell deficiency; lymphoid cell deficiency.
 XX
 OS Homo sapiens.
 XX
 PN W0200177288-A2.
 XX
 PD 18-OCT-2001.
 XX
 XX 29-MAR-2001; 2001WO-US10224.
 XX
 PF 06-APR-2000; 2000US-195582P.
 XX
 PR (GEMY) GENETICS INST INC.
 XX
 PA Wong GG, Clark HF, Fichtel K, Agostino MJ, Howes SH, Resnick RJ;
 PI Gullukota K, Graham JR;
 XX
 DR WPI; 2002-179321/23.
 XX
 XX Five hundred and ninety two polynucleotides derived from a variety of
 human tissue sources which encode secreted proteins, useful for
 PT treating immune deficiencies and disorders such as autoimmune disorders
 PT

Claim 1; Page 261-262; 372pp; English.
 XX
 CC The invention relates to 592 polynucleotides which have been derived from
 a variety of human tissue sources and which encode novel secreted
 CC proteins. The polynucleotides can be used as probes for the
 CC identification and isolation of full length cDNA and genomic DNA. The
 CC polynucleotides and proteins can also be used as nutritional supplements.
 CC The proteins are useful in the treatment of various immune deficiencies
 CC and disorders such as viral infections, bacterial infections, fungal
 CC infections, autoimmune disorders (e.g. rheumatoid arthritis, multiple
 CC sclerosis, autoimmune thyroiditis and diabetes) and allergic reactions
 CC and conditions (e.g. asthma). They are also useful for treating
 CC neurodegenerative diseases (e.g. Alzheimer's disease, Parkinson's
 CC disease), liver fibrosis, coagulation disorders (e.g. haemophilia),
 CC inflammatory disorders (e.g. Crohn's disease) and tumours. They are also

CC useful for tissue regeneration, for wound healing and in the treatment of
 CC burns, incisions and ulcers. The proteins are also useful for regulating
 CC hematopoiesis and for treating myeloid or lymphoid cell deficiencies.
 CC Sequences ABK34863-ABK35454 represent polynucleotides of the invention.
 XX
 SQ

Query Match	79.68;	Score 1363.2;	DB 24;	Length 1608;	
Best Local Similarity	99.88;	Pred. No. 0;			
Matches 1365;	Conservative 0;	Mismatches 3;	Indels 0;	Gaps 0;	
Qy 337	CGACAAAGGTGACCTGGGGCCCTCGAGGGAGCGGGGCGAGCATGCCGCCAAAGAGAGAA	396			
Db 1	CGACAAAGGTGACCTGGGGCCCTCGAGGGAGCGGGGCGAGCATGCCGCCAAAGAGAGAA	60			
Qy 397	GGGTACCCGGGGATTCACACAGAACCTTCAGATTGCATTGCTCTCTGGCAACCCA	456			
Db 61	GGGTACCCGGGGATTCACACAGAACCTTCAGATTGCATTGCTCTCTGGCAACCCA	120			
Qy 457	CTTCAGCAATCAGAACAGTGGGATTATCTTCAGCAGTGTTCAGACCAACATTTGGAAACTT	516			
Db 121	CTTCAGCAATCAGAACAGTGGGATTATCTTCAGCAGTGTTCAGACCAACATTTGGAAACTT	180			
Qy 517	CTTTGATGTCTAGTGGTGGGCCCCAGTATCAGGTGTGTATTTCTTCACCTT	576			
Db 181	CTTTGATGTCTAGTGGTGGGCCCCAGTATCAGGTGTGTATTTCTTCACCTT	240			
Qy 577	CAGCATGATGAGGATGAGGATTTGAGGAAGTGTATGTGTACCTTATGCAATGGCAA	636			
Db 241	CAGCATGATGAGGATGAGGATTTGAGGAAGTGTATGTGTACCTTATGCAATGGCAA	300			
Qy 637	CACAGTCTTCAGCATGTACAGCTATGAATGAAGGCAAAATCAGATCATCCAGCAATCA	696			
Db 301	CACAGTCTTCAGCATGTACAGCTATGAATGAAGGCAAAATCAGATCATCCAGCAATCA	360			
Qy 697	TGCTGTGCTGAAGCTAGCTAGCTCTTGGGGAAGCTGTAGCTGAGCTGATTTGTTACG	756			
Db 361	TGCTGTGCTGAAGCTAGCTAGCTCTTGGGGAAGCTGTAGCTGAGCTGATTTGTTACG	420			
Qy 757	CCATGGGGACCAACAGCTTCTCCACCTTTGCAGGATTCCTGCTCTTTGAACTAAGTA	816			
Db 421	CCATGGGGACCAACAGCTTCTCCACCTTTGCAGGATTCCTGCTCTTTGAACTAAGTA	480			
Qy 817	AATATATGACTAGAAATAGCTCCACTTTGGGGAAGCTGTAGCTGAGCTGATTTGTTACG	876			
Db 481	AATATATGACTAGAAATAGCTCCACTTTGGGGAAGCTGTAGCTGAGCTGATTTGTTACG	540			
Qy 877	ATCTGAGGAACATTAAGTTGAGGTTTACATTTGCTGTATTCAAAAAATTTATGGTTGC	936			
Db 541	ATCTGAGGAACATTAAGTTGAGGTTTACATTTGCTGTATTCAAAAAATTTATGGTTGC	600			
Qy 937	AATGTTGTTACGCTACAGGTACACCAATATGTTGGCAATTCAGGGCTCAGAGAAAT	996			
Db 601	AATGTTGTTACGCTACAGGTACACCAATATGTTGGCAATTCAGGGCTCAGAGAAAT	660			
Qy 997	CAACCAAAAATAGCTTCTCAGATGACCTTTGACTAATATATACATCTTTTATCACTC	1056			
Db 661	CAACCAAAAATAGCTTCTCAGATGACCTTTGACTAATATATACATCTTTTATCACTC	720			
Qy 1057	TTTCCTTGGCACCTTAAAGATAATTCCTCTGACGAGGTTGGAATATTTTTTCTAT	1116			
Db 721	TTTCCTTGGCACCTTAAAGATAATTCCTCTGACGAGGTTGGAATATTTTTTCTAT	780			
Qy 1117	CACAGAGTCAATTTGCAAGAAATTTGACTACTCTGCTTTTAAATTAATACCACTTTCA	1176			
Db 781	CACAGAGTCAATTTGCAAGAAATTTGACTACTCTGCTTTTAAATTAATACCACTTTCA	840			
Qy 1177	GGAAACCCCTGAAGTTTAAAGTTTCATTTCTTTTATAACATTTGAGAGATCGGATGAGT	1236			
Db 841	GGAAACCCCTGAAGTTTAAAGTTTCATTTCTTTTATAACATTTGAGAGATCGGATGAGT	900			
Qy 1237	GATATGACAGGGCTGGGCGAAGAACAGGGGCATCTAGCTGCTTATTTAGCTAAATTTAGTGC	1296			

Db 901	GATATGACAGGGCTGGGCGAAGAACAGGGGCATCTAGCTGCTTATTAGCTAATTTAGTGC	960
Qy 1297	CCTCCGTTGTTACAGCTTAGCCCTTTGACCCCTTTCCCTTTTCATCCACAAATACATTAARACT	1356
Db 961	CCTCCGTTGTTACAGCTTAGCCCTTTGACCCCTTTCCCTTTTCATCCACAAATACATTAARACT	1020
Qy 1357	CTGAATTCACATCAATAGCTTATTTTAAAGTCAATAGATTTTATAGCTATAAAGTGTGACC	1416
Db 1021	CTGAATTCACATCAATAGCTTATTTTAAAGTCAATAGATTTTATAGCTATAAAGTGTGACC	1080
Qy 1417	AGTAATGTGGTGTAAATTTTGTGTATGTTTCCCCACATCGCCCCCACTTCGGATGTGGG	1476
Db 1081	AGTAATGTGGTGTAAATTTTGTGTATGTTTCCCCACATCGCCCCCACTTCGGATGTGGG	1140
Qy 1477	GTCAGGAGGTTGAGGTTCACTATTAAACAAATGTCATAAATATCTCATAGAGGTACAGTGC	1536
Db 1141	GTCAGGAGGTTGAGGTTCACTATTAAACAAATGTCATAAATATCTCATAGAGGTACAGTGC	1200
Qy 1537	CAATAGATATTTCAAAATGTTGCATGTTGACCCAGAGGGGATTTTATATCTGAAGAACATACAC	1596
Db 1201	CAATAGATATTTCAAAATGTTGCATGTTGACCCAGAGGGGATTTTATATCTGAAGAACATACAC	1260
Qy 1597	TATTAATAAATACCTTAGAGAAAGATTTTGACCTGGCTTTAGATAAAGTGTGCAAGAA	1656
Db 1261	TATTAATAAATACCTTAGAGAAAGATTTTGACCTGGCTTTAGATAAAGTGTGCAAGAA	1320
Qy 1657	AAATGTAATGAGCAATATATGGAATAAACAACACCTTTGTTTAAAGATA	1704
Db 1321	AAATGTAATGAGCAATATATGGAATAAACAACACCTTTGTTTAAAGATA	1368

RESULT 9

AA161016/c
 ID AA161016 standard; cdna; 1799 BP.

XX AC	AA161016;
XX AC	AA161016;
XX DT	22-OCT-2001 (first entry)
XX XX	Human polynucleotide SEQ ID NO 5005.
XX KW	Human; nontropic; immunosuppressant; cytostatic; gene therapy; cancer;
XX KW	peripheral nervous system; neuropathy; central nervous system; CNS;
XX KW	Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
XX KW	anyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
XX KW	chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
XX KW	leukaemia; ss.
XX OS	Homo sapiens.
XX OS	Homo sapiens.
XX PN	WO200153312-A1.
XX PD	26-JUL-2001.
XX PF	26-DEC-2000; 2000WO-US34263.
XX PR	21-JAN-2000; 2000US-0488725.
XX PR	25-APR-2000; 2000US-052317.
XX PR	09-JUL-2000; 2000US-0598042.
XX PR	19-JUL-2000; 2000US-0620312.
XX PR	03-AUG-2000; 2000US-0653450.
XX PR	14-SEP-2000; 2000US-0662191.
XX PR	19-OCT-2000; 2000US-0693036.
XX PR	29-NOV-2000; 2000US-0727344.
XX PA	(HYSE-) HYSEQ INC.
XX PI	Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;
XX PI	Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J;
XX PI	Zhao QA, Zhou P, Goodrich R, Drmanac RT;
XX DR	WPI; 2001-442253/47.
XX DR	P-PSDB; AAM41860.

xx Novel nucleic acids and polypeptides, useful for treating disorders
 PT such as central nervous system injuries -
 xx
 PS Claim 1; SEQ ID NO 5005; 10078pp; English.
 xx
 CC The invention relates to human nucleic acids (AA157798-AA161369) and
 CC the encoded polypeptides (AA157798-AA161369) with nootropic,
 CC immunosuppressant and cytostatic activity. The polynucleotides are useful
 CC in gene therapy. A composition containing a polypeptide or polynucleotide
 CC of the invention may be used to treat diseases of the peripheral nervous
 CC system, such as peripheral nervous injuries, peripheral neuropathy and
 CC localised neuropathies and central nervous system diseases, such as
 CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
 CC lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
 CC utilisation of the activities such as: Immune system suppression,
 CC Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
 CC and thrombolytic activity, cancer diagnosis and therapy, drug screening,
 CC assays for receptor activity, arthritis and inflammation, leukemias and
 CC C.N.S disorders.
 CC Note: The sequence data for this patent did not form part of the printed
 CC specification.
 xx
 SQ Sequence 1799 BP; 531 A; 389 C; 344 G; 535 T; 0 Other;

Query Match 75.7%; Score 1295.4; DB 22; Length 1799;
 Best Local Similarity 93.6%; Pred. No. 0;
 Matches 1401; Conservative 0; Mismatches 1; Indels 95; Gaps 1;

Qy 303 CCACCTGCTCATCAAGAGCCCAAGGTGAGAGGGGACAAAGGTGACCTGGGGCCCTCGAG 362
 Db 1799 CCATGGTTCATGAAGAGCCCAAGGTGAGAGGGGACAAAGGTGACCTGGGGCCCTCGAG 1740
 Qy 363 GGGAGCGGGGCGAGCATGCCGCCAAAGAGAGAGAGGGGTACCCGGGGATTCCACCCAGAAC 422
 Db 1739 GGGAGCGGGGCGAGCATGCCGCCAAAGAGAGAGGGGTACCCGGGGATTCCACCCAGAAC 1680
 Qy 423 TT----- 424
 Db 1679 TTCAGGCTGGAGTGCAGTGGTGTGATCTTGGCTCACTGCAGGCTCCACCAAGGTTCAAGC 1620
 Qy 425 -----CAGATTGATTCACTGGCTTCTCT 447
 Db 1619 GATTCCTCTTCCCTCAACCTCTGGAGTAGCTGGGATTACAGATTGCTATCTGCTTCTCT 1560
 Qy 448 GGCACCCACCTTCAGCAATCAGAACAGTGGGATTATCTTCAGCAGTGTGGAGACCAACAT 507
 Db 1559 GGCACCCACCTTCAGCAATCAGAACAGTGGGATTATCTTCAGCAGTGTGGAGACCAACAT 1500
 Qy 508 TGGAACTTCTTTGATGTCATGACGTGGTAGATTGGGGCCCGCAGTATCAGGTGTGATTT 567
 Db 1499 TGGAACTTCTTTGATGTCATGACGTGGTAGATTGGGGCCCGCAGTATCAGGTGTGATTT 1440
 Qy 568 CTTCACTTCAGCATGATCAAGCATGAGGATGTTGAGGAGTCTATGCTACCTTATGCA 627
 Db 1439 CTTCACTTCAGCATGATCAAGCATGAGGATGTTGAGGAGTCTATGCTACCTTATGCA 1380
 Qy 628 CAATGGCAACACAGCTTCAGCATGTACAGTATGAAATGAAGGGCAAAATCAGATACATC 687
 Db 1379 CAATGGCAACACAGCTTCAGCATGTACAGTATGAAATGAAGGGCAAAATCAGATACATC 1320
 Qy 688 CAGCAATCATGCTGTGCTGAAGCTAGCCAAAGGGGATGAGGTTTGGCTGCGAATGGGCA 747
 Db 1319 CAGCAATCATGCTGTGCTGAAGCTAGCCAAAGGGGATGAGGTTTGGCTGCGAATGGGCA 1260
 Qy 748 TGGCGCTCTCCATGGGGACCAACAGCTTCTCCACCTTTCAGGATTCCTCTCTTGA 807
 Db 1259 TGGCGCTCTCCATGGGGACCAACAGCTTCTCCACCTTTCAGGATTCCTCTCTTGA 1200
 Qy 808 AACTAAGTAATATATGACTAGACTAGCTTCCACTTGGGGAAGACTTGTAGCTGAGCTCA 867
 Db 1199 AACTAAGTAATATATGACTAGACTAGCTTCCACTTGGGGAAGACTTGTAGCTGAGCTCA 1140

Qy 858 TTTGTTACGATCTGAGGAACATTAAAGTTGAGGGTTTACATTTGCTGTATCAAAAATT 927
 Db 1139 TTTGTTACGATCTGAGGAACATTAAAGTTGAGGGTTTACATTTGCTGTATCAAAAATT 1080
 Qy 928 ATTGTTGCAATGTTTTCAGCTACAGTACACCAATAAAGTTGGACAATTTCAGGGCT 987
 Db 1079 ATTGTTGCAATGTTTTCAGCTACAGTACACCAATAAAGTTGGACAATTTCAGGGCT 1020
 Qy 988 CAGAGAATCAACCAACCAAAATAGTCTTCTCAGATGACCTTGGACTAATAATACATCT 1047
 Db 1019 CAGAGAATCAACCAACCAAAATAGTCTTCTCAGATGACCTTGGACTAATAATACATCT 960
 Qy 1048 TTATCAGTCTTCTTCCCTGGCACCCTAAAGATAAATCTCTCAGCAGGTTGGAAATAT 1107
 Db 959 TTATCAGTCTTCTTCCCTGGCACCCTAAAGATAAATCTCTCAGCAGGTTGGAAATAT 900
 Qy 1108 TTTTCTATCACAGAAGTCATTGTCAAAAGAAATTTTGAAGTACTCTCTTTTAATTAATAC 1167
 Db 899 TTTTCTATCACAGAAGTCATTGTCAAAAGAAATTTTGAAGTACTCTCTTTTAATTAATAC 840
 Qy 1168 CAGTTTTCAGGAACCCCTGAAGTTTAAAGTTCATTATTTTATAACATTTTGAGAGAAAT 1227
 Db 839 CAGTTTTCAGGAACCCCTGAAGTTTAAAGTTCATTATTTTATAACATTTTGAGAGAAAT 780
 Qy 1228 GGATGATGATATGACAGGCGTGGGCAAGAACAGAGGGGCTAGCTGCTTATTAAGTAT 1287
 Db 779 GGATGATGATATGACAGGCGTGGGCAAGAACAGAGGGGCTAGCTGCTTATTAAGTAT 720
 Qy 1288 ATTTAGTCCCTCCCTGTTTCAGCTTTAGCTTTGACCTTTGACCTTTGATCCACAAATAC 1347
 Db 719 ATTTAGTCCCTCCCTGTTTCAGCTTTAGCTTTGACCTTTGACCTTTGATCCACAAATAC 660
 Qy 1348 ATTTAAACTCTGAATTCACATACATGCTATTTTAAAGTCAATAGATTTTAGCTATAAG 1407
 Db 659 ATTTAAACTCTGAATTCACATACATGCTATTTTAAAGTCAATAGATTTTAGCTATAAG 600
 Qy 1408 TCGTTGACCAAGTATGCTGTTGTAATTTTGTATGTTTCCCGCCACATCGCCCCCACTTC 1467
 Db 599 TCGTTGACCAAGTATGCTGTTGTAATTTTGTATGTTTCCCGCCACATCGCCCCCACTTC 540
 Qy 1468 GGATGCGGGTTCAGGAGTTCAGCTTACTTATAAATAATGTCATAAATATCTCATAGAG 1527
 Db 539 GGATGCGGGTTCAGGAGTTCAGCTTACTTATAAATAATGTCATAAATATCTCATAGAG 480
 Qy 1528 GTACAGTCCCAATAGATATTCAAATGTTGCTATGTTGACCCAGAGGATTTTATATCTGAAG 1587
 Db 479 GTACAGTCCCAATAGATATTCAAATGTTGCTATGTTGACCCAGAGGATTTTATATCTGAAG 420
 Qy 1588 AACATACACTATTATAAATACCTTTAGAGAAAGATTTTACCTGGCTTTAGATAAACTG 1647
 Db 419 AACATACACTATTATAAATACCTTTAGAGAAAGATTTTACCTGGCTTTAGATAAACTG 360
 Qy 1648 TGGCAAGAAAATGTAATGAGCAATATATGGAATAAATAACACACCTTTTGTAAAGATA 1704
 Db 359 TGGCAAGAAAATGTAATGAGCAATATATGGAATAAATAACACACCTTTTGTAAAGATA 303

RESULT 10
 AAF94076
 ID AAF94076 standard; DNA; 810 BP.
 XX
 AC AAF94076;
 XX
 DT 23-MAY-2001 (first entry)
 XX
 DE Primer specific for DNA encoding secretory/membrane protein SEQ ID 510.
 XX
 KW Human; secretory protein; membrane protein; vaccine; gene therapy;
 KW rheumatoid arthritis; diabetes; PCR primer; ss.
 XX
 OS Synthetic.
 XX
 PN EP1067182-A2.

XX PD 10-JAN-2001.
XX PF 07-JUL-2000; 2000EP-0114090.
XX PR 08-JUL-1999; 99JP-0194179.
XX PR 11-JAN-2000; 2000JP-0118775.
XX PR 02-MAY-2000; 2000JP-0183766.
XX PA (HELI-) HELIX RES. INST.
XX PI Ota T, Isogai T, Nishikawa T, Kawai Y, Sugiyama T, Hayashi K;
XX DR WPI; 2001-093989/11.
XX Nucleic acids encoding secretory proteins/membrane proteins, useful in
PT gene therapy or as candidate target molecules in drug development -
XX PS Claim 4; SEQ ID 510; 609pp + CD ROM; English.
XX CC This invention relates to nucleic acid sequences AAF93744 - AAF93916
CC which encode human secretory or membrane proteins represented by
CC AAB88317 - AAB88419. Included in the invention are primers
CC AAF93917 - AAF94295 and AAF62232 - AAF62235 which are used to isolate the
CC cDNA sequences of the invention. The invention also includes methods for
CC the production of antibodies directed against the proteins, and cDNA
CC sequences, which can be used in vaccines. The polynucleotide sequences
CC can be used in gene therapy. The polynucleotide sequences and the
CC proteins they encode may be used in the prevention, treatment and
CC diagnosis of diseases associated with inappropriate secretory
CC protein/membrane protein expression. The nucleic acids and complementary
CC sequences may also be used as DNA probes in diagnostic assays
CC (e.g. polymerase chain reactions (PCR)) to detect and quantitate the
CC presence of similar nucleic acid sequences in samples. They may also be
CC used to study the expression and function of secretory proteins/membrane
CC polypeptides and their role in metabolism. The polypeptides may be used
CC as antigens in the production of antibodies against them and in assays to
CC identify modulators (agonists and antagonists) of expression and
CC activity. The antibodies and antagonists may also be used as therapeutic
CC agents to down regulate expression and activity. The antibodies may also
CC be used as diagnostic agents for detecting the presence of the
CC polypeptides in samples (e.g. by enzyme linked immunosorbant assay
CC (ELISA)). Examples of diseases which may be treated include rheumatoid
XX arthritis and diabetes.
SQ Sequence 810 BP; 200 A; 201 C; 218 G; 188 T; 3 other;
Query Match 44.8%; Score 766.6; DB 22; Length 810;
Best Local Similarity 98.9%; Pred. No. 1.3e-212;
Matches 791; Conservative 0; Mismatches 7; Indels 2; Gaps 2;
QY 1 GGCATCTGCCGAGGAGACCCAGCTCCCTGGAGCTCTGCTGCTCTCAGGAGACTCTGA 60
DB 13 GGCATCTGCCGAGGAGACCCAGCTCCCTGGAGCTCTGCTGCTCTCAGGAGACTCTGA 72
QY 61 GGCCTCTGTGAGAAATCATGCTTTGGAGGAGCTCATCTATTGGCAACTGCTGGCTTTGTT 120
DB 73 GGCCTCTGTGAGAAATCATGCTTTGGAGGAGCTCATCTATTGGCAACTGCTGGCTTTGTT 132
QY 121 TTTCCTCCCTTTTTCCTCTGTGTAAGATGAATACATGAGTCTCCACAAACCGGAGGACT 180
DB 133 TTTCCTCCCTTTTTCCTCTGTGTAAGATGAATACATGAGTCTCCACAAACCGGAGGACT 192
QY 181 ACCCCAGACTGCAGTAAGTTGTTCATGGAGACTACAGCTTCGAGCTACCAAGGCC 240
DB 193 ACCCCAGACTGCAGTAAGTTGTTCATGGAGACTACAGCTTCGAGCTACCAAGGCC 252
QY 241 CCTTGGGACCCGGCCCTCTCTGGCAATTCAGGAAACCATGGAACAAATGCAACAATGG 300
DB 253 CCTTGGGACCCGGCCCTCTCTGGCAATTCAGGAAACCATGGAACAAATGCAACAATGG 312
QY 301 AGCCACTGGTTCATGAGGAGCCCAAGGTGAGAAGGGCGACAAAGGTGACCTGGGCGCTCG 360
|||||

DB 313 AGCCACTGGTTCATGAGGAGCCAAAGGTGAGAAAGGGCGACAAAGGTGACCTGGGCGCTCG 372
QY 361 AGGGAGCGGGGGGAGCATGGCCCCCAAGGAGAGAGAGGCTACCCGGGGATTCCACCAGA 420
DB 373 AGGGAGCGGGGGGAGCATGGCCCCCAAGGAGAGAGAGGCTACCCGGGGATTCCACCAGA 432
QY 421 ACTTCAGATTGCAATTCATGCTTCTCTGGCAACCCACTTCAGCAATCAGAACAGTGGGAT 480
DB 433 ACTTCAGATTGCAATTCATGCTTCTCTGGCAACCCACTTCAGCAATCAGAACAGTGGGAT 492
QY 481 TATCTTCAGCAGTGTGTGAGACCAACATTTGGAAACTTCTTTTGATGTCATGACTGGTAGATT 540
DB 493 TATCTTCAGCAGTGTGTGAGACCAACATTTGGAAACTTCTTTTGATGTCATGACTGGTAGATT 552
QY 541 TGGGGCCCCAGTATCAGTGTGTATTTCTTACCTTCAGCATGATGAAGCATGAGGATGT 600
DB 553 TGGGGCCCCAGTATCAGTGTGTATTTCTTACCTTCAGCATGATGAAGCATGAGGATGT 612
QY 601 TCAGGAAGTGTATGTATACCTTTATGCACAATGGCAACACAGTCTTCAGCATGTACAGCTA 660
DB 613 TGAGGAAGTGTATGTATACCTTTATGCACAATGGCAACACAGTCTTCAGCATGTACAGCTA 672
QY 661 TGAATGAAGGGCAAAATCAGATACATCAGCAATCAGTGTGCTGGAAGCTAGCCAAAGG 720
DB 673 TGAATGAAGGGCAAAATCAGATACATCAGCAATCAGTGTGCTGCTGAA-CTAGCCAAAG 731
QY 721 GGATCAGTGTGGCTGCGAATGGGCAATGGGCTCTCCATGGGGACCACCAAGCTTCTC 780
DB 732 GGATCAGTGTGGCTGCGAATGGGCAATGGGCTCTCCATGGGGACCACCAAGCTTCTC 790
QY 781 CACCTTTGCAGGATTCCTGCG 800
DB 791 CACCTTTGCAGGATTCCTGCG 810
RESULT 11
ABK35591
ID ABK35591 standard; DNA; 741 BP.
AC ABK35591;
DT 08-MAY-2002 (first entry)
XX Gene encoding novel human secreted or membrane-associated protein #10.
KW Human; secreted protein; membrane-associated protein; hypertension;
KW inflammatory disorder; neurological disorder; haematopoietic disorder;
KW skeletal developmental disorder; growth abnormality; autoimmune disorder;
KW neurodegenerative disorder; nervous system disorder; bacterial infection;
KW peripheral myelinopathy; viral infection; cancer; obesity; diabetes;
KW hypotension; sexual development disorder; blood disorder; gene; ds.
OS Homo sapiens.
PN WO200204600-A2.
PD 17-JAN-2002.
PF 12-JUL-2001; 2001WO-US21985.
XX 12-JUL-2000; 2000US-218033P.
PR 21-AUG-2000; 2000US-226517P.
XX (SMK) SMITHKLINE BEECHAM CORP.
PA (SMK) SMITHKLINE BEECHAM PLC.
PA (GLAX) GLAXO GROUP LTD.
XX Agarwal P, Cogswell JP, Lai Y, Martensen SA, Rizvi SK, Strum JC;
PI Smith RF, Xiang Z, Xie Q;
XX WPI; 2002-188468/24.
DR P-PSDB; AAU84371.
XX

KW	immunomodulator; anti-inflammatory; cytostatic; neuroprotective; gene;
KW	ss.
XX	Rattus sp.
OS	WO200190357-A1.
FN	29-NOV-2001.
XX	
PD	24-MAY-2001; 2001WO-NZ00099.
XX	
PF	24-MAY-2000; 2000US-20650P.
XX	
PR	25-JUL-2000; 2000US-221232P.
XX	
XX	(GENE-) GENESIS RES & DEV CORP LTD.
PA	
XX	
P1	Watson JD, Strachan L, Sleeman M, Onrust R, Murison JG, Kumble KD
XX	
DR	WPI; 2002-122020/16.
XX	
PT	New polynucleotides and polypeptides encoded by the polynucleotides
PT	isolated from skin cells, useful for treating skin wounds, cancers,
PT	growth and developmental defects, inflammatory diseases, or for
PT	modulating immune responses
XX	
PS	Claim 1; Page 262; 46pp; English.
XX	
CC	The present invention provides the protein and coding sequences of cDNAs
CC	isolated from human, murine and rat skin cell libraries. The sequences
CC	can be used in the development of therapeutic agents useful in the
CC	treatment of skin diseases, including skin wounds, cancer, growth
CC	defects, developmental defects and inflammatory diseases. The proteins
CC	have important roles in the induction of hair growth, cell proliferation
CC	and cell-cell interaction, in maintaining tissue integrity, in wound
CC	healing and in modulating immune responses. The present sequence is a
CC	cDNA of the invention.
XX	
SQ	Sequence 1035 BP; 255 A; 242 C; 298 G; 240 T; 0 other;
	Query Match 40.7%; Score 696.2; DB 24; Length 1035;
	Best Local Similarity 82.8%; Pred No. 5.1e-192;
	Matches 819; Conservative 0; Mismatches 188; Indels 2; Gaps
Qy	33 CTCTGTCTCTTCACAGGAGACTCGAGGCTCTCTTGAGAATCATGCTTTGGAGGCAGC 92
Dd	
Dd	48 CCCATCAGCTTCCC CGGGAGATTCTGCCGATTTGCTACGAGGCACTGTCAGGAGGCAGC 107
Qy	93 TCATCATTTGGCAACTGCTGGCTTTGTTTTTCTCCCTTTTGGCTGTGTCAAGATGAAT 152
Dd	
Dd	108 TCGTGTGGTGGCACCTGCTGGCTTTGCTTTTCTCCCTCCCAATTTGGCTGTGTCAAGATGAAT 167
Qy	153 ACATGGAGTCTCCACAACACGGAGGACTACCCACAGCTGCAGTAAGTGTGTTCATGGAG 212
Dd	
Dd	168 ACATGGAGTCTCCACAAGCTGGAGGACTGCCCCACAGCTGCAGCAAGTGTGCCATGGAG 227
Qy	213 ACTACAGCTTTGAGGCTACC AAGGCCCCCTCGGGCCACCGGGCCCCCTCGGCATTCACG 272
Dd	
Dd	228 ATTATGGATTCCGTGTTACCAAGGGCCCCCTGGAGCCCAAGGTCCTCTGGCATTCACG 287
Qy	273 GAACCATGGAACAATGCGACAATGAGGCACCTGCTCATGAAAGGACCCAAAGGTGAGA 332
Dd	
Dd	288 GAACCATGGAACAATGGAATAACGAGGACCTGGGCCACGAAGGGGSCCAAGGGTGAGA 347
Qy	333 AGGCGCACAAAAGGTGACCTGGGGCCCTCGAGGGGAGCGGGGCACATGCGCCCAAGGAG 392
Dd	
Dd	348 AAGACACAAGGCGACCTGGGGCCCTCGAGGGGAACGGGGGCACATGCGCCCAAGGAT 407
Qy	393 AGAAGGGCTACCCGGGGAATTCACCAAGAACTTCAGATTGCATTTCATGGCTTCTCTGGCAA 452
Dd	
Dd	408 AGAAGGGAATACCAAGGGTGCCACCAAGAGCTGCAGATTGCGTTTCATGGCTTCTTAGCCA 467
Qy	453 CCACCTTCAGCAATCAGAACAGCTGGGATTATCTTCAGCAGTGTGTGAGACCAATTTGGAA 512

Human; rat; mouse; skin cell; skin wound; cancer; growth defect;
developmental defect; inflammatory disease; dermatological; vulnery;

Db 468 CTCACCTCAGCAATCAGAACAGTGCATTATCTTTCAGCAGTCTTCAGACCAACATTGGAA 527
 QY 513 ACTTCTTTGATGTCATGACTGGTAGATTGGGGCCCCAGTATCAGGTGTGTATTTCTTCA 572
 Db 528 ACTTCTTGCATGTCATGACTGGTAGATTGGGGCCCCAGTATCAGGTGTGTATTTCTTCA 587
 QY 573 CTTTCAGCATGATGAAGCATGAGGATGTTGAGGAAGTGTATGTGTATGACCTATGACCAATG 632
 Db 588 CTTTCAGCATGATGAAGCATGAGGATGTTGAGGAAGTGTATGTGTATGACCTATGACCAATG 647
 QY 633 GCAACAGCTCTTCAGCATGATGATGAATGAAGGCAAAATCAGATACATCCAGCA 692
 Db 648 GTAACACGGTCTTCAGCATGATGATGAATGAAGGCAAAATCAGATACATCCAGCA 707
 QY 693 ATCATGCTGCTGAAGTACCAAGGATGAGGATGTTGGCTGCGAATGGCAATGGCG 752
 Db 708 ACCATGCACTGCTGAAGTGGCCAAAGGAGATGAAGTCTGGCTAAGAATGGCAACGGTG 767
 QY 753 CTCCTCATGGGACCAACCAAGCTTCTCCACCTTTGCAAGGATCTGCTCTTTGAAACTA 812
 Db 768 CCTTCATGGGACCAACCAAGCTTCTCCACCTTTGCAAGGATCTGCTCTTTGAAACTA 827
 QY 813 AGTAATATATGACTAGTAATAGCTCCACTTTGGGAAGACTTGTAGCTGAGCT-GATTG 871
 Db 828 AGTGATGAGGAAGTCAAGTATAGCTCCATGCTTAAGGCGATTTGTAGGTGAGCTAGGGTTG 887
 QY 872 TTACGATCTGAGGAACATTAAGTTGAGGTTTACATGCTGTATTCATCAAAATATTG 931
 Db 888 TTAGGATCTGAGGCTGTTGGAGTTG-GGCTTCTATGAGTATTAATGTTTACATG 946
 QY 932 GTTCAATGTTGTCACGCTACAGTACACCAATTAATGTTGCAATTCAGGGGCTCAGA 991
 Db 947 GTCACATGCTTACATCTTAATGGCATACCAATTAATGTTGATGATCTTTAGGGGCTAGGA 1006
 QY 992 AGAATCAACCAAAATAGTCTTCTCAGA 1020
 Db 1007 AGAATCAACCAAGGTAATATCCAGCA 1035

RESULT 14
 AA261633
 ID AA261633 standard; cDNA; 1123 BP.
 XX
 AC AA261633;
 XX
 DT 27-MAR-2000 (first entry).
 XX
 DE cDNA encoding rat skin cell secreted protein, SEQ ID NO:28.
 XX
 KW Skin; dermal papilla; keratinocyte; neonatal foreskin fibroblast;
 KW embryonic skin cell; keratinocyte stem cell; transit amplifying cell;
 KW secreted; transmembrane; inflammation; cancer; neurological disease;
 KW angiogenesis; tumour vascularisation; growth disorder;
 KW developmental disorder; skin wound; hair follicle disorder;
 KW anti-inflammatory; cytostatic; neuroprotective; vulnery; ss.
 OS Rattus sp.
 XX
 XX WO9955865-A1.
 XX
 XX 04-NOV-1999.
 XX
 XX 29-APR-1999; 99WO-N200051.
 XX
 XX 29-APR-1998; 98US-0069726.
 XX
 XX 09-NOV-1998; 98US-0188930.
 XX
 XX (GENE-) GENESIS RES & DEV CORP LTD.
 XX
 XX Strachan L, Sleeman M, Watson JD, Onrust R, Kumble A, Murlison JG;
 XX WPI; 2000-072177/06.
 XX

PT Novel polynucleotides useful for the treatment of various conditions
 PT including wounds and cancer
 PS Claim 1: Page 73; 235pp; English.
 XX
 CC The invention relates to novel nucleic acid sequences derived from rat
 CC dermal papilla, human keratinocytes and neonatal foreskin fibroblasts,
 CC and mouse embryonic skin, keratinocyte stem cells and transit amplifying
 CC cells. Polypeptides of the invention may be used to treat inflammation,
 CC cancer and neurological diseases. The proteins may be used to stimulate
 CC the growth and motility of keratinocytes, to inhibit the growth of
 CC cancer cells, to modulate angiogenesis and tumour vascularisation, to
 CC modulate skin inflammation, to modulate epithelial cell growth and to
 CC inhibit binding of HIV-1 to leukocytes. The invention may also be used
 CC to treat growth and developmental defects, skin wounds and hair follicle
 CC disorders. Sequences AA261606-261832 represent cDNA sequences derived
 CC from several mouse, rat or human skin cell types. Sequences
 CC AA261606-261649, AA261725-261765, AA261802-261811 and AA261826 encode
 CC proteins with an N-terminal signal sequence, indicating that the proteins
 CC are secreted. Sequences AA261650-261668, AA261766-261780, AA261812-261817
 CC and AA261827-261829 encode proteins with one or more putative
 CC transmembrane domains.
 XX
 SQ Sequence 1123 BP; 277 A; 266 C; 321 G; 258 T; 1 other;

Query Match 40.7%; Score 696.2; DB 21; Length 1123;
 Best Local Similarity 82.8%; Pred. No. 5.3e-192;
 Matches 819; Conservative 0; Mismatches 168; Indels 2; Gaps 2;

QY 33 CPTCTCTCTCTCTCAGGAGACTCTGAGGCTCTGTGAGATCATGCTTTCGAGGCGAGC 92
 Db 136 CCATCAGCTTCCCCGGGAGATCTCGCGATTGTTCAGGACCCATGCTCAGAGGCGAGC 195
 QY 93 TCATCTATTGGCAACTGCTGGCTTTTCTCTCCCTTTTTCCTCTGCTGTCAAGATGAAT 152
 Db 196 TCGTCTGGTGGCACTGCTGGCTTTGCTTTCTCCCATTTTGGCTGTCAAGATGAAT 255
 QY 153 ACATGGAGTCTCCCAAAACCGGAGGACTTACCCCGAGACTGCACTGAGTGTCTCATGGAG 212
 Db 256 ACATGGAGTCTCCCAAAACCGGAGGACTTACCCCGAGACTGCACTGAGTGTCTCATGGAG 315
 QY 213 AGTACAGCTTTCGAGGCTACCAAGGCCCTCTGGGCGACCCCTCTCTGCTTCCAG 272
 Db 316 ATTTAGGATTCGCTGTACCAAGGGCCCTCTGGAGCCCGCCAGCTCTCTGCTGCTCCAG 375
 QY 273 GAAACCATGGAAACAATGGCAACAATGGAGCCACTGGTTCATGAAGGAGCAAAAGGTGAGA 332
 Db 376 GAAACCATGGAAACAATGGCAACAATGGAGCCACTGGCCACCAAGGGCGCAAGGTGAGA 435
 QY 333 AGGGCGACAAAGGTGACCTGGGCGCTCGAGGGGAGCGGGGCGAGCATGGCCCCAAGGAG 392
 Db 436 AAGGAGACAAAGGCGACCTGGGCGCTCGAGGGGAGCGGGGCGAGCATGGCCCCAAGGAT 495
 QY 393 AGAAGGGCTACCCGGGGATTCACCAGCAACTTCAGATTCGCTTCTCTCTGCGAA 452
 Db 496 AGAAGGGATACCCGGGGTGCACCAGAGCTGCACATTCGCTTCATGGCTCTCTAGCGA 555
 QY 453 CCCACTTCAGCAATCAGAACAGTGGGATTTATCTTCAGCAGTGTTCAGACCAACATTGGAA 512
 Db 556 CTCACCTTCAGCAATCAGAACAGTGGGATTTATCTTCAGCAGTGTTCAGACCAACATTGGAA 615
 QY 513 ACTTCTTTGATGTCATGACTGTAGATTGGGGCCCCAGTATCAGGTGTGTATTTCTTCA 572
 Db 616 ACTTCTTCGATGTCATGACTGTAGATTGGGGCCCCAGTATCAGGTGTGTATTTCTTCA 675
 QY 573 CTTTCAGCATGATGAAGCATGAGGATGTTGAGGAAGTGTATGTGTATGACCTATGACCAATG 632
 Db 676 CTTTCAGCATGATGAAGCATGAGGATGTTGAGGAAGTGTATGTGTATGACCTATGACCAATG 735
 QY 633 GCAACACAGCTTTCAGCATGATGATGAATGAAGGCAAAATCAGATACATCCAGCA 692
 Db 736 GTACACAGCTTTCAGCATGATGATGAATGAAGGCAAAATCAGATACATCCAGCA 795

KW	Rat; skin cell; cytostatic; antiinflammatory; anti-HIV;
KW	neotropic; neuroprotective; vulnerary; immunomodulatory; vaccine;
KW	keratinocyte growth stimulation; cancer; angiogenesis inhibition;
KW	inflammation; neurological disease; ss.
XX	
XX	Rattus sp.
XX	
XX	WO200069884-A2.
XX	
PD	23-NOV-2000.
XX	
PF	15-MAY-2000; 2000WO-NZ00075.
XX	
PR	14-MAY-1999; 99US-0312283.
XX	
XX	(GENE-) GENESIS RES & DEV CORP LTD.
PA	
PI	Watson JD, Strachan L, Onrust R, Sleeman M, Kumble KD, Murison JG;
XX	
XX	WPI: 2001-007495/01.
DR	P-PSDB; AAB55958.
DR	
XX	
PT	New isolated polynucleotide used in the identification of genetic
PT	disorders and encoding polypeptides used for treating inflammatory
PT	disease, cancer and neurological diseases
XX	
XX	Claim 1; Page 176-177; 352pp; English.
PS	
XX	
CC	The present polynucleotide encodes a polypeptide which is expressed in
CC	mammalian skin cells. The polypeptide is useful for stimulating
CC	keratinocyte growth and motility, inhibiting the growth of cancer cells,
CC	modulating angiogenesis, inhibiting angiogenesis and vascularisation of
CC	tumours, modulating skin inflammation, stimulating the growth of
CC	epithelial cells, inhibiting the binding of human immunodeficiency virus
CC	(HIV)-1 to leukocytes, and treating inflammatory disease, cancer and
CC	neurological diseases. The polynucleotide can be used as a marker, in
CC	the identification of genetic disorders, and for the design of
CC	oligonucleotides for examining expression patterns.
XX	
XX	Sequence 1123 BP: 277 A: 266 C: 321 G: 258 T: 1 other:

Query Match	40.7%	Score	696.2	DB	22	Length	1123		
Best Local Similarity	82.0%	Pred.	No. 5.3e-192						
Matches	819	Conservative	0	Mismatches	168	Indels	2	Gaps	2

QY	33	CTCTGCTGCTTCTTCACGGGAGACTCTGAGGCTCTGTTGAGAAATCATGCTTTGGAGGCGAG	92
Db	136	CCCATCAGCTTCCCGGGGAGATTCTGCGGATTTGTCTACGAGCCATGCTCAGGAGGCGAGC	195
QY	93	TCATCTATTGCGAACTGCTGGCTTTGTGTTTTTCCCTCCCTTTTGGCTGTGTCAAGATGAAT	152
Db	196	TCGTCTGGTGGCACTGCTGGCTTTGTGTTTTCCTCCCATTTTGCCTGTGTCAAGATGAAT	255
QY	153	ACATGGAGTCTCCACAACCGGAGGACTACCCACAGACTGCACGTAAAGTTGTTCATGGAG	212
Db	256	ACATGGAGTCTCCACAAGCTGGAGGATGCCCCCAGACTGCAGCAAGTTGTGCCATGGAG	315
QY	213	ACTACAGCTTTCGAGGCTACCAAGGCCCCCCCTGGGCCACCGGGCCCTCTCGCATTTCCAG	272
Db	316	ATTATGGATTTCCGTGGTTACCAAGGGCCCCCTGGACCCCGAGGTCCTCTCGCATTTCCAG	375
QY	273	GAACCATGGAACAANTGGCAACAATGGAGCCACTGGTCATGATGAGGAGCCAAAGGTCGAGA	332
Db	376	GAACCATGGAACAANTGGAAATTAACGAGGACCTGGCCACGAAAGGGGCCAAGGGTGAGA	435
QY	333	AGGCGCAACAAGGTGACCTGGGGCTCTCGAGGGGAGCGGGGACGATGGCCCCCAAGGAG	392
Db	436	AGGAGACAAGGCGACTTGGGGCTCTGAGGGGAACGGGGGACGATGGCCCCCAAGGAT	495
QY	393	AGAAGGCTACCCGGGGATTCCACCAAGCAATTCAGATTGCATTTTCATGGCTTCTCTGGCAA	452
Db	496	AGAAGGATACCCAGGGGTGCCACAGACTGCAAGTTGCAGATTCGCTTCATGGCTTCTTAGCGA	555

Qy	453	CCCACCTTCAGCAATCAGAACAAGTGGGATTATATCTTCAGCAGATGTTCAGACCACAACATTTGGAA	512
Db	556	CTCACCTTCAGCAATCAGAACAAGTGGCATTTATCTTCAGCAGATGTTCAGACCACAACATTTGGAA	615
Qy	513	ACTTCTTTTGATGCATGACACTGGTAGATTTTGGGGCCCCCAGTATCAGGTGCTGTATTCTTCTCA	572
Db	616	ACTTCTTTCGATGTCATGACTGGTAGATTTTGGGGCCCCCGTATCAGGCCGTGTAATTTCTTCA	675
Qy	573	CCTTCAGCATGATGAAGCATGAGGATGTTTGAGGAAGTGTATGTGTACCTTATGCAACAATG	632
Db	676	CCTTCAGCATGATGAAGCATGAGGACGTGGAGGAAGTGTATGTGTACCTTATGCAACAATG	735
Qy	633	GCAACACAGTCTTCAGCATGTACAGCTATGAAATGAAGGGCAAATCAGATACATCCACGA	692
Db	736	GTAACACGGTGTTCAGCATGTACAGCTATGAAACAAAGGAAAAATCAGATACATCCACGA	795
Qy	693	ATCATGCTGTCTGAAGCTAGCCAAAAGGGGATGAGGTTTGGCTGCGAATGGGCAATGGCG	752
Db	796	ACCATGCAAGTCTGAAGTGTGGCCAAAAGGAGATGAAGTCTGGCTAAGAATGGGCAACGGTG	855
Qy	753	CTCTCCATGGGGACCACCAACGCTTCTCCACCTTTTGCAGGATTTCTGCTCTTTGAAACTA	812
Db	856	CCCTCCATGGGGACCACCACGCTTCTTACCTTCGAGGCTTCTGCTTTTTGAAACTA	915
Qy	813	AGTAAATATATGACTAGAATAGCTCCACCTTTTGGGGAAGACTTTGTAGCTCAGCT-GATTG	871
Db	916	AGTGATCAGGAAGTCAGGATAGCTCCATGCTTAAGGGCGATTTGTAGGTGACGTAGGGTTG	975
Qy	872	TTAGCATCTGAGGAACAATTAAGTTGAGGGTTTTACATTTCTGTATTCAAAAAATATTATG	931
Db	976	TTAGGATCTGAGGGGTGTTGSAGTTG-GGCTTCTCTATGGAGTATTTAACTGTTACATTG	1034
Qy	932	GTTCCAATGTTGTTTCAGCGTCACAGSTPACACCAATAATGTTGGACAATTCAGGGGCTCAGA	991
Db	1035	GTCACACTGCTACTCATTCATATGGCATACCAATATATGTTGGTACTTTAGGGGCTAGGA	1094
Qy	992	AGAAATCAACCAAAAAATAGTCTTCTCAGA	1020
Db	1095	AGAAATCAACCAACAGGTAATATTTCCACAGA	1123
RESULT	18		
ABL34718	ID	ABL34718 standard; cdNA; 1123 BP.	
XX	AC	ABL34718;	
XX	DT	04-APR-2002 (first entry)	
XX	DE	Rat cDNA isolated from skin cells SEQ ID NO: 28.	
KW	Human; rat; mouse; skin cell; skin wound; cancer; growth defect; developmental defect; inflammatory disease; dermatological; vulnerary; immunomodulator; anti-inflammatory; cytostatic; neuroprotective; gene; ss.		
OS	Rattus sp.		
XX	PN	WO200190357-A1.	
XX	PD	29-NOV-2001.	
PF	PE	24-MAY-2001; 2001WO-NZ00099.	
XX	PR	24-MAY-2000; 2000US-206650P.	
XX	PA	(GENE-) GENESIS RES' & DEV CORP LTD.	
PI	Watson JD, Strachan L, Sleeman M, Onrust R, Murison JG, Kumble KD		
DR	WPI; 2002-122020/16.		

QY 33 CTCGCTCTCTCTCAGGAGGAGCTCTGAGGCTCTCTTGTGAGATCATGCTTTGGAGGCGAC 92
 DB 136 CCCATCAGCTTCCCGGGGAGATTCTGCGGATTTGTACGAGCCATGCTCAGGAGGCGAC 195
 QY 93 TCATCTATTGGCACTGCTGGCTTTGTTTCCCTCCCTCTTGTGCTGCTGCTCAAGATGAAT 152
 DB 196 TCGTCTGGTGGACCTGCTGCTTTGCTTTCTCTCCCAATTTGCTGCTGTCAAGATGAAT 255
 QY 153 ACATGGAGCTCTCCACAACCGGAGGAGCTACCCAGAGCTGCAAGTAAAGTGTGCTATGGAG 212
 DB 256 ACATGGAGCTCTCCACAAGCTGGAGGAGTGGCCAGAGCTGCGAGCAAGTGTGCTCCATGGAG 315
 QY 213 ACTACAGCTTTCGAGGCTTACCAAGGCCCTCTGGGCCACCGGGCCCTCTGCGCATTCAG 272
 DB 316 ATATGAGATTCGCTGTTTACCAAGGGCCCTTGGACCCCGAGGCTCTCTGCGCATTCAG 375
 QY 273 GAAACATGGAACAATGGCAACATGAGCCACTGGTTCATGAAGGAGCCAAAGGTGAGA 332
 DB 376 GAAACATGGAACAATGGAATAACGAGGAGCCACTGGCCACCAAGGGCCCAAGGTGAGA 435
 QY 333 AGGCGCAACAAGGTGAGCTGGGGCTTCGAGGGAGCGGGGCGAGCATGGCCCCCAAGGAG 392
 DB 436 AAGGAGACAAGGCGAGCTGGGGCTTCGAGGGAGCAAGGGGCGAGCATGGCCCCCAAGGAT 495
 QY 393 AGAAGGCTACCCGGGGATTCACACAGAACTTCAGATTGCAATTCATGCTTCTCTGGCAA 452
 DB 496 AGAAGGATACCCAGGGGTGCGACAGAGCTGCAGATTGCGTTTCATGCTTCTAGGCGA 555
 QY 453 CCCACTTCAGCAATCAGAACATGGGATATCTTCAGCAGTGTTCAGACCAACATTTGAA 512
 DB 556 CTCACCTTCAGCAATCAGAACATGGGATATCTTCAGCAGTGTTCAGACCAACATTTGAA 615
 QY 513 ACTCTTTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 572
 DB 616 ACTCTTTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 675
 QY 573 CTTTCAGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 632
 DB 676 CTTTCAGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 735
 QY 633 GCAACAGTCTTCAGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 692
 DB 736 GCAACAGTCTTCAGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 795
 QY 693 ATCATGCTGCTGAAGTACCAAGGGGATGAGGTTGGCTGCGAATGGCAATGGCG 752
 DB 796 ACCATGCACTGAAGTGGCCCAAGGAGATGAAGTCTGGCTAAGAAATGGCAAGGCTG 855
 QY 753 CTCTCATGGGGACCAACCAAGCTTCTCCACCTTTGCGAGGATTCCTGCTCTTTGAACATA 812
 DB 856 CCTTCATGGGGACCAACCAAGCTTCTCTACCTTCGAGGCTTCTGCTCTTTGAACATA 915
 QY 813 AGTAATATATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 871
 DB 916 AGTATGAGGAGTACAGTACCTGCTTAAGGCGGATTTGTAGTGAAGTGAAGTGAAGTGAAG 975
 QY 872 TTACATCTGAGGAACATTAAGTTGAGGTTTACATTTGATGATGATGATGATGATGATGATGAT 931
 DB 976 TTAGATCTGAGGGGTGTTGGAGTTG-GGCTCTCTCTATGGAGTATTTAACTCTTACATTTG 1034
 QY 932 GTTGCAATGTTCTTCACGCTACAGTACCAACATTAATGTTGACAAATTCAGGGGCTCAGA 991
 DB 1035 GTCACATGCTACT 1094
 QY 992 AGAATCAACCAACAAATAGTCTCTCTCAGA 1020
 DB 1095 AGAATGACCAACAGGTAATATCCACAGA 1123
 RESULT 20
 AAC64064
 ID AAC64064 standard; DNA; 1117 BP.

XX AAC64064;
 AC 19-FEB-2001 (first entry)
 DT Mouse zacr2p2 DNA, SEQ ID NO:11.
 XX
 DE Mouse zacr2p2; adipocyte complement related protein homologue;
 KW ACRP30; C1q domain; collagen-like domain; energy balance modulation;
 KW cellular metabolism; metabolic disorder; obesity; anorexia;
 KW antimicrobial agent; infection; platelet aggregation inhibition;
 KW adhesion; activation; vascular injury; antibacterial; antiviral;
 KW human zacr3p3 homologue; ds.
 XX
 OS Mus musculus.
 OS WO200063377-A1.
 PN 26-OCT-2000.
 PD 19-APR-2000; 2000WO-US10454.
 XX 20-APR-1999; 99US-0294943.
 PR (ZYMO) ZYMOGENETICS INC.
 PA Piddington CS, Bishop PD;
 PI WPI; 2000-665243/64.
 XX P-PSDB; AAB29582.
 DR Novel zacr3p3 polypeptides used to treat or prevent bacterial or viral
 PT infections, for wound healing, improving blood flow, and to analyze
 PT energy efficiency in mammals -
 XX
 PS Disclosure; Page 115-117; 123pp; English.
 XX
 CC The invention relates to the human zacr3p3 protein (AAB29580) and to
 CC nucleic acids which encode it (AAC64058, AAC64063). Zacr3p3 is a homologue
 CC of adipocyte complement related protein (ACRP30) and contains a
 CC collagen-like domain comprising Gly-Xaa-Xaa or Gly-Xaa-Pro repeats, and a
 CC C-terminal C1q domain comprising 10 beta-strands. The zacr3p3 gene is
 CC located on chromosome 5p12. The invention also relates to zacr3p3
 CC fragments, fusion proteins containing zacr3p3 polypeptides,
 CC zacr3p3-specific antibodies, expression constructs and host cells
 CC comprising zacr3p3 nucleic acids, and methods of recombinant production of
 CC zacr3p3. Human zacr3p3, and its agonists and antagonists may be used in the
 CC study and modulation of cellular metabolism and energy balance in
 CC mammals, and may therefore be used to treat disorders such as obesity and
 CC anorexia, and conditions associated with these disorders. Due to its C1q
 CC like domain, zacr3p3 and zacr3p3-containing fusion proteins may be useful
 CC as antimicrobial agents, promoting lysis or phagocytosis of infectious
 CC organisms such as bacteria or viruses. Zacr3p3, its fragments, fusion
 CC proteins, antibodies and activity modulators may also be used to inhibit
 CC collagen-induced platelet aggregation, adhesion, or activation, and may
 CC therefore have potential for promoting blood flow within the vasculature
 CC of a mammal e.g., to treat injury to the vasculature or other collagenous
 CC tissue. Human zacr3p3 and its antibodies may additionally be used to study
 CC dimerisation and oligomerisation. The present sequence represents DNA
 CC encoding mouse zacr2p2, a homologue of human zacr3p3.
 XX
 SQ Sequence 1117 BP; 284 A; 272 C; 293 G; 268 T; 0 other;
 Query Match 40.6%; Score 695.8; DB 21; Length 1117;
 Best Local Similarity 85.5%; Pred. No. 6.9e-192;
 Matches 786; Conservative 0; Mismatches 132; Indels 1; Gaps 1;
 QY 72 GAATCATGCTTTGGAGGAGGCTCATCTATTGGCAACTGCTGGCTTTGTTTCTCCCTT 131
 DB 106 GAGCCATGCTCGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 165
 QY 132 TTTGCTGTGTCAAGATGAATGAGTGTCTCCCAACACCGGAGGAGGAGGAGGAGGAGGAGGAG 191
 ID AAC64064 standard; DNA; 1117 BP.

Db 166 TTTGCTGTGTCAAGATGATGAGTCTCCACAAGCTGGAGGACTGCCCCAGACT 225
 Qy 192 CGAGTAAGTGTGTGTCATGAGACTACAGCTTTTCGAGGCTTACCAAGGCCCTTGGGCCAC 251
 Db 226 GCAGCAAGTGTGTCATGAGATTTGCTGTTTACCAAGGCCCTTGGGCCACTC 285
 Qy 252 CGGGCCCTCTGCGCATTCAGGAACCATGGAACAAATGGCAACATGAGCACTGTGTC 311
 Db 286 CAGGTCTCTGCGCATTCAGGAACCATGGAACAAATGGCAACATGAGCACTGTGTC 345
 Qy 312 ATGAAGGAGCCCAAGGTCAGAGGCGGACAAAGGTGACCTGGGGCTCGAGGGGAGCGGG 371
 Db 346 ATGAAGGGGCCAAAGGTGAGAAAGGAGAGCAAAAGGCGCACTAGGCGCTCGAGGAGAACGG 405
 Qy 372 GGCACATGGCCCCAAAGGAGAGAGGCTTACCCGGGATTCACCAAGCACTTCAGATTG 431
 Db 406 GGCAGCATGGCCCCAAAGGAGAGAGGCTTACCCGGGATTCACCAAGCACTTCAGATTG 465
 Qy 432 CATTTCATGGCTTCTCTGCAACCCCACTTCAGCAATCAGCAAGTGGGATTTATCTTCAGCA 491
 Db 466 CATTTCATGGCTTCTCTGCAACCCCACTTCAGCAATCAGCAAGTGGGATTTATCTTCAGCA 525
 Qy 492 GTGTTGAGACCAACATTCGAACTTCTTTGATGTCATGACTGGTGTAGATTTGGGCCCCAG 551
 Db 526 GTGTTGAGACCAACATTCGAACTTCTTCGATGTCATGACTGGGAGATTTGGGCCCCCG 585
 Qy 552 TATCAGGTGTGATTTCTTCACCTTCAGCATGATGAACCATGAGATTTGAGGAAGTGT 611
 Db 586 TATCAGGTGTGATTTCTTCACCTTCAGCATGATGAACCATGAGGACGTAGAGGAAGTGT 645
 Qy 612 ATGTCTACCTTATGCAACATGCAACACAGTCTTCAGCATGTACAGCTATGAATGAAGG 671
 Db 646 ATGTCTACCTTATGCAACATGCAACACAGTCTTCAGCATGTACAGCTATGAATGAAGG 705
 Qy 672 GCAATCAGATACATCCAGCAATCAGTGTGCTGAAGCTAGCCCAAGGGGATGAGGTTT 731
 Db 706 GAAATCAGATACATCCAGCAACCATGCAAGTGTGAAGTTCGCCAAGGAGATGAAGTCT 765
 Qy 732 GGCTCGCAATGGCAATGGCGCTCTCCATGGGGACCACCAAGCTTCTCCACCTTTGCGAG 791
 Db 766 GGCTGAAGATGGCAAGCGGCTCTCCACGGGGACCACCAAGCTTCTCCACCTTTGCGAG 825
 Qy 792 GATTCCTGCTCTTTGAACTAAGTAAATATATGACTAGAATAGCTCCACTTTGGGGAAGA 851
 Db 826 GCTTCTGCTCTTTGAACTAAGTAAATATATGACTAGAATAGCTCCACTTTGGGGAAGA 885
 Qy 852 CTGTTAGCTGAGCT-GATTCTTACGATCTGAGGAACATTAAGTTGAGGTTTACATTT 910
 Db 886 TTTATAGCTGAGCTAGGCTTGTAGGATATGAAGGATCTTGAAGTCGGGGTCTCTTATG 945
 Qy 911 GCTGATTTCAAAAATTTATGTTGCAATGTTGTTGCACTTACAGCTTACAGCAATAATGT 970
 Db 946 GAGCATTTAAGTGTGTCATGCTCAGCTGCTACTTCTTAATGGCATACCAATAATGT 1005
 Qy 971 TGGACAATTCAGGGGCTCA 989
 Db 1006 TGGATGCTTACGGGGCTCA 1024

RESULT 21
 ID ABK35590
 XX ABK35590 standard; DNA; 960 BP.
 AC ABK35590;
 XX
 DT 08-MAY-2002 (first entry)
 XX Gene encoding novel human secreted or membrane-associated protein #9.
 DE Human; secreted protein; membrane-associated protein; hypertension;
 KW inflammatory disorder; neurological disorder; haematopoietic disorder;
 KW skeletal developmental disorder; growth abnormality; autoimmune disorder;
 KW neurodegenerative disorder; nervous system disorder; bacterial infection;

KW peripheral myelinopathy; viral infection; cancer; obesity; diabetes;
 XX hypotension; sexual development disorder; blood disorder; gene; ds.
 OS Homo sapiens.
 PN WO200204600-A2.
 XX 17-JAN-2002.
 PD 12-JUL-2001; 2001WO-US21985.
 PF 12-JUL-2000; 2000US-218033P.
 PR 21-AUG-2000; 2000US-226517P.
 XX (SMIK) SMITHKLINE BEECHAM CORP.
 PA (SMIK) SMITHKLINE BEECHAM PLC.
 PA (GLAX) GLAXO GROUP LTD.
 XX Agarwal P, Cogswell JP, Lai Y, Martensen SA, Rizvi SK, Strum JC;
 PI Smith RF, Xiang Z, Xie Q;
 XX WPI; 2002-188468/24.
 DR P-PSDB; AAU84370.
 XX Novel secreted and membrane-associated polypeptides and polynucleotides
 encoding the polypeptides, for preventing, treating and ameliorating
 cancers, mental or sexual developmental disorders, and malignant tumours
 Claim 2; Page 106; 151pp; English.
 XX The present invention relates to the isolation of novel human secreted
 or membrane-associated proteins and the genes encoding them. The
 sequences of the invention are useful for treating, preventing and
 ameliorating various diseases such as inflammatory disorders (e.g.
 asthma), neurological disorders (e.g. dementia), haematopoietic
 disorders, skeletal developmental disorders, growth abnormalities,
 neurodegenerative disorders (e.g. Huntington's disease), nervous system
 disorders, autoimmune disorders (e.g. rheumatoid arthritis),
 peripheral myelinopathies, viral and bacterial infections,
 alpha-mannosidosis, diabetes, cancers, malignant tumours, delirium,
 hypotension, obesity, bulimia, anorexia, manic depression, delirium,
 mental retardation, Tourette's syndrome, schizophrenia, growth, mental
 or sexual development disorders, and dysfunctions of the blood cascade
 system including those leading to stroke. ABK35582-ABK35609 represent
 the genes encoding the novel human secreted or membrane-associated
 proteins of the invention.
 XX Sequence 960 BP; 261 A; 232 C; 262 G; 205 T; 0 other;

Query Match 38.5%; Score 659; DB 24; Length 960;
 Best Local Similarity 100.0%; Pred. No. 3.3e-181;
 Matches 659; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 159 AGTCTCCACAACCGGAGGACTACCCCGAGCTGAGTAAGTGTGTCATGGAGACTACA 218
 Db 302 AGTCTCCACAACCGGAGGACTACCCCGAGCTGAGTAAGTGTGTCATGGAGACTACA 361
 Qy 219 GCTTTTCGAGGCTACCAAGGCCCTTGGGCCACCGGGCTCTCTGGCATTCAGGAAACC 278
 Db 362 GCTTTTCGAGGCTACCAAGGCCCTTGGGCCACCGGGCTCTCTGGCATTCAGGAAACC 421
 Qy 279 ATGGAACAATGGCAACAATGAGGCACTGTGTCATGAAGGAGCCAAAGTGAAGAGGCG 338
 Db 422 ATGGAACAATGGCAACAATGAGGCACTGTGTCATGAAGGAGCCAAAGTGAAGAGGCG 481
 Qy 339 ACAAGGTTGACCTGGGGCTCGAGGGGAGCGGGGACGATGGCCCCAAAGAGAGAGG 398
 Db 482 ACAAGGTTGACCTGGGGCTCGAGGGGAGCGGGGACGATGGCCCCAAAGAGAGAGG 541
 Qy 399 GCTACCCGGGATTCACCAAGCAATTCAGATTGCAATTCATGGCTTCTCTGCAACCCACT 458
 Db 542 GCTACCCGGGATTCACCAAGCAATTCAGATTGCAATTCATGGCTTCTCTGCAACCCACT 601

QY 459 TCAGCAATCAGAACAGTGGGATTATCTTCAGCAGTGTTCAGACCAACATTCGAACTCT 518
DB 602 TCAGCAATCAGAACAGTGGGATTATCTTCAGCAGTGTTCAGACCAACATTCGAACTCT 661
QY 519 TTGATGTCATGACTGGTATGTTGGGGCCCAAGTATCAGGTGTGTTTCTTCACTTCA 578
DB 662 TTGATGTCATGACTGGTATGTTGGGGCCCAAGTATCAGGTGTGTTTCTTCACTTCA 721
QY 579 GCATGATGAGCATGAGATGTTGAGGAAGTGTATGTGTACCTTATGACATGCGACACA 638
DB 722 GCATGATGAGCATGAGATGTTGAGGAAGTGTATGTGTACCTTATGACATGCGACACA 781
QY 639 CAGTCTTCAGCATGATGATGAAATGAAGGCAATTCAGATACATCCAGCAATCATG 698
DB 782 CAGTCTTCAGCATGATGATGAAATGAAGGCAATTCAGATACATCCAGCAATCATG 841
QY 699 CTGTGCTGAAGCTAGCCAAAGGGGATGAGTTTGGCTGCGAATGGCGCTCTCC 758
DB 842 CTGTGCTGAAGCTAGCCAAAGGGGATGAGTTTGGCTGCGAATGGCGCTCTCC 901
QY 759 ATGGGACCAACCAAGCTCTCCACCTTTCAGGATTCCTGCTCTTTGAACCTAAGTAA 817
DB 902 ATGGGACCAACCAAGCTCTCCACCTTTCAGGATTCCTGCTCTTTGAACCTAAGTAA 960

RESULT 22
AAC64063
ID AAC64063 standard; DNA; 738 BP.
XX
AC AAC64063;
XX
DT 19-FEB-2001 (first entry)
XX
DE Human zacr3p3 degenerate DNA, SEQ ID NO:10.
XX
KW Human zacr3p3; adipocyte complement related protein homologue;
KW ACRP30; C1q domain; collagen-like domain; energy balance modulation;
KW cellular metabolism; metabolic disorder; obesity; anorexia;
KW antimicrobial agent; infection; platelet aggregation inhibition;
KW adhesion; activation; vascular injury; antibacterial; antiviral; ds.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200063377-A1.
XX
PD 26-OCT-2000.
XX
PF 19-APR-2000; 2000WO-US10454.
XX
PR 20-APR-1999; 99US-0294943.
XX
PA (ZYMO) ZYMOGENETICS INC.
XX
PI Piddington CS, Bishop PD;
XX
DR WPI; 2000-665243/64.
XX
PT Novel zacr3p3 polypeptides used to treat or prevent bacterial or viral
PT infections, for wound healing, improving blood flow, and to analyze
PT energy efficiency in mammals -
XX
PS Claim 10; Page 115; 123pp; English.
XX
CC The invention relates to the human zacr3p3 protein (AAB29580) and to
CC nucleic acids which encode it (AAC64058, AAC64063). Zacr3p3 is a homologue
CC of adipocyte complement related protein (ACRP30) and contains a
CC collagen-like domain comprising Gly-Xaa-Xaa or Gly-Xaa-Pro repeats, and a
CC C-terminal C1q domain comprising 10 beta-strands. The zacr3p3 gene is
CC located on chromosome 5p12. The invention also relates to zacr3p3
CC fragments, fusion proteins containing zacr3p3 polypeptides,
CC zacr3p3-specific antibodies, expression constructs and host cells

comprising zacr3p3 nucleic acids, and methods of recombinant production of
zacr3p3. Human zacr3p3, and its agonists and antagonists may be used in the
study and modulation of cellular metabolism and energy balance in
mammals, and may therefore be used to treat disorders such as obesity and
anorexia, and conditions associated with these disorders. Due to its C1q
like domain, zacr3p3 and zacr3p3-containing fusion proteins may be useful
as antimicrobial agents, promoting lysis or phagocytosis of infectious
organisms such as bacteria or viruses. Zacr3p3, its fragments, fusion
proteins, antibodies and activity modulators may also be used to inhibit
collagen-induced platelet aggregation, adhesion, or activation, and may
therefore have potential for promoting blood flow within the vasculature
of a mammal e.g., to treat injury to the vasculature or other collagenous
tissue. Human zacr3p3 and its antibodies may additionally be used to study
dimerisation and oligomerisation. The present sequence represents a
degenerate DNA sequence encoding human zacr3p3.

XX
SQ Sequence 738 BP; 130 A; 74 C; 145 G; 99 T; 290 other;

Query Match 31.8%; Score 544.2; DB 21; Length 738;
Best Local Similarity 60.7%; Pred. No. 7.9e-148;
Matches 448; Conservative 165; Mismatches 125; Indels 0; Gaps 0;

QY 77 ATGCTTTGGAGGCGAGCTCATCTATTGGCACTGCTGCTTTTCTTCTCCCTTTTTC 136

DB 1 ATGVTNTGCGNCARYTNATHAVTGGCARVTNTNGCNYTNTTYYTNTCCNTTYTG 60

QY 137 CTGTGTCNAGATGATACATGAGTCTCCACAAACCGGAGGACTACCCAGAGTGCAGT 196

DB 61 YTNTRYCARGAYGARTAYATGGARNSNCNCARACNGNGNGNYTNCNCNCNGAYTYGWSN 120

QY 197 AAGTGTGTCATGAGACTACAGCTTTTCGAGGCTACCAAGGCCCTCCCTGGCCACCGGC 256

DB 121 AARTGYGYCAYGGNGAYTAYWSNTTYMGNGNTAYCARGGNCNCNGCNCNCNGN 180

QY 257 CCTCTGCTGATCCAGGAAACCATGGAAACATGGCAACATGGAGCCACTGGTGCATGAA 316

DB 181 CCNCCNGNTHCCNGGNAAYCAYGGNAAYAYGNAAYAYGGNGCNCACNGNCAYCAR 240

QY 317 GGACCCAAAGTGTGAGAGGCGACAAAGTGCACCTGGGCGCTCGAGGCGCGGGGCGAG 376

DB 241 GGNGCNAARGNGARAARGNGAYTNGGNGGAYTNGGNGGNGGNGGNGGNGCAR 300

QY 377 CATGGCCCCAAGAGAGAGGCTATCCCGGGGATTCACCCAGAGACTTCAGATTGCATTC 436

DB 301 CAYGNCNNAARGNGARAARGNTAYCCNGSNATHCCNCNCNGARYTNCARATHGCNTTY 360

QY 437 ATGGCTTCTCTGGCAACCCACTTCAGCAATCAGAACAGTGGGATTCAGCAGTGT 496

DB 361 ATGGCNSNNTNGCNCACNCAVTTYWSNAAYCARAAYWSNGNATHATHTTYWSNWSN 420

QY 497 GAGACCAATGGAAGTCTCTTGTGATGTCATGACTGATGATGTTGGGCCCCAGTATCA 556

DB 421 GARACNAIATHGGNAAYTITTYGATGATGACNGNGMNTTYGGNGCNCNGTNN 480

QY 557 GGTGTATTTCTTCCACTTCAGCATGATGAAGCATGAGGATGTTGAGGAAGTGTATGTG 616

DB 481 GNGTNTATYTTYACNTTYWSNATGATGAARCAAYGARGAYTNGARGSTNTAYGTN 540

QY 617 TACCTTATGCAATGGCAACACAGTCTTACAGATGTACAGCTATGAATGAAGGGCAAA 676

DB 541 TAYTNTATGCAAYAGGNAAYACNCTTYSNATGTAYWSNTAYGARATGAARGGNAAR 600

QY 677 TCAGATACATCCAGCAATCATGCTGTGCTGAGCTACCCAAAGGGGATGAGTGTGCTG 736

DB 601 WSNAGACNWSNWSNAAYCAYGNCNTYTNARYTNGCNAARGNGNGAYGRTNTGGT 660

QY 737 CGAATGGCAATGGCGCTCTCCATGGGACCAACCAAGCTTCTCCACTTTCAGGATTC 796

DB 661 MGNATGGNAAYGGNGCNYTNCAYGGNGAYCAYCARMGNTTYWSNACNTTYGCGNGNTY 720

QY 797 CTGCTCTTTGAACTAAG 814

DB 721 YTNVTNTTYGARACNAAR 738

Qy	1215	ATTTTAGAGAAATCGGATGTAGTGTATGATACAGAGGCTGGGGCAAGAACAGGGGCACCTAGCT	1217
Db	482	ATTTTGGAGAAATCGGATGTAGTGTATGATG-CAGGGCTGGGGCAAGAACAGGGGCACCTAGCT	424
Qy	1275	GCCTTATTAGCTAATTTAGTGGCCCTCCGTTTCACGTTAGCCTTTGACCCCTTTCCCTTTTG	1334
Db	423	GCCTTATTAGCTAATTTAGTGGCCCTCCGTTTCACGTTAGCCTTTGACCCCTTTCCCTTTTG	364
Qy	1335	ATCCACAAAATACATTAAAACTCTGAATTTTCACATACAATGCTATTATTTAAAGTCAATAGAT	1394
Db	363	ATCCACAAAATACATTAAAACTCTGAATTTTCACATACAATGCTATTATTTAAAGTCAATAGAT	304
Qy	1395	TTTAGCTATAAAGTGTGTTGACCAAGTAAATGTGGTGTGTAATTTTGTGTATGTTTCCCCACAT	1454
Db	303	TTTAGCTATAAAGTGTGTTGACCAAGTAAATGTGGTGTGTAATTTTGTGTATGTTTCCCCACAT	244
Qy	1455	CGCCCCCAACTTCGGATGTGGGTGAGGAGGTTGAGGTTTCACTATTACAAATGTCATAA	1514
Db	243	CGCCCCCAACTTCGGATGTGGGTGAGGAGGTTGAGGTTTCACTATTACAAATGTCATAA	184
Qy	1515	ATATCTCATAGAGGTACAGTGGCCAATAGATATTCAAATGTTTGCATGTTGACCAAGAGGAT	1574
Db	183	ATATCTCATAGAGGTACAGTGGCCAATAGATATTCAAATGTTTGCATGTTGACCAAGAGGAT	124
Qy	1575	TTTATATCTGGAAGAATACACTATTATTAATAATACCTTTAGAGAAAGATTTTGACCTGGCT	1634
Db	123	TTTATATCTGGAAGAATACACTATTATTAATAATACCTTTAGAGAAAGATTTTGACCTGGCT	64
Qy	1635	TTAGATAAAACTCTGGCAAGAAAATGTAATGAGCAATATATGGAATAATAACACACCTTT	1694
Db	63	TTAGATAAAACTCTGGCAAGAAAATGTAATGAGCAATATATGGAATAATAACACACCTTT	4
Qy	1695	GTT 1697	
Db	3	GTT 1	
RESULT 24			
AAC02874			
ID	AAC02874 standard; cDNA; 471 BP.		
XX	AAC02874;		
XX	06-OCT-2000 (first entry)		
XX	Human secreted protein 5' EST, SEQ ID NO: 2872.		
XX	Human; 5' EST; expressed sequence tag; secreted protein; cDNA isolation		
KW	gene therapy; chromosome mapping; ss.		
XX	Homo sapiens.		
XX	EP1033401-A2.		
XX	06-SEP-2000.		
XX	21-FEB-2000; 2000EP-0200610.		
XX	26-FEB-1999; 99US-0122487.		
XX	(GIST) GENSET.		
XX	Dumas Milne Edwards J, Duclert A, Giordano J;		
XX	WPI; 2000-500381/45.		
DR	P-PSDB; AAG02868.		
XX	New nucleic acid that is a 5' expressed sequence tag (5' EST) for		
PT	obtaining cDNAs and genomic DNAs that correspond to 5' ESTs and for		
PT	diagnostic, forensic, gene therapy and chromosome mapping procedures		
XX	Claim 1; SEQ ID 2872; 71pp + CD-ROM; English.		
PS			
XX			

CC The present sequence is one of a large number of 5' ESTs derived from
 CC mRNAs encoding secreted proteins. An ORF has been identified within the
 CC sequence. The 5' ESTs were prepared from total human RNAs or polyA+ RNAs
 CC derived from 30 different tissues. EST sequences usually correspond
 CC mainly to the 3' untranslated region (UTR) of the mRNA because they are
 CC often obtained from oligo-dT primed cDNA libraries. Such ESTs are not
 CC well suited for isolating cDNA sequences derived from the 5' ends of
 CC mRNAs and even in those cases where longer cDNA sequences have been
 CC obtained, the full 5' UTR is rarely included. 5' ESTs are derived from
 CC mRNAs with intact 5' ends and can therefore be used to obtain full length
 CC cDNAs and genomic DNAs. 5' ESTs are also used in diagnostic, forensic,
 CC gene therapy and chromosome mapping procedures. They are used to obtain
 CC upstream regulatory sequences and to design expression and secretion
 CC vectors.

XX Sequence 471 BP; 107 A; 130 C; 134 G; 99 T; 1 other;

Query Match 26.4%; Score 452; DB 21; Length 471;
 Best Local Similarity 99.6%; Pred. No. 4.4e-121;
 Matches 452; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1 GGCATCTCCCGAGGAGACCGCTCTGGAGCTCTGCTCTCTCAGGAGACTCTGA 60
 Db 12 GGCATCTCCCGAGGAGACCGCTCTGGAGCTCTGCTCTCTCAGGAGACTCTGA 71
 Qy 61 GGCTCTGTGAGAAATCATGCTTTGGAGCAGCTCATCTATTGGCAACTGCTGGCTTTGTT 120
 Db 72 GGCTCTGTGAGAAATCATGCTTTGGAGCAGCTCATCTATTGGCAACTGCTGGCTTTGTT 131
 Qy 121 TTTCCTCCCTTTTGGCTGTGTCAGATGAATACATGGAGTCTCCACAAACCGGAGGACT 180
 Db 132 TTTCCTCCCTTTTGGCTGTGTCAGATGAATACATGGAGTCTCCACAAACCGGAGGACT 191
 Qy 181 ACCCCAGACTGCAGTAAGTGTTCATGGAGACTACAGCTTTCAGGCTACCAAGGCC 240
 Db 192 ACCCCAGACTGCAGTAAGTGTTCATGGAGACTACAGCTTTCAGGCTACCAAGGCC 251
 Qy 241 CCCTGGGCGACCGGGCCCTCTCTGGCATTCAGGAAACCATGGAACAATGCAACAATGG 300
 Db 252 CCCTGGGCGACCGGGCCCTCTCTGGCATTCAGGAAACCATGGAACAATGCAACAATGG 311
 Qy 301 AGCCACTGGTCATGAAGGAGCCAAAGGTGAGAGGGCGACAAAGGTACCTTGGGCGCTCG 360
 Db 312 AGCCACTGGTCATGAAGGAGCCAAAGGTGAGAGGGCGACAAAGGTACCTTGGGCGCTCG 371
 Qy 361 AGGGAGCGGGGCGAGCATGGCCCCCAAGAGAGAGAGGGCTACCCGGGATTCACACAGA 420
 Db 372 AGGGAGCGGGGCGAGCATGGCCCCCAAGAGAGAGAGGGCTACCCGGGATTCACACAGA 431
 Qy 421 ACTTCAGATTGCATTCATGGCTTCTCTGGCAACC 454
 Db 432 ACTTCAGATTGCATTCATGGCTTCTCTGGMACCC 465

RESULT 25

AAX39551
 ID AAX39551 standard; DNA; 472 BP.

XX AAX39551;

XX 21-JUN-1999 (first entry)

DE Human secreted protein 5' EST SEQ ID No 149.

XX Human; secreted protein; EST; expressed sequence tag; diagnosis;
 KW forensic; gene therapy; chromosome mapping; signal peptide;
 KW upstream regulatory sequence; cytokine activity; cell proliferation;
 KW differentiation; haematopoiesis regulation; tissue growth regulation;
 KW reproductive hormone regulation; chemotactic; chemokinetic; haemostatic;
 KW thrombolytic; anti-inflammatory; tumour inhibition; ds.

OS Homo sapiens.

XX

PN WO9906551-A2.

XX 11-FEB-1999.

XX 31-JUL-1998; 98WO-IB01235.

XX 01-AUG-1997; 97US-0905133.

XX (GEST) GENSET.

XX Duclert A, Dumas Milne Edwards J, Lacroix B;

XX WPI; 1999-153781/13.

XX P-PSDB; AAY11485.

XX New nucleic acids encoding human secreted - proteins obtained from
 PT cDNA libraries prepared from substantia nigra, cerebellum, surrenals
 PT and fetal brain tissue

XX Claim 1; Page 263; 434pp; English.

XX AAX39440 to AAX39597 represent 5' expressed sequence tags (ESTs) for
 CC human secreted proteins, and encode the proteins given in AAY11374 to
 CC AAY11531, respectively. The proteins given represent the signal peptide
 CC and an N-terminal fragment of a secreted protein. The nucleic acid
 CC sequences can be used for producing secreted human gene products. They
 CC can also be used to develop products for diagnosis and therapy. The
 CC proteins obtained may have cytokine activity, cell
 CC proliferation/differentiation activity, haematopoiesis regulating
 CC activity, tissue growth regulating activity, reproductive hormone
 CC regulating activity, chemotactic/ chemokinetic activity, haemostatic and
 CC thrombolytic activity, receptor/ ligand activity, anti-inflammatory
 CC activity, tumour inhibition activity or other activities. The products
 CC can be used in forensic, gene therapy and chromosome mapping procedures.
 CC The sequences can also be used for obtaining corresponding promoter
 CC sequences. The nucleic acids encoding the signal peptide can be used for
 CC directing extracellular secretion of a polypeptide or the insertion of a
 CC polypeptide into a membrane, or importing a polypeptide into a cell.

XX Sequence 472 BP; 108 A; 130 C; 134 G; 99 T; 1 other;

Query Match 26.4%; Score 452; DB 20; Length 472;
 Best Local Similarity 99.6%; Pred. No. 4.4e-121;
 Matches 452; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1 GGCATCTCCCGAGGAGACCGCTCTGGAGCTCTGCTCTCTCAGGAGACTCTGA 60
 Db 13 GGCATCTCCCGAGGAGACCGCTCTGGAGCTCTGCTCTCTCAGGAGACTCTGA 72
 Qy 61 GGCTCTGTGAGAAATCATGCTTTGGAGCAGCTCATCTATTGGCAACTGCTGGCTTTGTT 120
 Db 73 GGCTCTGTGAGAAATCATGCTTTGGAGCAGCTCATCTATTGGCAACTGCTGGCTTTGTT 132
 Qy 121 TTTCCTCCCTTTTGGCTGTGTCAGATGAATACATGGAGTCTCCACAAACCGGAGGACT 180
 Db 133 TTTCCTCCCTTTTGGCTGTGTCAGATGAATACATGGAGTCTCCACAAACCGGAGGACT 192
 Qy 181 ACCCCAGACTGCAGTAAGTGTTCATGGAGACTACAGCTTTCAGGCTACCAAGGCC 240
 Db 193 ACCCCAGACTGCAGTAAGTGTTCATGGAGACTACAGCTTTCAGGCTACCAAGGCC 252
 Qy 241 CCCTGGGCGACCGGGCCCTCTCTGGCATTCAGGAAACCATGGAACAATGCAACAATGG 300
 Db 253 CCCTGGGCGACCGGGCCCTCTCTGGCATTCAGGAAACCATGGAACAATGCAACAATGG 312
 Qy 301 AGCCACTGGTCATGAAGGAGCCAAAGGTGAGAGGGCGACAAAGGTACCTTGGGCGCTCG 360
 Db 313 AGCCACTGGTCATGAAGGAGCCAAAGGTGAGAGGGCGACAAAGGTACCTTGGGCGCTCG 372
 Qy 361 AGGGAGCGGGGCGAGCATGGCCCCCAAGAGAGAGAGGGCTACCCGGGATTCACACAGA 420
 Db 373 AGGGAGCGGGGCGAGCATGGCCCCCAAGAGAGAGAGGGCTACCCGGGATTCACACAGA 432

CC screening for new therapeutic molecules and generation of antisense RNA
CC and DNA.
XX Sequence 546 BP; 149 A; 129 C; 155 G; 108 T; 5 other;
SQ Query Match 12.1%; Score 208; DB 22; Length 546;
Best Local Similarity 99.5%; Pred. No. 5.9e-50;
Matches 208; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 159 AGTCTCACAAACCGGAGGACTACCCAGACTGCAGTGAAGTGTTCATGGAGACTACA 218
DB 338 AGTNTCCAAACCGGAGGACTACCCAGACTGCAGTGAAGTGTTCATGGAGACTACA 397
OY 219 GCTTTTCGAGCTACCAAGGCCCTCTGGCCACCGGGCCCTCTGGCATTCAGGAAACC 278
DB 398 GCTTTTCGAGCTACCAAGGCCCTCTGGCCACCGGGCCCTCTGGCATTCAGGAAACC 457
OY 279 ATGGAACAATGGCAACAAATGGAGCCACTGGTCATGAAGGAGCCAAAGGTGAGAAGGGCG 338
DB 458 ATGGAACAATGGCAACAAATGGAGCCACTGGTCATGAAGGAGCCAAAGGTGAGAAGGGCG 517
OY 339 ACAAGGTGACCTGGGGCTCGAGGGGAG 367
DB 518 ACAAGGTGACCTGGGGCTCGAGGGGAG 546

RESULT 28
ABA60188
ID ABA60188 standard; DNA; 548 BP.
XX AC ABA60188;
XX DT 01-FEB-2002 (first entry)
XX DE Human foetal liver single exon nucleic acid probe #8493.
XX KW Human; foetal liver; gene expression; single exon nucleic acid probe; ss.
XX OS Homo sapiens.
XX PN WO200157277-A2.
XX PD 09-AUG-2001.
XX PF 30-JAN-2001; 2001WO-US00669.
XX PR 04-FEB-2000; 2000US-0180312.
XX PR 26-MAY-2000; 2000US-0207456.
XX PR 30-JUN-2000; 2000US-0608408.
XX PR 03-AUG-2000; 2000US-0632366.
XX PR 21-SEP-2000; 2000US-0234687.
XX PR 27-SEP-2000; 2000US-0236359.
XX PR 04-OCT-2000; 2000GB-0024263.
XX PA (MOLE-) MOLECULAR DYNAMICS INC.
XX PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX WPI; 2001-483447/52.
XX Human genome-derived single exon nucleic acid probes useful for
XX analyzing gene expression in human foetal liver -
XX Claim 1; SEQ ID NO 8493; 639pp + sequence listing; English.
XX The invention relates to a single exon nucleic acid probe for
XX measuring human gene expression in a sample derived from human foetal
XX liver. The single exon nucleic acid probes may be used for predicting,
XX measuring and displaying gene expression in samples derived from human
XX foetal liver. The present sequence is a single exon nucleic acid
XX probe of the invention.
XX Note: The sequence data for this patent did not form part of the
XX printed specification, but was obtained in electronic format directly

CC from WIPO at ftp.wipo.int/pub/published_pct_sequences.
XX Sequence 548 BP; 182 A; 81 C; 101 G; 184 T; 0 other;
SQ Query Match 8.0%; Score 136.2; DB 22; Length 548;
Best Local Similarity 97.9%; Pred. No. 4.9e-29;
Matches 138; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 422 CTTGAGATTCATTCATGGCTTCTCTGGCAACCCACTTCAGCATCAGAACAGTGGGATT 481
DB 326 CCTTAGATTCATTCATGGCTTCTCTGGCAACCCACTTCAGCATCAGAACAGTGGGATT 385
OY 482 ATCTTCAGCAGTGTGAGACCAACATTGGAAACTCTTTGATGTCATGACTGGTAGATT 541
DB 386 ATCTTCAGCAGTGTGAGACCAACATTGGAAACTCTTTGATGTCATGACTGGTAGATT 445
OY 542 GGGGCCCCAGTATCAGGTGTG 562
DB 446 GGGGCCCCAGTATCAGGTGTG 466

RESULT 29
AAK08465
ID AAK08465 standard; DNA; 548 BP.
XX AC AAK08465;
XX DT 05-NOV-2001 (first entry)
XX DE Human brain expressed single exon probe SEQ ID NO: 8456.
XX KW Human; brain expressed exon; gene expression; analysis; probe;
XX KW microarray; Alzheimer's disease; multiple sclerosis; schizophrenia;
XX KW epilepsy; cancer; ss.
XX OS Homo sapiens.
XX PN WO200157275-A2.
XX PD 09-AUG-2001.
XX PF 30-JAN-2001; 2001WO-US00667.
XX PR 04-FEB-2000; 2000US-0180312.
XX PR 26-MAY-2000; 2000US-0207456.
XX PR 30-JUN-2000; 2000US-0608408.
XX PR 03-AUG-2000; 2000US-0632366.
XX PR 21-SEP-2000; 2000US-0234687.
XX PR 27-SEP-2000; 2000US-0236359.
XX PR 04-OCT-2000; 2000GB-0024263.
XX PA (MOLE-) MOLECULAR DYNAMICS INC.
XX PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX WPI; 2001-483446/52.
XX Single exon nucleic acid probes for analyzing gene expression in human
XX brains -
XX Example 4; SEQ ID NO: 8456; 650pp + Sequence Listing; English.
XX The present invention provides a number of single exon nucleic acid
XX probes which are derived from genomic sequences expressed in the human
XX brain. They can be used to measure gene expression in brain cell samples,
XX which may enable the diagnosis and improved treatment of nervous system
XX diseases such as Alzheimer's disease, multiple sclerosis, schizophrenia,
XX epilepsy and cancers. The present sequence is one of the probes of the
XX invention.
XX Sequence 548 BP; 182 A; 81 C; 101 G; 184 T; 0 other;
SQ Query Match 8.0%; Score 136.2; DB 22; Length 548;

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

RESULT 1	
ABK35591	
ID	ABK35591 standard; DNA; 741 BP.
XX	
XX	ABK35591;
XX	
DT	08-MAY-2002 (first entry)
XX	
DE	Gene encoding novel human secret
XX	
KW	Human; secreted protein; membr
KW	inflammatory disorder; neurolog
KW	skeletal developmental disorder
KW	neurodegenerative disorder; neu
KW	peripheral myelinopathy; viral
KW	hypotension; sexual development
XX	
OS	Homo sapiens.

XX
PN W0200204600-A2.
XX
XX 17-JAN-2002.
XX
XX 12-JUL-2001; 2001WO-US211985.
XX
XX 12-JUL-2000; 2000US-218033P.
XX 21-AUG-2000; 2000US-226517P.
XX
XX (SMIK) SMITHKLINE BEECHAM CORP.
PA (SMIK) SMITHKLINE BEECHAM PLC.
XX (GLAXO) GLAXO GROUP LTD.
XX
XX Agarwal P, Cogswell JP, Lai Y, Martensen SA, Rizvi SK, Strum JC;
PI Smith RF, Xiang Z, Xie Q;
XX
XX WPI; 2002-188468/24.
DR P-PSDB; AAU84371.
XX
XX Novel secreted and membrane-associated polypeptides and polynucleotides
PT encoding the polypeptides, for preventing, treating and ameliorating
PT cancers, mental or sexual developmental disorders, and malignant tumours
PT
PT
XX
XX Claim 2: Page 106; 151pp; English.
XX
XX The present invention relates to the isolation of novel human secreted
CC or membrane-associated proteins and the genes encoding them. The
CC sequences of the invention are useful for treating, preventing and
CC ameliorating various diseases such as inflammatory disorders (e.g.
CC asthma), neurological disorders (e.g. dementia), haematopoietic
CC disorders, skeletal developmental disorders, growth abnormalities,
CC neurodegenerative disorders (e.g. Huntington's disease), nervous system
CC disorders, autoimmune disorders (e.g. rheumatoid arthritis),
CC peripheral myelinopathies, viral and bacterial infections,
CC alpha-mannosidosis, diabetes, cancers, malignant tumours, hyper- and
CC hypotension, obesity, bulimia, anorexia, manic depression, delirium,
CC mental retardation, Tourette's syndrome, schizophrenia, growth, mental
CC or sexual development disorders, and dysfunctions of the blood cascade
CC system including those leading to stroke. ABK35582-ABK35609 represent
CC the genes encoding the novel human secreted or membrane-associated
CC proteins of the invention.
XX
XX Sequence 741 BP; 191 A; 178 C; 200 G; 172 T; 0 other;

Alignment Scores:
Pred. No.: Length: 745e-100 741
Score: 1367.00 Matches: 246
Percent Similarity: 100.00% Conservative: 0
Best Local Similarity: 100.00% Mismatches: 0
Query Match: 100.00% Indels: 0
DB: 24 Gaps: 0

US-10-036-041-2 (1-246) x ABK35591 (1-741)

QY 1 MetLeuTrpArgGlnLeuIleTyrTrpGlnLeuAlaLeuPhePheLeuPropheCys 20
DB 1 ATGCTTTGGAGGCGAGCTCATCTATTGGCAACTGCTGGCTTTGTTCTCCCTTTTTCG 60
QY 21 LeuCysGlnAspGluTyrMetGluSerProGlnThrGlyGlyLeuProProAspCysSer 40
DB 61 CTGTGTCAAGATGAATACATGGAGTCTCCACAACCGGAGGACTACCCCGAGACTGCAGT 120
QY 41 LysCysCysHisGlyAspTyrSerPheArgGlyTyrGlnGlyProProGlyProGly 60
DB 121 AAGTGTGTTCATGGAGCTACAGCTTTCGAGGCTACCAAGGCCCTCGGCCACCGGC 180
QY 61 ProProGlyIleProGlyAsnHisGlyAsnAsnGlyAsnGlyAlaThrGlyHisGlu 80
DB 181 CCTCTGGCATTCAGGAACCAATGGAAACAATGGCAACAATGGAGCCACTGTGTCATGAA 240
QY 81 GlyAlaLysGlyGluLysGlyAspLysGlyAspLeuGlyProArgGlyGluArgGlyGln 100

DB 241 GGAGCCAAAGGTGAGAAGGCGCAAAAGGTGACCTGGGGCTCAGGGGAGCGGGCAG 300
QY 101 HisGlyProLysGlyGluLysGlyTyrProGlyIleProGluLeuGlnIleAlaPhe 120
DB 301 CATGGCCCCAAAGGAGAGAGGGCTACCCGGGATTCACCAGAACTTCAGATTGCATTC 360
QY 121 MetAlaSerLeuAlaThrHisPheSerAsnGlnAsnSerGlyIleIlePheSerSerVal 140
DB 361 ATGGCTTCTCTGGCAACCCCACTTCAGCAATCAGAACAAGTGGGATTTATCTTCAGCAGTGT 420
QY 141 GluThrAsnIleGlyAsnPhePheAspValMetThrGlyArgPheGlyAlaProValSer 160
DB 421 GAGACCAACATTTGAAACTCTTTTGTATGTCATGCTAGTGTGGGGCCCCAGGATCA 480
QY 161 GlyValTyrPhePheThrPheSerMetMetLysHisGluAspValGluGluValTyrVal 180
DB 481 GGTGTGTATTTCTTCCACCTTCAGCATGATCAAGCATGAGCATGTTGAGGAAGTGTATGTG 540
QY 181 TyrLeuMetHisAsnGlyAsnThrValPheSerMetTyrSerTyrGluMetLysGlyLys 200
DB 541 TACCTTATGCAATGGCAACACAGCTTTCAGCATGTACAGCTATGAATGAAGGGCAAA 600
QY 201 SerAspThrSerSerAsnHisAlaValLeuLysLeuAlaLysGlyAspGluValTyrLeu 220
DB 601 TCAGATACATCCAGCAATCATGCTGTGCTGAAGCTAGCCAAAGGGATGAGTTGGCTG 660
QY 221 ArgMetGlyAsnGlyAlaLeuHisGlyAspHisGlnArgPheSerThrPheAlaGlyPhe 240
DB 661 CGAATGGCAATGGCTCTCCATGGGGACCACCAAGCTTCTCCACCTTTGCGAGGATTC 720
QY 241 LeuLeuPheGluThrLys 246
DB 721 CTGCTCTTTGAAACTAAG 738

RESULT 2
AAC64058
ID AAC64058 standard; cDNA; 1696 BP.
XX
XX AAC64058;
XX
DT 19-FEB-2001 (first entry)
XX
DE Human zacr3p3 cDNA, SEQ ID NO:1.
XX
XX Human zacr3p3; adipocyte complement related protein homologue;
KW ACRP30; C1q domain; collagen-like domain; energy balance modulation;
KW cellular metabolism; metabolic disorder; obesity; anorexia;
KW antimicrobial agent; infection; platelet aggregation inhibition;
KW adhesion; activation; vascular injury; antibacterial; antiviral; ss.
OS Homo sapiens.
XX
XX W0200063377-A1.
XX
XX 26-OCT-2000.
XX
PF 19-APR-2000; 2000WO-US10454.
XX
XX 20-APR-1999; 99US-0294943.
XX
XX (ZYMO) ZYMOGENETICS INC.
XX
XX Piddington CS, Bishop PD;
PI
XX
XX WPI; 2000-665243/64.
DR P-PSDB; AAB29580.
XX
XX Novel zacr3p3 polypeptides used to treat or prevent bacterial or viral
PT infections, for wound healing, improving blood flow, and to analyze
PT energy efficiency in mammals -
XX
XX Claim 31; Page 107-109; 123pp; English.

XX The invention relates to the human zacr3 protein (AAB29580) and to
 CC nucleic acids which encode it (AAC64058, AAC64063). Zacr3 is a homologue
 CC of adipocyte complement related protein (ACRP30) and contains a
 CC collagen-like domain comprising Gly-Xaa-Xaa or Gly-Xaa-Pro repeats, and a
 CC C-terminal C1q domain comprising 10 beta-strands. The zacr3 gene is
 CC located on chromosome 5p12. The invention also relates to zacr3
 CC fragments, fusion proteins containing zacr3 polypeptides,
 CC zacr3-specific antibodies, expression constructs and host cells
 CC comprising zacr3 nucleic acids, and methods of recombinant production of
 CC zacr3. Human zacr3, and its agonists and antagonists may be used in the
 CC study and modulation of cellular metabolism and energy balance in
 CC mammals, and may therefore be used to treat disorders such as obesity and
 CC anorexia, and conditions associated with these disorders. Due to its C1q
 CC like domain, zacr3 and zacr3-containing fusion proteins may be useful
 CC as antimicrobial agents, promoting lysis or phagocytosis of infectious
 CC organisms such as bacteria or viruses. Zacr3, its fragments, fusion
 CC proteins, antibodies and activity modulators may also be used to inhibit
 CC collagen-induced platelet aggregation, adhesion, or activation, and may
 CC therefore have potential for promoting blood flow within the vasculature
 CC of a mammal e.g., to treat injury to the vasculature or other collagenous
 CC tissue. Human zacr3 and its antibodies may additionally be used to study
 CC dimerisation and oligomerisation. The present sequence represents cDNA
 CC encoding human zacr3.
 XX

SQ Sequence 1696 BP; 482 A; 355 C; 386 G; 473 T; 0 other;

Alignment Scores:

Pred. No.:	1.94e-99	Length:	1696
Score:	1367.00	Matches:	246
Percent Similarity:	100.00%	Conservative:	0
Best Local Similarity:	100.00%	Mismatches:	0
Query Match:	100.00%	Indels:	0
DB:	21	Gaps:	0

US-10-036-041-2 (1-246) x AAC64058 (1-1696)

QY	1	MetLeuTrpArgGlnLeuIleTyrTrpGlnLeuLeuAlaLeuPhePheLeuProPheCys	20
DB	69	ATGCTTTGGAGCAGCTCATCTATTGGGCACTGCTGGCTTTGTTTCTCCCTTTTGC	128
QY	21	LeuCysGlnAspGluTyrMetGluSerProGlnThrGlyLeuProProAspCysSer	40
DB	129	CTGTGTCAGATGAATACATGAGCTCTCCACAAACGGAGGACTACCCCCAGACTGC	188
QY	41	LysCysCysHisGlyAspTyrSerPheArgGlyTyrGlnGlyProProGlyProGly	60
DB	189	AAGTGTGTCTATGGAGACTACAGCTTTCGAGCTACCAAGGCCCTCCGGCCACCGGC	248
QY	61	ProProGlyIleProGlyAsnHisGlyAsnGlyAsnGlyAsnGlyAlaThrGlyHisGlu	80
DB	249	CCTCTGGCATTCAGGAACCATGGAAACATGGCAACATGGAGCCACTGTCATGAA	308
QY	81	GlyAlaLysGlyGluLysGlyAspLysGlyAspLeuGlyProArgGlyGluArgGlyGln	100
DB	309	GGAGCAAGAGTGAAGGGGCACAAAGTGACCTGGGGCCCTCGAGGGGCGGCGAG	368
QY	101	HisGlyProLysGlyGluLysGlyTyrProGlyIleProProGluLeuGlnIleAlaPhe	120
DB	369	CATGGCCCCAAAGGAGAGAGGGCTACCGGGGGATTCACCAAGAACTTCAGATTGC	428
QY	121	MetAlaSerLeuAlaThrHisPheSerAsnGlnAsnSerGlyIlePheSerVal	140
DB	429	ATGGCTTCTCTGGCAACCCCTCAGCAATCAGACAGTGGGATTTCTTCAGAGTGTT	488
QY	141	GlyThrAsnIleGlyAsnPhePheAspValMetThrGlyArgPheGlyAlaProValSer	160
DB	489	GAGACCAACATTGGAAACTCTTTTGTATGTCATGCTAGTGGTGGGGCCCGAGTATCA	548
QY	161	GlyValTyrPhePheThrPheSerMetMetLysHisGluAspValGluGluValTyrVal	180
DB	549	GGTGTGTATTTCTTCACTTACGATGATGAAGCATGAGGATGTTGAGGAAGTGTATGTG	608

QY	181	TyrLeuMetHisAsnGlyAsnThrValPheSerMetTyrSerTyrGluMetLysGlyLys	200
DB	609	TACCTTATCCACAAATGGCAACACAGCTCTCAGCATGTACATGATGAAGGCAAA	668
QY	201	SerAspThrSerSerAsnHisAlaValLeuLysLeuAlaLysGlyAspGluValTrpLeu	220
DB	669	TGAGATACATCCAGCAATCATGCTGTGCTGAAGCTAGCCAAAGGGGATGAGGTTGGCTG	728
QY	221	ArgMetGlyAsnGlyAlaLeuHisGlyAspHisGlnArgPheSerThrPheAlaGlyPhe	240
DB	729	CGAATGGGCAATGGGCTCTCCATGGGACCAACAGCTTCCACCTTCAGGATTC	788
QY	241	LeuLeuPheGluThrLys	246
DB	789	CTGCTCTTTGAACACTAAG	806
RESULT 3			
AAF93874			
ID	AAF93874	standard; cDNA; 1709 BP.	
XX			
AC	AAF93874;		
XX			
DT	23-MAY-2001	(first entry)	
XX			
DE		Human cDNA encoding a membrane or secretory protein clone PSEC0232.	
KW		Human; secretory protein; membrane protein; vaccine; gene therapy;	
KW		rheumatoid arthritis; diabetes; ss.	
OS		Homo sapiens.	
XX			
PN		EP1067182-A2.	
XX			
PD		10-JAN-2001.	
XX			
PF		07-JUL-2000; 2000EP-0114090.	
XX			
PR		08-JUL-1999; 99JP-0194179.	
PR		11-JAN-2000; 2000JP-0118775.	
PR		02-MAY-2000; 2000JP-0183766.	
XX			
PA		(HELI-) HELIX RES INST.	
XX			
PI		Ota T, Isogai T, Nishikawa T, Kawai Y, Sugiyama T, Hayashi K;	
XX			
DR		WPI: 2001-093989/11.	
DR		P-PSDB; AAB88447.	
XX			
PT		Nucleic acids encoding secretory proteins/membrane proteins, useful in	
PT		gene therapy or as candidate target molecules in drug development -	
PS		Claim 1; SEQ ID 261; 609pp + CD ROM; English.	
XX			
CC		This invention relates to nucleic acid sequences AAF93744 - AAF93916	
CC		which encode human secretory or membrane proteins represented by	
CC		AAF88317 - AAB88419. Included in the invention are primers	
CC		AAF93917 - AAF94295 and AAF62232 - AAF62235 which are used to isolate the	
CC		cDNA sequences of the invention. The invention also includes methods for	
CC		the production of antibodies directed against the proteins, and cDNA	
CC		sequences, which can be used in vaccines. The polynucleotide sequences	
CC		can be used in gene therapy. The polynucleotide sequences and the	
CC		proteins they encode may be used in the prevention, treatment and	
CC		diagnosis of diseases associated with inappropriate secretory	
CC		protein/membrane protein expression. The nucleic acids and complementary	
CC		sequences may also be used as DNA probes in diagnostic assays	
CC		(e.g. polymerase chain reactions (PCR)) to detect and quantitate the	
CC		presence of similar nucleic acid sequences in samples. They may also be	
CC		used to study the expression and function of secretory proteins/membrane	
CC		polypeptides and their role in metabolism. The polypeptides may be used	
CC		as antigens in the production of antibodies against them and in assays to	
CC		identify modulators (agonists and antagonists) of expression and	
CC		activity. The antibodies and antagonists may also be used as therapeutic	
CC		agents to down regulate expression and activity. The antibodies may also	

CC be used as diagnostic agents for detecting the presence of the
 CC polypeptides in samples (e.g. by enzyme linked immunosorbant assay
 CC (ELISA). Examples of diseases which may be treated include rheumatoid
 CC arthritis and diabetes.

XX
 SQ Sequence 1709 BP; 480 A; 363 C; 390 G; 476 T; 0 other:

Alignment Scores:
 Pred. No.: 1.96e-99 Length: 1709
 Score: 1367.00 Matches: 246
 Percent Similarity: 100.00% Conservative: 0
 Best Local Similarity: 100.00% Mismatches: 0
 Query Match: 100.00% Indels: 0
 DB: 22 Gaps: 0

US-10-036-041-2 (1-246) x AAF93874 (1-1709)

QY 1 MetLeuTrpArgGlnLeuIleTyrTrpGlnLeuLeuAlaLeuPhePheLeuProPheCys 20
 Db 89 ATGCTTGGAGGCGACTATCTATTTGGCAACTGCTGGCTTTGTTTCTCTCTTTTCC 148
 QY 21 LeuCysGlnAspGluTyrMetGluSerProGlnThrGlyGlyLeuProAspCysSer 40
 Db 149 CTGTGTCAAGATGAATACATGAGTCTCCACAAACGGAGGACTACCCCGAGACTGCAC 208
 QY 41 LysCysCysHisGlyAspTyrSerPheArgGlyTyrGlnGlyProGlyProGly 60
 Db 209 AAGTGTGTTCATGGAGACTACAGCTTTTCGAGGCTACCAAGGCCCTCGGGCCACCGGC 268
 QY 61 ProProGlyIleProGlyAsnHisGlyAsnAsnGlyAsnGlyAlaThrGlyHisGlu 80
 Db 269 CTCTCTGGCATTCAGGAACCATGAACATGGCAATGGCACTGGTCTGATGAA 328
 QY 81 GlyAlaLysGlyGlyGlyAspLysGlyAspLeuGlyProArgGlyGluArgGlyGln 100
 Db 329 GGAGCAAAAGTGAGAAAGGCCACAAAGGTGACCTGGGGCCCTCGAGGGGAGCGGCG 388
 QY 101 HisGlyProLysGlyGlyGlyTyrProGlyIleProGlyLeuGlnIleAlaPhe 120
 Db 389 CATGGCCCCAAAGGAGAGAAAGGGCTACCCGGGGATTCACCAAGAACTTCAGATTG 448
 QY 121 MetAlaSerLeuAlaThrHisPheSerAsnGlnAsnSerGlyIleIlePheSerVal 140
 Db 449 ATGGCTTCTCTGCAACCACTTCAGCAATCAGACAGTGGGATATCTTCAGCAGTGT 508
 QY 141 GluThrAsnIleGlyAsnPhePheValMetThrGlyArgPheGlyAlaProValSer 160
 Db 509 GAGACCAACATTTGGAACCTCTTTGATGTCATGACTGTGATGTTGGGCCCCAGTATCA 568
 QY 161 GlyValTyrPhePheThrPheSerMetLysHisGluAspValGluGluValTyrVal 180
 Db 569 GTGTGTATTTCTTCCCTTACGATGATGATGATGATGATGATGATGATGATGATG 628
 QY 181 TyrLeuMetHisAsnGlyAsnThrValPheSerMetTyrSerTyrGluMetLysGlyLys 200
 Db 629 TACCTTATGACAAATGGCAACACAGCTCTCAGCATGTACAGCTATGAATGAGGGC 688
 QY 201 SerAspThrSerSerAsnHisAlaValLeuLysLeuAlaLysGlyAspGluValTrpLeu 220
 Db 689 TCAGATATATCCAGCAATCATCTGTGTGAGAGTACCAAGGGGAGTGGTGGTGG 748
 QY 221 ArgMetGlyAsnGlyAlaLeuHisGlyAspHisGlnArgPheSerThrPheAlaGlyPhe 240
 Db 749 CGAATGGGCAATGGCGCTCTCATGGGAGGACCAACCAACCTTCTCCACCTTTG 808
 QY 241 LeuLeuPheGluThrLys 246
 Db 809 CTGCTCTTTGAACTAAG 826

RESULT 4

AAA96336

ID AAA96336 standard; cDNA: 1712 BP.

XX

AC AAA96336;
 XX 08-FEB-2001 (first entry)
 DT cDNA encoding a novel polypeptide designated PRO1484.
 DE
 XX
 KW Secreted protein; transmembrane protein; PRO1484; PRO4334; PRO1122;
 KW PRO1889; PRO1890; PRO1887; PRO4353; PRO4357; PRO4405; PRO4356;
 KW PRO4352; PRO4380; PRO4354; PRO4408; PRO5737; PRO4425; PRO5990; PRO6030;
 KW PRO4424; PRO4422; PRO4430; PRO4499; tumour; obesity; diabetes;
 KW insulinemia; kidney disorder; Bergers disease; nephropathy;
 KW Schonlein-Henoch purpura; celliac disease; dermatitis herpetiformis;
 KW Crohns disease; ss.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT CDS 77..817
 FT /tag= a
 FT sig_peptide 77..142
 FT /tag= b
 XX
 PN WO200056889-A2.
 XX
 PD 28-SEP-2000.
 XX
 PF 01-MAR-2000; 2000WO-US05601.
 XX
 PR 23-MAR-1999; 99US-0125774.
 PR 23-MAR-1999; 99US-0125778.
 PR 24-MAR-1999; 99US-0125826.
 PR 31-MAR-1999; 99US-0127035.
 PR 05-APR-1999; 99US-0127706.
 PR 21-APR-1999; 99US-0130359.
 PR 27-APR-1999; 99US-0131270.
 PR 27-APR-1999; 99US-0131272.
 PR 27-APR-1999; 99US-0131291.
 PR 04-MAY-1999; 99US-0132371.
 PR 04-MAY-1999; 99US-0132379.
 PR 05-MAY-1999; 99US-0132383.
 PR 25-MAY-1999; 99US-0135750.
 PR 08-JUN-1999; 99US-0138166.
 PR 20-JUL-1999; 99US-0144791.
 PR 03-AUG-1999; 99US-0146970.
 PR 09-DEC-1999; 99US-0170262.
 XX
 PA (GETH) GENENTECH INC.
 PI Desnoyers L, Eaton DL, Goddard A, Godowski PJ, Gurney AL, Pan J;
 PI Stewart TA, Watanabe CK, Wood WL, Zhang Z;
 XX
 DR WPI; 2000-628263/60.
 DR P-PSDB; AAB18909.
 XX
 PT Novel secreted and transmembrane polypeptides useful for diagnosing
 PT tumour in a mammal, for identifying agonists and antagonists of the
 PT polypeptide and for therapeutic use
 XX
 PS Claim 2; Fig 1; 222pp; English.
 XX
 CC The present sequence encodes a secreted or transmembrane polypeptide.
 CC The specification describes polypeptides designated PRO1484, PRO4334,
 CC PRO1122, PRO1889, PRO1890, PRO1887, PRO1785, PRO4353, PRO4405, PRO4403,
 CC PRO4356, PRO4380, PRO4354, PRO4408, PRO4409, PRO5737, PRO4425, PRO5990,
 CC PRO6030, PRO4424, PRO4422, PRO4430 and PRO4499. PRO1889 polypeptide is
 CC useful for diagnosing tumour in a mammal. The polypeptides, their
 CC agonists and antagonists are useful treating a condition associated with
 CC expression or activity of the polypeptide. Conditions treated include
 CC obesity, diabetes or hyper-or hypo-insulinemia. The polypeptides are
 CC capable of inducing proliferation of mammalian kidney mesangial cells
 CC and are therefore useful for treating kidney disorders associated with
 CC decreased mesangial cell function such as Bergers disease or other
 CC nephropathies associated with Schonlein-Henoch purpura, celliac disease,

CC dermatitis herpeticiformis or Crohns disease. The nucleic acids may be used
 CC to generate transgenic animals for use in development and screening of
 CC therapeutically useful reagents and also for chromosome identification
 CC and tissue typing.

XX SQ Sequence 1712 BP; 491 A; 358 C; 388 G; 475 T; 0 other;

Alignment Scores:
 Pred. No.: 1.96e-99 Length: 1712
 Score: 1367.00 Matches: 246
 Percent Similarity: 100.00% Conservative: 0
 Best Local Similarity: 100.00% Mismatches: 0
 Query Match: 100.00% Indels: 0
 DB: 21 Gaps: 0

US-10-036-041-2 (1-246) x AAA96336 (1-1712)

Qy 1 MetLeuTrpArgGlnLeuIleTyrTrpGlnLeuLeuAlaLeuPhePheLeuProPheCys 20
 Db 77 ATGCTTTGGAGCAGCTCATCTATTGGCACTGCTGGCTTTGTTTCTCCCTTTTGC 136
 Qy 21 LeuCysGlnAspGluTyrMetGluSerProGlnThrGlyGlyLeuProProAspCysSer 40
 Db 137 CTGTCTCAAGATGAATACATGAGTCTCCACAAACCGGAGGACTACCCACAGACTGCAGT 196
 Qy 41 LysCysCysHisGlyAspTyrSerPheArgGlyTyrGlnGlyProProGlyProGly 60
 Db 197 AAGTCTTGTGATGGAGACTACAGCTTTTCGAGGCTACCAAGGCCCTTGGGCGCACGGGC 256
 Qy 61 ProProGlyIleProGlyAsnHisGlyAsnAsnGlyAsnGlyValAlaThrGlyHisGlu 80
 Db 257 CCTCTGTCATCCAGGAACCATGGAACCAATGCGACATGGAGCCACTGGTCATGAA 316
 Qy 81 GlyAlaLysGlyGluLysGlyAspLysGlyAspLeuGlyProArgGlyGluArgGlyGln 100
 Db 317 GGAGCAAGGTGAGAAGGGCCACAAAGTCACTGGGCTCGAGGGGAGCGGGGGCAG 376
 Qy 101 HisGlyProLysGlyGluLysGlyTyrProGlyIleProProGluLeuGlnIleAlaPhe 120
 Db 377 CATGGCCCAAGGAGAGAGAGGGCTTACCCGGGGATTCCACCAGAACTTCAGATTGCATTC 436
 Qy 121 MetAlaSerLeuAlaThrHisPheSerAsnGlnAsnSerGlyIleIlePheSerSerVal 140
 Db 437 ATGGCTTCTTGGCAACCCACTTCAGCAATCAGAACAGTGGGATATCTTCAGCAGTGT 496
 Qy 141 GluThrAsnIleGlyAsnPhePheAspValMetThrGlyArgPheGlyAlaProValSer 160
 Db 497 GAGACCAACATGGAAACTTCTTTCATGTCATGCTAGTGTAGATTGGGGCCCCCAGTATCA 556
 Qy 161 GlyValTyrPheThrPheSerMetLysHisGluAspValGluLysValTyrVal 180
 Db 557 GGTGTGTATTCTTCACCTTCAGCATGATGAAGCATGAGGATGTTGAGGAAGTGTATGTG 616
 Qy 181 TyrLeuMetHisAsnGlyAsnThrValPheSerMetTyrSerTyrGluMetLysGlyLys 200
 Db 617 TACCTTATGACAAATGGCAACACACTCTTCAGCATGTACAGTATGAATGAAGGCGAA 676
 Qy 201 SerAspThrSerSerAsnHisAlaValLeuLysLeuAlaLysGlyAspGluValTrpLeu 220
 Db 677 TCAGATACATCAGCAATCATGCTGCTGAAGCTAGCAAAAGGGGATGAGGTTTGGCTG 736
 Qy 221 ArgMetGlyAsnGlyAlaLeuHisGlyAspHisGlnArgPheSerThrPheAlaGlyPhe 240
 Db 737 GGAATGGGCAATGGGCGCTCTCATGGGAGCACCAACCACTTCTCCACCTTTGCGAGTTC 796
 Qy 241 LeuLeuPheGluThrLys 246
 Db 797 CTGCTCTTTGAACCTAAG 814

RESULT 5
 AAA95787
 ID AAA95787 standard; cDNA; 1760 BP.
 XX

AC AAA95787;

XX 28-FEB-2001 (first entry)

XX Human immune system molecule cDNA from Incyte clone 1890540.

XX Anti-inflammatory; keratolytic; anti-HIV; anti-allergic; antianaemic;
 KW antiarteriosclerotic; antiasthmatic; antidiabetic; nephrotropic; cancer;
 KW antigout; dermatological; antithyroid; virucide; hepatotropic; antibody;
 KW immunosuppressive; cytostatic; fungicide; protozoicide; antibacterial;
 KW gene therapy; diagnostic; immunological disorder; viral infection; ss;
 XX bacterial infection; fungal infection; parasitic infection; immunogen.
 OS Homo sapiens.

XX WO200060080-A2.

XX 12-OCT-2000.

XX 04-APR-2000; 2000WO-US09072.

XX 05-APR-1999; 99US-0127852.

XX 05-MAY-1999; 99US-01132647.

XX (INCY-) INCYTE PHARM INC.

XX Yue H, Lal P, Tang YT, Baughn MR, Azimzai Y, Lu DAM;

XX WPI; 2000-665005/64.

XX P-PSDB; AAB15548.

XX New human immune system molecules 1-15 and polynucleotides encoding
 PT them useful for diagnosing, treating or preventing e.g. immunological
 PT disorders, infections, cell proliferative disorders, microbial
 PT infections

XX Claim 4; Page 93; 95pp; English.

XX This sequence represents the cDNA for a human immune system molecule
 CC (IMOL) isolated as clone 1890540 from the Incyte BLA00707 library.
 CC The human IMOLs (AAB1536-B15550) and their encoding polynucleotides
 CC (AAA95775-A95789), and compositions comprising them are useful for the
 CC diagnosis, treatment or prevention of immunological disorders,
 CC infections and cell proliferative disorders, including cancer. The IMOL
 CC may be used to treat or prevent disorders associated with decreased
 CC expression or activity of IMOL, such as immunological disorders
 CC (e.g. inflammation, actinic keratosis, AIDS, Addison's disease),
 CC haematopoietic cancer, infections caused by virus (e.g. adenovirus,
 CC parvovirus, coronavirus), bacteria (e.g. Staphylococcus, Streptococcus,
 CC Shigella), fungi (e.g. Aspergillus, Blastomycetes), parasites (e.g.
 CC Plasmodium, Trypanosoma, intestinal protozoa), cell proliferative
 CC disorders (e.g. actinic keratosis, arteriosclerosis, bursitis), and
 CC cancers (e.g. leukemia, melanoma, sarcoma). The peptides are also
 CC useful as immunogens for the development of antibodies that
 CC specifically recognize these peptides. The polynucleotides may be used
 CC to detect and quantify gene expression in biopsied tissues in which
 CC expression of IMOL may be correlated with the disease, as targets in a
 CC microarray, to detect differences in gene sequences among normal,
 CC carrier and affected individuals, and for screening libraries of
 CC compounds in drug screening techniques. Antibodies which specifically
 CC bind to IMOL may be used for the diagnosis of disorders characterized
 CC by expression of IMOL, or in assays to monitor patients being treated
 CC with IMOL or agonists, antagonists, or inhibitors of IMOL.

XX Sequence 1760 BP; 505 A; 376 C; 395 G; 484 T; 0 other;

XX Alignment Scores:

Pred. No.: 2.02e-99 Length: 1760
 Score: 1367.00 Matches: 246
 Percent Similarity: 100.00% Conservative: 0
 Best Local Similarity: 100.00% Mismatches: 0
 Query Match: 100.00% Indels: 0
 DB: 21 Gaps: 0

US-10-036-041-2 (1-246) x AAA95787 (1-1760)

Qy	1	MetLeuTrpArgGlnLeuIleTyrTrpGlnLeuLeuAlaLeuPhePheLeuProPheCys	20
Db	124	ATGCTTTGGAGGAGCTCATCTATTGGCAACTGCTGGCTTGTGTTTCTCCCTTTTTCG	183
Qy	21	LeuCysGlnAspGluTyrMetGluSerProGlnThrGlyGlyLeuProProAspCysSer	40
Db	184	CTGTGTCACAGTAACATATGGAGTCTCCACAACCGAGGACTACCCCCAGACTCGAGT	243
Qy	41	LysCysCysHisGlyAspTyrSerPheArgGlyTyrGlnGlyProGlyProProGly	60
Db	244	AAGTGTGTGTCATGGAGACTACAGCTTTCGAGGCTACCAAGGCCCCCTGGGCCACCGGC	303
Qy	61	ProProGlyIleProGlyAsnHisGlyAsnAsnGlyAsnAsnGlyAlaThrGlyHisGlu	80
Db	304	CCTCTGGCATTCAGAGAACCATGGAAACAAATGGCAACATGGAGCCACTGGTTCATGAA	363
Qy	81	GlyAlaLysGlyGlnLysGlyAspLysGlyAspLeuGlyProArgGlyGluArgGlyGln	100
Db	364	GGAGCCCAAGGTGAGAAGGCGCACAAAGTGACCTGGGGCTTCGAGGGAGCGGGGCGAG	423
Qy	101	HisGlyProLysGlyGlnLysGlyTyrProGlyIleProGluLeuGlnIleAlaPhe	120
Db	424	CATGGCCCCAAAGAGAGAAGGCTACCCGGGGATTCCACCAGAACTTCAGATTGCATTC	483
Qy	121	MetAlaSerLeuAlaThrHisPheSerAsnGlnAsnSerGlyIleIlePheSerSerVal	140
Db	484	ATGGCTTCTCTGGCAACCCACTTCAGCAATCAGAACAGTGGGATTATCTTCAGCAGCTGT	543
Qy	141	GluThrAsnIleGlyAsnPhePheAspValMetThrGlyArgPheGlyAlaProValSer	160
Db	544	GAGACCAACATGGAAACTCTTTTGATGTCATGACTGGTAGATTTGGGGCCCCAGATCA	603
Qy	161	GlyValTyrPhePheThrPheSerMetMetLysHisGluAspValGluGluValTyrVal	180
Db	604	GGTGTGTATTTCTTCACCTTCACATGATGAGACATGAGGATGTTGAGGAAGTGTATGTCG	663
Qy	181	TyrLeuMetHisAsnGlyAsnThrValPheSerMetTyrSerTyrGluMetLysGlyLys	200
Db	664	TACCTTATGCACAATGGCAACACAGCTCTTCAGCATGTGTACAGCTATGAAATGAAGGCAAA	723
Qy	201	SerAspThrSerSerAsnHisAlaValLeuLysLeuAlaLysGlyAspGluValTrpLeu	220
Db	724	TCAGATACATCCAGCAATCATGCTGTGCTGAAGTACGCCAAAGGGATGAGGTTTGGCTG	783
Qy	221	ArgMetGlyAsnGlyAlaLeuHisGlyAspHisGlnArgPheSerThrPheAlaGlyPhe	240
Db	784	CGAATGGCAATGGCGCTCTCCATGGGGACCACCAACGCTTCTCCACCTTTGCAGGATTC	843
Qy	241	LeuLeuPheGluThrLys	246
Db	844	CTGCTCTTTGAAACTAAG	861

RESULT 6

ABK35590
ID ABK35590 standard; DNA; 960 BP.

AC ABK35590:

DT 08-MAY-2002 (first entry)

Gene encoding novel human secreted or membrane-associated protein #9.

XX	Human;
XX	secreted protein; membrane-associated protein; hypertension;
KW	inflammatory disorder; neurological disorder; haematopoietic disorder
KW	skeletal developmental disorder; growth abnormality; autoimmune disorder
KW	neurodegenerative disorder; nervous system disorder; bacterial infection
KW	peripheral myelinopathy; viral infection; cancer; obesity; diabetes;
XX	hypotension; sexual development disorder; blood disorder; gene; ds.
OS	Homo sapiens.

XX	WO200204600-A2.	
PN	XX	
XX	17-JAN-2002.	
PD	XX	
XX	12-JUL-2001; 2001WO-US21985.	
PF	XX	
XX	12-JUL-2000; 2000US-218033P.	
PR	XX	
PR	21-AUG-2000; 2000US-226517P.	
XX		
PA	(SMIK) SMITHKLINE BEECHAM CORP.	
PA	(SMIK) SMITHKLINE BEECHAM PLC.	
PA	(GLAX) GLAXO GROUP LTD.	
XX		
PI	Agarwal P, Cogswell JP, Lai Y, Martensen SA, Rizvi SK, Strum JC;	
PI	Smith RF, Xiang Z, Xie Q;	
XX		
XX	WPI; 2002-188468/24.	
DR	P-PSDB; AAU84370.	
DR		

Novel secreted and membrane-associated polypeptides and polynucleotides encoding the polypeptides, for preventing, treating and ameliorating cancers, mental or sexual developmental disorders, and malignant tumours

Claim 2; Page 106; 151pp: English.

The present invention relates to the isolation of novel human secreted or membrane-associated proteins and the genes encoding them. The sequences of the invention are useful for treating, preventing and ameliorating various diseases such as inflammatory disorders (e.g. asthma), neurological disorders (e.g. dementia), haematopoietic disorders, skeletal developmental disorders, growth abnormalities, neurodegenerative disorders (e.g. Huntington's disease), nervous system disorders, autoimmune disorders (e.g. rheumatoid arthritis), peripheral myelinopathies, viral and bacterial infections, alpha-mannosidosis, diabetes, cancers, malignant tumours, hyper- and hypotension, obesity, bulimia, anorexia, manic depression, delirium, mental retardation, Tourette's syndrome, schizophrenia, growth, mental or sexual development disorders, and dysfunctions of the blood cascade system including those leading to stroke. ABK35582-ABK35609 represent the genes encoding the novel human secreted or membrane-associated proteins of the invention.

Sequence 960 BP; 261 A; 232 C; 262 G; 205 T; 0 other;

Alignment Scores:

Pred. No.:	4,94e-96	Length:	960
Score:	1320.50	Matches:	246
Percent Similarity:	77.12%	Conservative:	0
Best Local Similarity:	77.12%	Mismatches:	0
Query Match:	96.60%	Indels:	73
DB:	24	Gaps:	1

US-10-036-041-2 (1-246) X ABK35590 (1-960)

Qy	1	MetLeuTrpArgGlnLeuIleTyrTrpGlnLeuLeuAlaLeuPheLeuProPheCys	20
Db	1	ATGCTTTGGAGCAGCTCATCTATTGGCAACTGCTGGCTTTGTTTTCTCCCTTTTTCG	60
Qy	21	LeuCysGlnAspGluTyrMetGlu-	28
Db	61	CTGTGTCAAGATGAATACATGGAGGTGAGCGGAAGAAGCTATAAAGTGGTGGCAAGAATA	120
Qy	28	- - - - -	28
Db	121	GTGCAAGCCACCAGCAGACTGGCCGTAGCCGTCACAGAGGGAGAAAGTCAGAGAGACGG	180
Qy	28	- - - - -	28
Db	181	AGCCATCCTAAACACTGGGACTGTGGATATAACACTTCTACAGACCTAAAATCCCTGAGA	240
Qy	28	- - - - -	28

241	CCAGATGAGCTACCGCACCCCGAGGCTAGATGACCTAGCCCGAGATCACACATTCCTGGGGC	300
29	---SerProGlnThrGlyGlyLeuProProAspCysSerLysCysCysHisGlyAspTyr	47
301	CAGTCTCCACAAACCGGAGACTACCCCGAGACTGCAGTAGTGTTCATGGAGACTAC	360
48	SerPheArgGlyTyrGlnGlyProGlyProGlyProProGlyProGlyIleProGlyAsn	67
361	AGCTTTCCAGGCTACCAAGGCCCCCTGGGCCACCGGGCCCTCTGCCATTCAGGAAC	420
68	HisGlyAsnAsnGlyAsnAsnGlyAlaThrGlyHisGluGlyAlaLysGlyGlyLysGly	87
421	CATGGAAACAATGGCAACAATGAGGCCATGGTCATGAAGAGCCAAAGGTGAGAAGGC	480
88	AspLysGlyAspLeuGlyProArgGlyGluArgGlyGlnHisGlyProLysGlyGlyLys	107
481	GACAAAGTGACCTGGGGCTTCAGGGGAGCGGGGCGAGCATGGCCCCCAAGGAGNAG	540
108	GlyTyrProGlyIleProProGluLeuGlnIleAlaPheMetAlaSerLeuAlaThrHis	127
541	GGCTACCCGGGGATTCCACGAGAACTTCAGATTGCATTCATGGCTTCTCTGGCAACCCAC	600
128	PheSerAsnGlnAsnSerGlyIleIlePheSerSerValCluThrAsnIleGlyAsnPhe	147
601	TTCAGCAATCAGAAACAGTGGGATTATCTTCAGCAGGTGTTGAGACCACCAATTGCAACTTC	660
148	PheAspValMetThrGlyArgPheGlyAlaProValSerGlyValTyrPhePheThrPhe	167
661	TTTGATGTCATGACTGGTAGATTTGGGGCCCACTATCAGGTGTGTATTCTTCACCTTC	720
168	SerMetMetLysHisGluAspValGluGluValTyrValTyrLeuMetHisAsnGlyAsn	187
721	AGCATGATGAAGCATGAGGATGTTGAGGAAGTCTATGTGTACCTTATGCACAATGGCAAC	780
188	ThrValPheSerMetTyrSerTyrGluMetLysGlyLysSerAspThrSerSerAsnHis	207
781	ACAGTCTTCAGCATGTACAGCTATGAATGAAGGGCAAAATCAGATACATCCAGCAATCAT	840
208	AlaValLeuLysLeuAlaLysGlyAspGluValTrpLeuArgMetGlyAsnGlyAlaLeu	227
841	GCTGTCTGAAGCTAGCCAAAGGGGATGAGTTTGGCTGGCAATGGCAATGGCGCTCTC	900
228	HisGlyAspHisGlnArgPheSerThrPheAlaGlyPheLeuLeuPheGluThrLys	246
901	CATGGGACCAACAGCTTCTCCACTTTGCAGGATTCCTGCTCTTTGAAACTAAG	957

RESULT 7	
AAC99776	
ID	AAC99776 standard; cDNA; 1035 BP.
XX	
AC	AAC99776;
XX	
AC	
XX	
DT	08-MAR-2001 (first entry)
XX	
XX	Skin cell cDNA, SEQ ID NO: 424.
DE	
XX	
XX	
KW	Rat; skin cell; cytostatic; antiinflammatory; anti-HIV;
KW	neotropic; neuroprotective; vulnerary; immunomodulatory; vaccine;
KW	keratinocyte growth stimulation; cancer; angiogenesis inhibition;
KW	Inflammation; neurological disease; ss.
XX	
OS	Rattus sp.
XX	
PN	WO200069884-A2.
XX	
XX	
PD	23-NOV-2000.
XX	
XX	
PF	15-MAY-2000; 2000WO-NZ00075.
XX	
XX	
PR	14-MAY-1999; 99US-0312283.
XX	
PA	(GENE-) GENESIS RES & DEV CORP LTD.

XX	Watson JD, Strachan L, Onrust R, Sleeman M, Kumble KD, Murison JG:
PI	WPI: 2001-007495/01.
DR	P-PSDB; AAB55908.
XX	
XX	New isolated polynucleotide used in the identification of genetic
PT	disorders and encoding polypeptides used for treating inflammatory
PT	disease, cancer and neurological diseases -
XX	
XX	Claim 1: Page 317-318; 352pp: English.
XX	
CC	The present polynucleotide encodes a polypeptide which is expressed in
CC	mammalian skin cells. The polypeptide is useful for stimulating
CC	keratinocyte growth and motility, inhibiting the growth of cancer cells,
CC	modulating angiogenesis, inhibiting angiogenesis and vascularisation of
CC	tumours, modulating skin inflammation, stimulating the growth of
CC	epithelial cells, inhibiting the binding of human immunodeficiency virus
CC	(HIV)-1 to leukocytes, and treating inflammatory disease, cancer and
CC	neurological diseases. The polynucleotide can be used as a marker, in
CC	the identification of genetic disorders, and for the design of
CC	oligonucleotides for examining expression patterns.
XX	
XX	Sequence 1035 BP: 255 A: 242 C: 298 G: 240 T: 0 other:
SO	

Alignment Scores:		
Pred. No.:	3,068-95	1035
Score:	1311.00	236
Percent Similarity:	97.15%	Matches:
Best Local Similarity:	95.93%	Conservative:
Query Match:	95.90%	Mismatches:
DB:	22	Indels:
		Gaps:

US-10-036-041-2 (1-246) x AAC99776 (1-1035)

Qy	1	MetLeuTrpArgGlnLeuIleTyrTrpGlnLeuLeuAlaLeuPhePheLeuProPheCys	20
Db	92	ATGCTCAGGAGGCAGCTGCTGTGGTGGCACCTGCTGGCTTTGCTTCTCCCATTTTGC	151
Qy	21	LeucysGlnAspGluTyrMetGluSerProGlnThrGlyLeuGlyLeuProAspCysSer	40
Db	152	CTGTGTCAAGATGAATACATGGAGTCTCCAAAGCTGGAGGACTGCCCCAGACTGCAGC	211
Qy	41	LysCysCysHisGlyAspTyrSerPheArgGlyTyrGlnGlyProProGlyProProGly	60
Db	212	AAGTGTTCCTACGACGATTATGGATTCCGTGTTACCAAGGGCCCCCTGGACCCCGCAGGT	271
Qy	61	ProProGlyIleProGlyAsnHisGlyAsnAsnGlyAsnAsnGlyAlaThrGlyHisGlu	80
Db	272	CCTCTGGCATTCAGAAACCATGGAACAATGAAATAACGGAGGCCACTGGCCACGAA	331
Qy	81	GlyAlaLysGlyGluLysGlyAspLysGlyAspLeuGlyProArgGlyGluArgGlyGln	100
Db	332	GGGGCCAAAGGCTCAGAAAGGAGACAAAGCGCACTGGGGCCCTCGAGGGGGAACGGGGCGAG	391
Qy	101	HisGlyProLysGlyGluLysGlyTyrProGlyIleProProGluLeuGlnIleAlaPhe	120
Db	392	CATGGCCCCAAAGGATAGAAAGGATACCCAGGGGTGCCACAGAGCTCGAGATTGCGTTC	451
Qy	121	MetAlaSerLeuAlaThrHisPheSerAsnGlnAsnSerGlyIleIlePheSerSerVal	140
Db	452	ATGGCTTCTCTACCGACTCACTTCAGCAATCAGACAGCTGGCATTATCTTCAGCAGCTGT	511
Qy	141	GluThrAsnIleGlyAsnPhePheAspValMetThrGlyArgPheGlyAlaProValSer	160
Db	512	GAGACCAACATTCGAAACTCTCTCATGTGTCATGACTGGTAGATTGGGGCCCCCGTATCA	571
Qy	161	GlyValTyrPhePheThrPheSerMetMetLysHisGluAspValGluGluValTyrVal	180
Db	572	GGCGTGTATTCTTCACCTTCAGCATGATGAAGCATGAGGACCTGGAGGAAGTGTATGTG	631
Qy	181	TyrLeuMethHisAsnGlyAsnThrValPheSerMetTyrSerTyrGluMetLysGlyLys	200

Db 632 TACCTTATGCACAAATGGTAACACCGGTCTTCAGCATGTACAGCTATGAAACAAAGGGAAAA 691

Oy 201 SerAspThrSerSerAsnHisAlaValLeuLysLeuAlaLysGlyAspGluValTrpLeu 220
 Db 692 TCAGATACATCCAGCAACCAATGCAAGTGTGAAGTTGGCCAAAGAGAGATGAAGTCTGGCTA 751

Oy 221 ArgMetGlyAsnGlyAlaLeuHisGlyAspHisGlnArgPheSerThrPheAlaGlyPhe 240
 Db 752 AGAATGGCAACAGGTGCCCTCCATGGGGACCACCAGCGCTTCTTACCTTCGCGAGGCTTT 811

Oy 241 LeuLeuPheGluThrLys 246
 Db 812 CTGCTTTTGAACCTAAG 829

RESULT 8
 ABL34928
 ID ABL34928 standard; cDNA; 1035 BP.
 XX
 AC ABL34928;
 XX
 DT 04-APR-2002 (first entry)
 XX
 DE Rat cDNA isolated from skin cells SEQ ID NO: 424.
 XX
 KW Human; rat; mouse; skin cell; skin wound; cancer; growth defect;
 KW developmental defect; inflammatory disease; dermatological; vulnerary;
 KW immunomodulator; anti-inflammatory; cytostatic; neuroprotective; gene;
 KW ss.
 XX
 OS Rattus sp.
 XX
 PN WO200190357-A1.
 XX
 PD 29-NOV-2001.
 XX
 XX 24-MAY-2001; 2001WO-N200099.
 XX
 XX 24-MAY-2000; 2000US-206650P.
 PR
 XX 25-JUL-2000; 2000US-221232P.
 XX
 PA (GENE-) GENESIS RES & DEV CORP LTD.
 XX
 PI Watson JD, Strachan L, Sleeman M, Onrust R, Murison JG, Kumble KD;
 XX
 DR WPI; 2002-122020/16.
 XX
 XX New polynucleotides and polypeptides encoded by the polynucleotides
 PT isolated from skin cells, useful for treating skin wounds, cancers,
 PT growth and developmental defects, inflammatory diseases, or for
 PT modulating immune responses -
 XX
 PS Claim 1; Page 262; 466pp; English.
 XX
 CC The present invention provides the protein and coding sequences of cDNAs
 CC isolated from human, murine and rat skin cell libraries. The sequences
 CC can be used in the development of therapeutic agents useful in the
 CC treatment of skin diseases, including skin wounds, cancer, growth
 CC defects, developmental defects and inflammatory diseases. The proteins
 CC have important roles in the induction of hair growth, cell proliferation
 CC and cell-cell interaction, in maintaining tissue integrity, in wound
 CC healing and in modulating immune responses. The present sequence is a
 CC cDNA of the invention.
 XX
 SQ Sequence 1035 BP; 255 A; 242 C; 298 G; 240 T; 0 other;

Alignment Scores:
 Pred. No.: 3,06e-95 Length: 1035
 Score: 1311.00 Matches: 236
 Percent Similarity: 97.15% Conservative: 3
 Best Local Similarity: 95.93% Mismatches: 7
 Query Match: 95.90% Indels: 0
 DB: 24 Gaps: 0

US-10-036-041-2 (1-246) x ABL34928 (1-1035)

Oy 1 MetLeuTrpArgGlnLeuIleTyrTrpGlnLeuLeuAlaLeuPhePheLeuProPheCys 20
 Db 92 ATGCTCAGAGGACGAGCTCGTCTGGTGGCACCTGCTGGTGGTCTTCTCTCCCAATTTGC 151

Oy 21 LeuCysGlnAspGluTyrMetGluSerProGlnThrGlyLeuProProAspCysSer 40
 Db 152 CTGTGTCAAGATGAATACATGAGTCTCCACAAGCTGGAGGACTGCCCCACAGCTGCAGC 211

Oy 41 LysCysCysHisGlyAspTyrSerPheArgGlyTyrGlnGlyProGlyProGlyProGly 60
 Db 212 AAGTGTGGCCATGGAGATTATGGATTCCGTGGTACCAGGCCGCCCTGGACCCCGAGT 271

Oy 61 ProProGlyIleProGlyAsnHisGlyAsnAsnGlyAsnAsnGlyAlaThrGlyHisGlu 80
 Db 272 CCTCTGGCATTCAGGAACCAATGGAACAATGGAACAATGGAACAATGGAACAATGGAACA 331

Oy 81 GlyAlaLysGlyGluLysGlyAspLysGlyAspLeuGlyProArgGlyGluArgGlyGln 100
 Db 332 GGGCCCAAGGTGAGAAAGAGAGAACAGCGACCTGGGGCCTCGAGGGAGACGGGGGAG 391

Oy 101 HisGlyProLysGlyGluLysGlyTyrProGlyIleProGlyLeuGlnIleAlaPhe 120
 Db 392 CATGGCCCCAAGATAGAGGATACCCAGGGTGGCCACAGAGCTGCAGATTGCGTTC 451

Oy 121 MetAlaSerLeuAlaThrHisPheSerAsnGlnAsnSerGlyIleIlePheSerSerVal 140
 Db 452 ATGGCTTCTCTAGCGACTCACTTCAGCAATCAGAACAGCTGGCATTTATCTCAGCAGTGT 511

Oy 141 GluThrAsnIleGlyAsnPhePheAspValMetThrGlyArgPheGlyAlaProValSer 160
 Db 512 GAGACCAACATTTGAAACTTCTTCATGTCATGACTGTAGATTGGGGCCCCCGTATCA 571

Oy 161 GlyValTyrPhePheThrPheSerMetMetLysHisGluAspValGluValTyrVal 180
 Db 572 GCGGTGATTCTTCACCTTCAGCATGATGAGCATGAGGACCTGGAGGAAGTGTATGTG 631

Oy 181 TyrLeuMetHisAsnGlyAsnThrValPheSerMetTyrSerTyrGluMetLysGlyLys 200
 Db 632 TACCTTATGCACAAATGGTAAACACGCTGTTCAGCATGTACAGCTATGAAACAAAGGAAA 691

Oy 201 SerAspThrSerSerAsnHisAlaValLeuLysLeuAlaLysGlyAspGluValTrpLeu 220
 Db 692 TCAGATACATCCAGCAACCAATGCTGCTGAAGTTGGCCAAAGAGAGATGAAGTCTGGCTA 751

Oy 221 ArgMetGlyAsnGlyAlaLeuHisGlyAspHisGlnArgPheSerThrPheAlaGlyPhe 240
 Db 752 AGAATGGCAACAGGTGCCCTCCATGGGGACCACCAGCGCTTCTTACCTTCGCGAGGCTTT 811

Oy 241 LeuLeuPheGluThrLys 246
 Db 812 CTGCTTTTGAACCTAAG 829

RESULT 9
 AAC64064
 ID AAC64064 standard; DNA; 1117 BP.
 XX
 AC AAC64064;
 XX
 DT 19-FEB-2001 (first entry)
 XX
 DE Mouse zacr2 DNA, SEQ ID NO:11.
 XX
 KW Mouse zacr2; adipocyte complement related protein homologue;
 KW ACRP30; C1q domain; collagen-like domain; energy balance modulation;
 KW cellular metabolism; metabolic disorder; obesity; anorexia;
 KW antimicrobial agent; infection; platelet aggregation inhibition;
 KW adhesion; activation; vascular injury; antibacterial; antiviral;
 XX human zacr3 homologue; ds.
 OS Mus musculus.

PN WO200063377-A1.
 XX 26-OCT-2000.
 XX 19-APR-2000; 2000WO-US10454.
 PF 20-APR-1999; 99US-0294943.
 XX (ZYMO) ZYMOGENETICS INC.
 PA Piddington CS, Bishop PD;
 PI WPI; 2000-665243/64.
 DR P-PSDB; AAB29582.
 XX Novel zacr3 polypeptides used to treat or prevent bacterial or viral
 PT infections, for wound healing, improving blood flow, and to analyze
 PT energy efficiency in mammals -
 XX Disclosure; Page 115-117; 123pp; English.
 XX The invention relates to the human zacr3 protein (AAB29580) and to
 CC nucleic acids which encode it (AAC64058, AAC64063). zacr3 is a homologue
 CC of adipocyte complement related protein (ACRP30) and contains a
 CC collagen-like domain comprising Gly-xaa-xaa or Gly-xaa-Pro repeats, and a
 CC C-terminal C1q domain comprising 10 beta-strands. The zacr3 gene is
 CC located on chromosome 5p12. The invention also relates to zacr3
 CC fragments, fusion proteins containing zacr3 polypeptides,
 CC zacr3-specific antibodies, expression constructs and host cells
 CC comprising zacr3 nucleic acids, and methods of recombinant production of
 CC zacr3. Human zacr3, and its agonists and antagonists may be used in the
 CC study and modulation of cellular metabolism and energy balance in
 CC mammals, and may therefore be used to treat disorders such as obesity and
 CC anorexia, and conditions associated with these disorders. Due to its C1q
 CC like domain, zacr3 and zacr3-containing fusion proteins may be useful
 CC as antimicrobial agents, promoting lysis or phagocytosis of infectious
 CC organisms such as bacteria or viruses. zacr3, its fragments, fusion
 CC proteins, antibodies and activity modulators may also be used to inhibit
 CC collagen-induced platelet aggregation, adhesion, or activation, and may
 CC therefore have potential for promoting blood flow within the vasculature
 CC of a mammal e.g., to treat injury to the vasculature or other collagenous
 CC tissue. Human zacr3 and its antibodies may additionally be used to study
 CC dimerisation and oligomerisation. The present sequence represents DNA
 CC encoding mouse zacr2, a homologue of human zacr3.
 XX
 SQ Sequence 1117 BP; 284 A; 272 C; 293 G; 268 T; 0 other;
 Alignment Scores:
 Pred. No.: 3.34e-95 Length: 1117
 Score: 1311.00 Matches: 236
 Percent Similarity: 96.75% Conservative: 2
 Best Local Similarity: 95.93% Mismatches: 8
 Query Match: 95.90% Indels: 0
 DB: 21 Gaps: 0
 US-10-036-041-2 (1-246) x AAC64064 (1-1117)
 QY 1 MetLeuTrpArgGlnLeuIleTyrTrpGlnLeuLeuAlaLeuPhePheLeuProPheCys 20
 DB 111 ATGCTCGGAGGAGCAGCATCTGGTGGCACCTGCTGCTTTCTCTCCCATTTTGC 170
 QY 21 LeuCysGlnAspGluTyrMetGluSerProGlnThrGlyGlyLeuProAspCysSer 40
 DB 171 CTGTGTCAAGATGAATACATGGAGTCTCCCAAGCTGGAGGACTGCCCCAGACTGCAGC 230
 QY 41 LysCysCysHisGlyAspTyrSerPheArgGlyTyrGlnGlyProProGlyProGly 60
 DB 231 AAGTGTGCCATGAGATATGATTCGTGTTACCAAGGCCCTCTGGACCTCCAGGT 290
 QY 61 ProProGlyIleProGlyAsnHisGlyAsnAsnGlyAsnGlyAlaThrGlyHisGlu 80
 DB 291 CCTCTGGCATTCAGGAAACCATGGAAACAATGGGAACAATGGAGCTACTGGCCATGAA 350
 QY 81 GlyAlaLysGlyGluLysGlyAspLysGlyAspLeuGlyProArgGlyGluArgGlyGln 100
 DB 351 GGGGCCAAGGTGAGAAAGGAGACAAAGGACCTAGGCCCTCGAGGAGAACGGGGCAG 410
 QY 101 HisGlyProLysGlyGluLysGlyTyrProGlyIleLeuProGluLeuGlnIleAlaPhe 120
 DB 411 CATGGCCCCAAAGGAGAGAAAGGCTACCCAGGGGTGCCACCAGAACTGCAGATTGCATT 470
 QY 121 MetAlaSerLeuAlaThrHisPheSerAsnGlnAsnSerGlyIleIlePheSerSerVal 140
 DB 471 ATGGCTTCTCTAGCAACTCATTTCAGCAATCAGAACAGCTGGCATTTATCTTCAGCAGTGT 530
 QY 141 GluThrAsnIleGlyAsnPhePheAspValMetThrGlyArgPheGlyAlaProValSer 160
 DB 531 GAGACCAACATTTGGAACACTTCTTCATGTCATGACTGGAGATTTGGGGCCCCCCTATCA 590
 QY 161 GlyValTyrPhePheThrPheSerMetMetLysHisGluAspValGluGluValTyrVal 180
 DB 591 GGTGTGTATTCTTCACCTTCAGCATGATGAAGCATGAGGACCTAGAGCAAGTGTATGTG 650
 QY 181 TyrLeuMetHisAsnGlyAsnThrValPheSerMetTyrSerTyrGluMetLysGlyLys 200
 DB 651 TACCTTATGCAACAGCGCAACACACTCTCAGCATGTACAGTATGAACAAGGGAATA 710
 QY 201 SerAspThrSerSerAsnHisAlaValLeuLysLeuAlaLysGlyAspGluValTrpLeu 220
 DB 711 TCAGATACATCCAGCAACCATGCTGCTGAAGTTGGCCAAAGGAGATGAAGTCTGGCTA 770
 QY 221 ArgMetGlyAsnGlyAlaLeuHisGlyAspHisGlnArgPheSerThrPheAlaGlyPhe 240
 DB 771 AGAATGGGCAACGGTGCCTCCACGGGACCACCAACGCGCTTCTCCACCTTCGACGGCTTT 830
 QY 241 LeuLeuPheGluThrLys 246
 DB 831 CTGCTCTTTGAAACTAAG 848
 RESULT 10
 ID AAZ61633 standard; cDNA; 1123 BP.
 XX
 AC AAZ61633;
 XX
 DT 27-MAR-2000 (first entry)
 XX
 DE cDNA encoding rat skin cell secreted protein, SEQ ID NO:28.
 XX
 KW Skin; dermal papilla; keratinocyte; neonatal foreskin fibroblast;
 KW embryonic skin cell; keratinocyte stem cell; transit amplifying cell;
 KW secreted; transmembrane; inflammation; cancer; neurological disease;
 KW angiogenesis; tumour vascularisation; growth disorder;
 KW developmental disorder; skin wound; hair follicle disorder;
 XX anti-inflammatory; cytostatic; neuroprotective; vulnery; ss.
 OS Rattus sp.
 XX
 XX WO9955865-A1.
 XX
 PD 04-NOV-1999;
 XX
 PF 29-APR-1999; 99WO-NZ00051.
 XX
 PR 29-APR-1998; 98US-0069726.
 PR 09-NOV-1998; 98US-0188930.
 XX
 PA (GENE-) GENESIS RES & DEV CORP LTD.
 XX
 PI Strachan L, Sleeman M, Watson JD, Onrust R, Kumble A, Murison JG;
 XX
 DR WPI; 2000-072177/06.
 XX
 PT Novel polynucleotides useful for the treatment of various conditions
 PT including wounds and cancer -
 XX

PS Claim 1; Page 73; 235pp; English.

XX The invention relates to novel nucleic acid sequences derived from rat dermal papilla, human keratinocytes and neonatal foreskin fibroblasts, and mouse embryonic skin, keratinocyte stem cells and transit amplifying cells. Polypeptides of the invention may be used to treat inflammation, cancer and neurological diseases. The proteins may be used to stimulate the growth and motility of keratinocytes, to inhibit the growth of cancer cells, to modulate angiogenesis and tumour vascularisation, to modulate skin inflammation, to modulate epithelial cell growth and to inhibit binding of HIV-1 to leukocytes. The invention may also be used to treat growth and developmental defects, skin wounds and hair follicle disorders. Sequences AAZ61606-261832 represent cDNA sequences derived from several mouse, rat or human skin cell types. Sequences AAZ61606-261649, AAZ61725-261811 and AAZ61826 encode proteins with an N-terminal signal sequence, indicating that the proteins are secreted. Sequences AAZ61650-261668, AAZ61766-261780, AAZ61812-261817 and AAZ61827-261829 encode proteins with one or more putative transmembrane domains.

XX SQ Sequence 1123 BP; 277 A; 266 C; 321 G; 258 T; 1 other;

Alignment Scores:

Pred. No.:	3-36e-95	Length:	1123
Score:	1311.00	Matches:	236
Percent Similarity:	97.15%	Conservative:	3
Best Local Similarity:	95.93%	Mismatches:	7
Query Match:	95.90%	Indels:	0
DB:	21	Gaps:	0

US-10-036-041-2 (1-246) x AAZ61633 (1-1123)

QY 1 MetLeuTrpArgGlnLeuIleTyrTrpGlnLeuLeuAlaLeuPheLeuProPheCys 20
 DB 180 ATGCTCAGGAGCGAGCTGCTGTGGTGCACCTGCTGCTTTTCTTCTCCATTTTGC 239
 QY 21 LeuCysGlnAspGluTyrMetGluSerProGlnThrGlyGlyLeuProAspCysSer 40
 DB 240 CTGTGTCAGATGAATACATGAGTCTCCACAGCTGGAGGAGCTGCCCCCAGAGCTGAGC 299
 QY 41 LysCysCysHisGlyAspTyrSerPheArgGlyTyrGlnGlyProGlyProGly 60
 DB 300 AAGTGTCCATGGAGTTATGATTCCTGCTGTTTACCAAGGCCCCCTGGACCCCAAGGT 359
 QY 61 ProGlyIleProGlyAsnHisGlyAsnAsnGlyAsnGlyAlaThrGlyHisGlu 80
 DB 360 CCTCTGGCATTCAGGAAACCATGGAACAATGGAATAACGAGGACCTGGCCACGAA 419
 QY 81 GlyAlaLysGlyGlyLysGlyAspLysGlyAspLeuGlyProArgGlyGluArgGlyGln 100
 DB 420 GGGGCCAAGGGTGAGAAAGAGACAAGGCGACCTGGGGCTCGAGGGGAACGGGGCAG 479
 QY 101 HisGlyProLysGlyGlyLysGlyTyrProGlyIleProGlyLeuGlnIleAlaPhe 120
 DB 480 CATGGCCCCAAGATAGAGGATACCCAGGGGTGCCACAGAGCTGCAGATTGCGTTC 539
 QY 121 MetAlaSerLeuAlaThrHisPheSerAsnGlnAsnSerGlyIleIlePheSerSerVal 140
 DB 540 ATGGCTTCTCTAGCGACTCACTTCAGCAATCAGAACAGTGGCATTATCTTCAGCAGTGT 599
 QY 141 GluThrAsnIleGlyAsnPhePheAspValMetThrClyArgPheGlyAlaProValSer 160
 DB 600 GAGACCAACATTGGAACCTCTTCGATGTCTATGACTGGTAGATTTGGGGCCCCCGTATCA 659
 QY 161 GlyValTyrPhePheThrPheSerMetMetLysHisGluAspValGluGluValTyrVal 180
 DB 660 GGGCTGATTTCTTCACTTCACCATGATGATGATGATGATGATGATGATGATGATGATG 719
 QY 181 TyrLeuMetHisAsnGlyAsnThrValPheSerMetTyrSerTyrGluMetLysGlyLys 200
 DB 720 TACCTTATGCAATGTAACAGGGTGTTCAGCATGTATACAGCTATGAAACAAGAGGAA 779
 QY 201 SerAspThrSerSerAsnHisAlaValLeuLysLeuAlaLysGlyAspGluValTrpLeu 220

Db 780 TCAGATACATCCAGCAACCATGCTGCTGAAGTTGGCCAAAGGAGATGAAGTCTGGCTA 839
 QY 221 ArgMetGlyAsnGlyAlaLeuHisGlyAspHisGlnArgPheSerThrPheAlaGlyPhe 240
 Db 840 AGAATGGGCAACGGTGGCCCTCCATGGGACCAACAGCGCTTCTTACCTTCGAGGCTTT 899
 QY 241 LeuLeuPheGluThrLys 246
 Db 900 CTGCTTTTGAACCTAAG 917
 RESULT 11
 AAZ61730
 ID AAZ61730 standard; cDNA; 1123 BP.
 XX
 AC AAZ61730;
 DT 27-MAR-2000 (first entry)
 XX
 DE cDNA encoding rat skin cell secreted protein, SEQ ID NO:203.

XX KW Skin; dermal papilla; keratinocyte; neonatal foreskin fibroblast;
 KW embryonic skin cell; keratinocyte stem cell; transit amplifying cell;
 KW secreted; transmembrane; inflammation; cancer; neurological disease;
 KW angiogenesis; tumour vascularisation; growth disorder;
 KW developmental disorder; skin wound; hair follicle disorder;
 KW anti-inflammatory; cytostatic; neuroprotective; vulnery; ss.
 OS Rattus sp.
 XX
 PN WO9955865-A1.
 XX
 PD 04-NOV-1999.
 XX
 PF 29-APR-1999; 99WO-NZ00051.
 XX
 PR 29-APR-1998; 98US-00699726.
 PR 09-NOV-1998; 98US-0188930.
 XX
 PA (GENE-) GENESIS RES & DEV CORP LTD.
 XX
 PI Strachan L, Sleeman M, Watson JD, Onrust R, Kumble A, Murison JG;
 XX
 DR WPI; 2000-072177/06.
 XX
 DR P-PSDB: AAY76025.
 XX
 PT Novel polynucleotides useful for the treatment of various conditions
 XX including wounds and cancer -
 XX
 PS Claim 1; Page 137; 235pp; English.

XX The invention relates to novel nucleic acid sequences derived from rat dermal papilla, human keratinocytes and neonatal foreskin fibroblasts, and mouse embryonic skin, keratinocyte stem cells and transit amplifying cells. Polypeptides of the invention may be used to treat inflammation, cancer and neurological diseases. The proteins may be used to stimulate the growth and motility of keratinocytes, to inhibit the growth of cancer cells, to modulate angiogenesis and tumour vascularisation, to modulate skin inflammation, to modulate epithelial cell growth and to inhibit binding of HIV-1 to leukocytes. The invention may also be used to treat growth and developmental defects, skin wounds and hair follicle disorders. Sequences AAZ61606-261832 represent cDNA sequences derived from several mouse, rat or human skin cell types. Sequences AAZ61606-261649, AAZ61725-261811 and AAZ61826 encode proteins with an N-terminal signal sequence, indicating that the proteins are secreted. Sequences AAZ61650-261668, AAZ61766-261780, AAZ61812-261817 and AAZ61827-261829 encode proteins with one or more putative transmembrane domains.

XX SQ Sequence 1123 BP; 277 A; 266 C; 321 G; 258 T; 1 other;

Alignment Scores:
 Pred. No.: 3-36e-95 Length: 1123

KW		inflammation; neurological disease; ss.
XX		
OS	Rattus sp.	
XX		
PN	WO200069884-A2.	
XX		
PD	23-NOV-2000.	
XX		
XX	15-MAY-2000: 2000WO-NZ00075.	
XX		
PF	14-MAY-1999: 99US-0312283.	
XX		
PR	(GENE-) GENESIS RES & DEV CORP LTD.	
XX		
PI	Watson JD, Strachan L, Onrust R, Sleeman M, Kumble KD, Murison JG;	
XX		
DR	WPI: 2001-007495/01.	
XX	P-PSDB; AAB55908.	
DR		
XX		
PT	New isolated polynucleotide used in the identification of genetic disorders and encoding polypeptides used for treating inflammatory disease, cancer and neurological diseases -	
XX		
PS	Claim 1; Page 87; 352pp; English.	
XX		
CC	The present polynucleotide encodes a polypeptide which is expressed in mammalian skin cells. The polypeptide is useful for stimulating keratinocyte growth and motility, inhibiting the growth of cancer cells, modulating angiogenesis, inhibiting angiogenesis and vascularisation of tumours, modulating skin inflammation, stimulating the growth of epithelial cells, inhibiting the binding of human immunodeficiency virus (HIV)-1 to leukocytes, and treating inflammatory disease, cancer and neurological diseases. The polynucleotide can be used as a marker, in the identification of genetic disorders, and for the design of oligonucleotides for examining expression patterns.	
XX		
SQ	Sequence 1123 BP; 277 A; 266 C; 321 G; 258 T; 1 other:	
 Alignment Scores:		
Pred. No.:	3,36e-95	Length: 1123
Score:	1311.00	Matches: 236
Percent Similarity:	97.15%	Conservative: 3
Best Local Similarity:	95.93%	Mismatches: 7
Query Match:	95.90%	Indels: 0
DB:	22	Gaps: 0
 US-10-036-041-2 (1-246) x AAC99566 (1-1123)		
Qy	1 MetLeuTrpArgGlnLeuIleTyrrGlnLeuLeuAlaLeuPhePheLeuProPheCys	20
Db	180 ATGTCTCAGGAGGCACGTCGCTGGTGGCACCTGCTGGCTTTGCTTTCTCCATTTTC	239
Qy	21 LeuCysGlnAspGluTyrrMetGluSerProGlnThrGlyGlyLeuProAspCysSer	40
Db	240 CTGTGTCAAGATGAATACATGGAGTCTCCACACTGGAGGACTGCCCCACACTCAGC	299
Qy	41 LysCysCysHisGlyAspTyrrSerPheArgGlyTyrrGlnGlyProGlyProproGly	60
Db	300 AACTGTTGCCATGAGATTATGATTCCGTTGTTACCAGGGCCCCCTGGACCCCAGGT	359
Qy	61 ProProGlyTleProGlyAsnHisGlyAsnAsnGlyAsnAsnGlyAlaThrGlyHisGlu	80
Db	360 CCTCTGTCATTCCAGAAACCATGGAAACAATGGAATAACGGAGCCACTGGCCACGAA	419
Qy	81 GlyAlaLysGlyGluLysGlyAspLysGlyAspleucGlyProArgGlyGluArgGlyGln	100
Db	420 GGGCCCAAGGGTGAGAAGGAGACAAAGGACCTCGGGGCTCGAGGGGAACGGGGGAG	479
Qy	101 HisGlyProLysGlyGluLysGlyTyrrProGlyTyleProGluLeuGlnIleAlaPhe	120
Db	480 CATGGCCCAAGGATAGAGGGATATCCAGGGGTGCCACAGCTGCAGATTGGTTC	539
Qy	121 MetaLaSerLeuAlaThrHisPheSerAsnGlnAsnSerGlyTleIlePheSeSerVal	140

```
|||||
Db 540 ATGGCTTCTCTACGGACTCACTTCAGCAATCAGAACAGTGGCATTATCTTCACGAGTGTT 599
QY 141 GluThrAsnIleGlyAsnPheAspValMetThrGlyArgPheGlyAlaProValSer 160
Db 600 GAGACCAACATTTGAAACTTCTTCGATGTCTACGTGGTAGATTGGGGCCCGGTATCA 659
QY 161 GlyValTyrPhePheThrPheSerMetMetLysHisGluAspValGluGluValTyrVal 180
Db 660 GGGGTGTATTCTTCACCTTCACCATGATGAACATCAGGACGCTGGAGGAAGTGTATGTG 719
QY 181 TyrLeuMetHisAsnGlyAsnThrValPheSerMetTyrSerTyrGluMetLysGlyLys 200
Db 720 TACCTTATGCACATCGTACACGGTGTTCAGCATGTACAGCTATGAAACAAGGGGAAAA 779
QY 201 SerAspThrSerSerAsnHisAlaValLeuLysLeuAlaLysGlyAspGluValTyrLeu 220
Db 780 TCAGATACATCCAGCAACCATGCTGCTGAAGTTGGCCAAAGGAGATGAAGTCTGGCTA 839
QY 221 ArgMetGlyAsnGlyAlaLeuHisGlyAspHisGlnArgPheSerThrPheAlaGlyPhe 240
Db 840 AGAATGGGCAACGGTCCCTCCATGGGGACCAACCGGCTTCTCTACCTTCGCGAGGCTTT 899
QY 241 LeuLeuPheGluThrLys 246
Db 900 CTGCTTTTGAACACTAAG 917
RESULT 13
AAC99663
ID AAC99663 standard; cDNA; 1123 BP.
XX
AC AAC99663;
XX
DT 08-MAR-2001 (first entry)
XX
DE Skin cell cDNA, SEQ ID NO: 203.
XX
KW Rat; skin cell; cytostatic; antiinflammatory; anti-HIV;
KW neutropic; neuroprotective; vulnery; immunomodulatory; vaccine;
KW keratinocyte growth stimulation; cancer; angiogenesis inhibition;
KW inflammation; neurological disease; ss.
XX
OS Rattus sp.
XX
PN WO200069884-A2.
XX
PD 23-NOV-2000.
XX
PF 15-MAY-2000; 2000WO-NZ00075.
XX
PR 14-MAY-1999; 99US-0312283.
XX
PA (GENE-) GENESIS RES & DEV CORP LTD.
XX
PI Watson JD, Strachan L, Onrust R, Sleeman M, Kumble KD, Murison JG;
XX WPI; 2001-007495/01.
XX P-PSDB; AAB55958.
XX
New isolated polynucleotide used in the identification of genetic
disorders and encoding polypeptides used for treating inflammatory
disease, cancer and neurological diseases -
Claim 1; Page 176-177; 352pp; English.
XX
The present polynucleotide encodes a polypeptide which is expressed in
mammalian skin cells. The polypeptide is useful for stimulating
keratinocyte growth and motility, inhibiting the growth of cancer cells,
modulating angiogenesis, inhibiting angiogenesis and vascularisation of
tumours, modulating skin inflammation, stimulating the growth of
epithelial cells, inhibiting the binding of human immunodeficiency virus
(HIV)-1 to leukocytes, and treating inflammatory disease, cancer and
neurological diseases. The polynucleotide can be used as a marker, in
```

```
CC the identification of genetic disorders, and for the design of
CC oligonucleotides for examining expression patterns.
XX
SQ Sequence 1123 BP; 277 A; 266 C; 321 G; 258 T; 1 other;
Alignment Scores:
Pred. No.: 3,36e-95 Length: 1123
Score: 1311.00 Matches: 236
Percent Similarity: 97.15% Conservative: 3
Best Local Similarity: 95.93% Mismatches: 7
Query Match: 95.90% Indels: 0
DB: 22 Gaps: 0
US-10-036-041-2 (1-246) x AAC99663 (1-1123)
QY 1 MetLeuTyrArgGlnLeuIleTyrTrpGlnLeuLeuAlaLeuPheLeuProPheCys 20
Db 180 ATCTCAGGAGGAGCTGCTGCTGGTGGCAGCTGCTGGCTTTGCTTTCTCCATTTGC 239
QY 21 LeuCySlnAspGluTyrMetGluSerProGlnThrGlyGlyLeuProProAspCysSer 40
Db 240 CTGTGTCAAGATGAATACATGAGTCTCCACAAGCTGGAGACTGCCCCAGACTGCAGC 299
QY 41 LysCysCysHisGlyAspTyrSerPheArgGlyTyrGlnGlyProGlyProGly 60
Db 300 AAGTGTGGCCATGGAGATTATGATTCCGTGGTTACCAAGGGCCCCCTGACCCCGAGGT 359
QY 61 ProProGlyIleProGlyAsnHisGlyAsnAsnGlyAsnAsnGlyAlaThrGlyHisGlu 80
Db 360 CCTCTGGCATTCAGGAACCATGGAACAATGGAATAACGAGGCCACTGCCACGAA 419
QY 81 GlyAlaLysGlyGluLysGlyAspLysGlyAspLeuGlyProArgGlyGluArgGlyGln 100
Db 420 GGGGCCAAGGCTGAGAAAGGAGACAAAGGCGCTCGGGCTCAGAGGGAACGGGCGAG 479
QY 101 HisGlyProLysGlyGluLysGlyTyrProGlyIleProGlyLeuGlnIleAlaPhe 120
Db 480 CATGGCCCCAAAGGATAGAAAGGATACCCAGGGGTGCCACGAGCTGCAGATTGGGTT 539
QY 121 MetAlaSerLeuAlaThrHisPheSerAsnGlnAsnSerGlyIleIlePheSerSerVal 140
Db 540 ATGGCTTCTCTACGACTCCTCCTCAGCAATCAGACAGTGGCATTTCTTCAGCAGTGT 599
QY 141 GluThrAsnIleGlyAsnPheAspValMetThrGlyArgPheGlyAlaProValSer 160
Db 600 GAGACCAACATTTGAAACTTCTTCGATGTCTACGTGGTAGATTGGGGCCCGGTATCA 659
QY 161 GlyValTyrPhePheThrPheSerMetMetLysHisGluAspValGluGluValTyrVal 180
Db 660 GGGGTGTATTCTTCACCTTCACCATGATGAACATGAGGACGCTGGAGGAAGTGTATGTG 719
QY 181 TyrLeuMetHisAsnGlyAsnThrValPheSerMetTyrSerTyrGluMetLysGlyLys 200
Db 720 TACCTTATGCACATCGTAAACACGGTGTTCAGCATGTACAGCTATGAAACAAGGGAAAA 779
QY 201 SerAspThrSerSerAsnHisAlaValLeuLysLeuAlaLysGlyAspGluValTyrLeu 220
Db 780 TCAGATACATCCAGCAACCATGCTGCTGAAGTTGGCCAAAGGAGATGAAGTCTGGCTA 839
QY 221 ArgMetGlyAsnGlyAlaLeuHisGlyAspHisGlnArgPheSerThrPheAlaGlyPhe 240
Db 840 AGAATGGGCAACGGTCCCTCCATGGGGACCAACCGGCTTCTCTACCTTCGCGAGGCTTT 899
QY 241 LeuLeuPheGluThrLys 246
Db 900 CTGCTTTTGAACACTAAG 917
RESULT 14
ABL34718
ID ABL34718 standard; cDNA; 1123 BP.
XX
AC ABL34718;
XX
```


04-APR-2002 (first entry)
Rat cDNA isolated from skin cells SEQ ID NO: 28.
Human: rat; mouse; skin cell; skin wound; cancer; growth defect;
developmental defect; inflammatory disease; dermatological; vulnary;
immunomodulator; anti-inflammatory; cytostatic; neuroprotective; gene;
ss.
Rattus sp.
WO200190357-A1.
29-NOV-2001.
24-MAY-2001; 2001WO-NZ00099.
24-MAY-2000; 2000US-206650P.
25-JUL-2000; 2000US-221232P.
(GENE-) GENESIS RES & DEV CORP LTD.
Watson JD, Strachan L, Sleeman M, Onrust R, Murison JG, Kumble KD;
WPI; 2002-122020/16.
New polynucleotides and polypeptides encoded by the polynucleotides
isolated from skin cells; useful for treating skin wounds, cancers,
growth and developmental defects, inflammatory diseases, or for
modulating immune responses
Claim 1; Page 86-87; 466pp; English.
The present invention provides the protein and coding sequences of cDNAs
isolated from human, murine and rat skin cell libraries. The sequences
can be used in the development of therapeutic agents useful in the
treatment of skin diseases, including skin wounds, cancer, growth
defects, developmental defects and inflammatory diseases. The proteins
have important roles in the induction of hair growth, cell proliferation
and cell-cell interaction, in maintaining tissue integrity, in wound
healing and in modulating immune responses. The present sequence is a
cDNA of the invention.
Sequence 1123 BP; 277 A; 266 C; 321 G; 258 T; 1 other;
Alignment Scores:
Pred. No.: 3.36e-95 Length: 1123
Score: 1311.00 Matches: 236
Percent Similarity: 97.15% Conservative: 3
Best Local Similarity: 95.93% Mismatches: 7
Query Match: 95.90% Indels: 0
DB: 24 Gaps: 0
US-10-036-041-2 (1-246) x ABL34718 (1-1123)
QY 1 MetLeuTrpArgGlnLeuIleTyrTrpGlnLeuLeuAlaLeuPheLeuProPheGys 20
Db 180 ATGCTCAGGAGGCGAGCTGCTGGTGGACCTCTGCTGCTTTCTTCTCCCATTTTC 239
QY 21 LeuCysGlnAspGluTyrMetGluSerProGlnThrGlyGlyLeuProProAspCysSer 40
Db 240 CTGTGTCAAGATCAATACATGAGTCTCCACAGCTGGAGGACTGCCCCAGACTGCAGC 299
QY 41 LysCysCysHisGlyAspTyrSerPheArgGlyTyrGlnGlyProGlyProProGly 60
Db 300 AAGTGTGGCATGGAGATTATGATTCCGTTGTTACCAAGGGCCCTGGAGCCGCCAGGT 359
QY 61 ProProGlyTleProGlyAsnHisGlyAsnAsnGlyAsnGlyAlaThrGlyHisGlu 80
Db 360 CCTCCTGGGATTCAGGAACACCATGGAAACAATGGAAATACGGAGCCACTGGCCAGAA 419
QY 81 GlyAlaLysGlyGlyLysGlyAspLysGlyAspLeuGlyProArgGlyGluArgGlyGln 100

Db 420 GGGCCCAAGGTTGAGAAAGGAGACAAAGCGACCTGGGGCTCTGAGGGGAACGGGGCAG 479
QY 101 HisGlyProLysGlyGluLysGlyTyrProGlyTyrProGlyLeuGlnIleAlaPhe 120
Db 480 CATGGCCCCAAAGATAGAGAGGATACCCAGGGGTGGCCACAGAGCTGCAGATTGGCGTTC 539
QY 121 MetAlaSerLeuAlaThrHisPheSerAsnGlnAsnSerGlyIleIlePheSerSerVal 140
Db 540 ATGGCTTCTTAGGACTCACTTCAGCAATCAGAACAGTGGCATTATCTTCAGCAGTGT 599
QY 141 GluThrAsnIleGlyAsnPhePheAspValMetThrGlyArgPheGlyAlaProValSer 160
Db 600 GAGACCAACATTTGAAACTTCTTCGATGTCTAGCTGATAGATTGGGGCCCGCTATCA 659
QY 161 GlyValTyrPhePheThrPheSerMetMetLysHisGluAspValGluGluValTyrVal 180
Db 660 GCGGTGTATTTCCTACCTTCAGCATGATGAAGCATGAGGACGTGGAGGAGTGTATGTG 719
QY 181 TyrLeuMetHisAsnGlyAsnThrValPheSerMetTyrSerTyrGluMetLysGlyLys 200
Db 720 TACCTTATGCACATGTAACACGGTGTTCAGCATGTACAGCTATGAACAAGGAAAA 779
QY 201 SerAspThrSerSerAsnHisAlaValLeuLysLeuAlaLysGlyAspGluValTrpLeu 220
Db 780 TCAGATACATCCAGCAACCATGCTGCTGAAGTTGGCAAGGAGATGAAGTCTGGCTA 839
QY 221 ArgMetGlyAsnGlyAlaLeuHisGlyAspHisGlnArgPheSerThrPheAlaGlyPhe 240
Db 840 AGAATGGGCAACGGTGGCCCTCCATGGGGACCAACAGCGCTTCTTACCTTCTAGGCTTT 899
QY 241 LeuLeuPheGluThrLys 246
Db 900 CTGCTTTTGAACATAAG 917
RESULT 15
ABL34815
ID ABL34815 standard; cDNA; 1123 BP.
XX
AC ABL34815;
XX
DT 04-APR-2002 (first entry)
XX
DE Rat cDNA isolated from skin cells SEQ ID NO: 203.
XX
KW Human: rat; mouse; skin cell; skin wound; cancer; growth defect;
KW developmental defect; inflammatory disease; dermatological; vulnary;
KW immunomodulator; anti-inflammatory; cytostatic; neuroprotective; gene;
XX
OS Rattus sp.
XX
PN WO200190357-A1.
XX
PD 29-NOV-2001.
XX
PF 24-MAY-2001; 2001WO-NZ00099.
XX
PR 24-MAY-2000; 2000US-206650P.
PR 25-JUL-2000; 2000US-221232P.
XX
PA (GENE-) GENESIS RES & DEV CORP LTD.
XX
PI Watson JD, Strachan L, Sleeman M, Onrust R, Murison JG, Kumble KD;
XX
DR WPI; 2002-122020/16.
XX
PT New polynucleotides and polypeptides encoded by the polynucleotides
PT isolated from skin cells; useful for treating skin wounds, cancers,
PT growth and developmental defects, inflammatory diseases, or for
PT modulating immune responses
XX
PS Claim 1; Page 155-156; 466pp; English.
XX

CC The present invention provides the protein and coding sequences of cDNAs
CC isolated from human, murine and rat skin cell libraries. The sequences
CC can be used in the development of therapeutic agents useful in the
CC treatment of skin diseases, including skin wounds, cancer, growth
CC defects, developmental defects and inflammatory diseases. The proteins
CC have important roles in the induction of hair growth, cell proliferation
CC and cell-cell interaction, in maintaining tissue integrity, in wound
CC healing and in modulating immune responses. The present sequence is a
CC cDNA of the invention.
XX

SQ Sequence 1123 BP; 277 A; 266 C; 321 G; 258 T; 1 other;

Alignment Scores:

Pred. No.: 3,36e-95 Length: 1123
Score: 1311.00 Matches: 236
Percent Similarity: 97.15% Conservative: 3
Best Local Similarity: 95.93% Mismatches: 7
Query Match: 95.90% Indels: 0
DB: 24 Gaps: 0

US-10-036-041-2 (1-246) x ABL34815 (1-1123)

QY 1 MetLeuTrpArgGlnLeuIleTyrTrpGlnLeuAlaLeuPheLeuProPheCys 20
DB 180 ATGCTCAGGAGGAGCTGCTGTGGTGCACCTCTGCTTTCCTTCCTCCCATTTGC 239
QY 21 LeuCysGlnAspGluTyrMetGluSerProGlnThrGlyGlyLeuProAspCysSer 40
DB 240 CTGTGTCAGATGAATACATGAGTCTCCACAGCTGGAGGACTGCCCCAGACTGCAGC 299
QY 41 LysCysCysHisGlyAspTyrSerPheArgGlyTyrGlnGlyProGlyProGlyProGly 60
DB 300 AAGTGTGTCCATGAGATTATGATTCCGTGTTACCAAGGGCCCTCGGACCCCCAGGT 359
QY 61 ProProGlyIleProGlyAsnHisGlyAsnAsnGlyAsnGlyAlaThrGlyHisGlu 80
DB 360 CCTCTCGGCAATCCAGAAACCATGGAACAATGGAATAACAGGACCACTGGCCACGAA 419
QY 81 GlyAlaLysGlyGluLysGlyAspLysGlyAspLeuGlyProArgGlyGluArgGlyGln 100
DB 420 GGGCCCAAGGCTGAGAAAGGAGACAAAGGCGCTCGAGGGCTCGAGGGAAAGGGGCGAG 479
QY 101 HisGlyProLysGlyGluLysGlyTyrProGlyIleProGlyLeuGlnIleAlaPhe 120
DB 480 CATGGCCCCAAAGATAGAAAGGATACCCAGGGGTGCCACAGAGCTGCAGATTGCGTTC 539
QY 121 MetAlaSerLeuAlaThrHisPheSerAsnGlnAsnSerGlyIleIlePheSerSerVal 140
DB 540 ATGGCTCTCTAGCGACTCACTTCAGCAATCAGACAGTGGCAATATCTTCAGCAGGTGT 599
QY 141 GluThrAsnIleGlyAsnPhePheAspValMetThrGlyArgPheGlyAlaProValSer 160
DB 600 GAGACCAACATTGGAACTTCTTCGATGTCTACATGCTAGATTGGGGCCCCCGTATCA 659
QY 161 GlyValTyrPhePheThrPheSerMetMetCysHisGluAspValGluGluValTyrVal 180
DB 660 GGGCGTGATTCTTCACTTTCAGCATGATGAAGCATGAGGACGCTGGAGGAAGTGTATGT 719
QY 181 TyrLeuMetHisAsnGlyAsnThrValPheSerMetTyrSerTyrGluMetLysGlyLys 200
DB 720 TACCTTATGCACAAATGGTAACGGGTGTTACGATGTACAGCTATGAAACAAAGGAAAA 779
QY 201 SerAspThrSerSerAsnHisAlaValLeuLysLeuAlaLysGlyAspGluValTyrLeu 220
DB 780 TCAGATACATCCAGCAACCATGAGTGTGTAAGTTCGCCAAGAGAGATGAAGTCTGGCTA 839
QY 221 ArgMetCysAsnGlyAlaLeuHisGlyAspHisGlnArgPheSerThrPheAlaGlyPhe 240
DB 840 AGAATGGCAACGGTGCCTTCCATGGGGACCAACAGCGCTTCTCTACCTTCGCGAGGCTTT 899
QY 241 LeuLeuPheGluThrLys 246
DB 900 CTGCTTTTGAACACTAAG 917

RESULT 16

AAD12584
ID AAD12584 standard; cDNA; 1927 BP.

XX
AC AAD12584;

XX
DT 25-SEP-2001 (first entry)

XX
DE Human protein having hydrophobic domain encoding cDNA clone HP10781.

XX
KW Human; hydrophobic domain; gene therapy; nutritional supplement;
KW cell proliferation; immunomodulatory; autoimmune disorder; antimicrobial;
KW multiple sclerosis; rheumatoid arthritis; insulin-dependent diabetes;
KW haematopoiesis; tissue growth activity; Parkinson's disease; cytostatic;
KW Huntington's disease; Alzheimer's disease; chemotactic; chemokinetic;
KW haemostatic; thrombolytic; tumour growth inhibitor; anabolic;
KW contraceptive; antiinfertility; antiinflammatory; ss.

XX
OS Homo sapiens.

XX
FH Key Location/Qualifiers
FT CDS 89..760

FT /tag= a
FT /product= "Human protein having hydrophobic domain"
FT /note= "CDS is specifically claimed in claim 3"

FT sig_peptide 89..157

FT /tag= b
FT mat_peptide 158..757

FT /tag= c
FT /product= "Mature human protein with hydrophobic domain"

FT WO200149728-A2.

XX
PN 12-JUL-2001.

XX
PF 28-DEC-2000; 2000WO-JP09359.

XX
PR 06-JAN-2000; 2000JP-0000585.

XX
PR 06-JAN-2000; 2000JP-0000588.

XX
PR 11-JAN-2000; 2000JP-0002299.

XX
PR 03-FEB-2000; 2000JP-0026862.

XX
PR 03-MAR-2000; 2000JP-0058367.

XX
PA (PROT-) PROTEGENE INC.
PA (SAGA) SAGAMI CHEM RES CENT.

XX
PI Kato S, Kimura T;

XX
WPI; 2001-418355/44.

XX
P-PSDB; AAE06589.

XX
Claim 4; Page 352-354; 563pp; English.

XX
CC The present sequence is human protein with hydrophobic domain encoding
CC cDNA clone HP10781. The polynucleotide and polypeptide of the invention
CC may be used in the prevention, diagnosis and treatment of diseases
CC associated with inappropriate polypeptide expression. The polynucleotides
CC may be used to produce the polypeptide, by inserting the nucleic acids
CC into a host cell and culturing the cell to express the protein. The
CC polynucleotides and its complementary sequences may also be used as DNA
CC probes in diagnostic assays and also used in gene therapy. The
CC polypeptides may also be used as antigens in the production of antibodies
CC and in assays to identify modulators of polypeptide expression and
CC activity. The polypeptides and nucleic acids may be used as nutritional
CC supplements, to modulate cytokine and cell proliferation activity, to
CC modulate immune stimulation or suppression (e.g. for the treatment of
CC microbial infections and autoimmune disorders such as multiple sclerosis,
CC rheumatoid arthritis and insulin-dependent diabetes), to modulate

CC haematopoiesis, to modulate tissue growth activity (e.g. for the
 CC treatment of Parkinson's disease, Huntington's disease and Alzheimer's
 CC disease), to modulate activin and inhibin activity (e.g. for controlling
 CC fertility), to modulate chemotactic and chemokinetic activity, to
 CC modulate haemostatic and thrombolytic activity, to modulate receptor
 CC ligand activity, to modulate inflammation and to inhibit tumour growth.
 XX
 SQ Sequence 1927 BP; 550 A; 416 C; 452 G; 509 T; 0 other;

Alignment Scores: 2,22e-93 Length: 1927
 Pred. No.: 1291.50 Matches: 245
 Score: 1291.50
 Percent Similarity: 76.80% Conservative: 0
 Best Local Similarity: 76.80% Mismatches: 1
 Query Match: 94.48% Indels: 74
 DB: 22 Gaps: 1

US-10-036-041-2 (1-246) x AAD12584 (1-1927)

QY 1 MetLeuTrpArgGlnLeuIleTyrTrpGlnLeuAlaLeuPheLeuProPheCys 20
 DB 89 ATGCTTTGGAGGAGCTCATCTATTGGCAACTGCTGGCTTTGTTTCTCCCTTTTTC 148
 QY 21 LeuCysGlnAspGluTyrMetGlu----- 28
 DB 149 CTGTGTCAGATGAATACATGGAGGTGAGCGGAAGAACTAATAAGTGTGGCAAGAATA 208
 QY 28 ----- 28
 DB 209 GTGCAAGCCAGCAGACAGCTGGCCGTAGCGGTCCAGGAGGAGAAAGTGAGAGACGG 268
 QY 28 ----- 28
 DB 269 AGCCATCTAAACTGGGACTGTGGATAATAACACTTCTACAGACCTAAATCCCTGAGA 328
 QY 28 ----- 28
 DB 329 CCAGATGAGCTACGCCACCCGAGGTAGATGACCTAGCTAGCCAGATCACCACATTCTGGGC 388
 QY 29 ---SerProGlnThrGlyGlyLeuProAspCysSerLysCysHisGlyAspTyr 47
 DB 389 CAGTCTCCAAACCGGAGGACTACCCCGAGACTGCAAGTGAAGTGTCTCATGGAGACTAC 448
 QY 48 SerPheArgGlyTyrGlnGlyProGlyProGlyProGlyProGlyProGlyProGlyAsn 67
 DB 449 AGCTTTCCGAGGTACCAAGGCCCCCTGGGCCACCGGCCCTCTCGCATTCAGGAAGAAC 508
 QY 68 HisGlyAsnAsnGlyAsnAsnGlyAlaThrGlyHisGluGlyAlaLysGlyGlyGly 87
 DB 509 CATGGAACAATGGCAACAATGGAGCCACTGGTTCATGAAGGAGGCCAAAGGTGAGAAGGC 568
 QY 88 AspLysGlyAspLeuGlyProArgGlyGlyGlyGlyGlyGlyGlyGlyGlyGlyGly 107
 DB 569 GACAAAGTGACCTGGGGGCTCGAGGGGAGCGGGGGGAGCATGGCCCAAGAGGAGAAG 628
 QY 108 GlyTyrProGlyIleProProGluLeuGlnIleAlaPheMetAlaSerLeuAlaThrHis 127
 DB 629 GGCTACCGGGGATTCCACCAGAACTTCAGATTGATTCATGCTTCTCTGGCAACCCAC 688
 QY 128 PheSerAsnGlnAsnSerGlyIleIlePheSerSerValGlnThrAsnIleGlyAsnPhe 147
 DB 689 TTCAGCAATCAGAACAGCTGGGATATCTTCAGCAGTCTTGAGACCAACATTTGGAACATTC 748
 QY 148 PheAspValMetThrGlyAcqPheGlyAlaProValSerGlyValTyrPhePheThrPhe 167
 DB 749 TT-GATGTCATGACTGGTAGATTTGGGGCCCCAGATATCAGGTGTGTATTCTTCACCTTC 807
 QY 168 SerMetMetLysHisGluAspValGluGluValTyrValTyrLeuMetHisAsnGlyAsn 187
 DB 808 AGCATGATGAAGCATGAGGATGTTGAGGAAGTGTATCTGTACCTTATGCAACATGGCAAC 867
 QY 188 ThrValPheSerMetTyrSerTyrGluMetLysGlyLysSerAspThrSerSerAsnHis 207

DB 868 ACAGTCTTCAGCATGTACAGCTATGAATGAAGGGCAAAATCAGATACATCCAGCAATCAT 927
 QY 208 AlaValLeuLysLeuAlaLysGlyAspGluValTrpLeuArgMetGlyAsnGlyAlaLeu 227
 DB 928 CTGTGCTGAAGTAGCCAAAGGGAGTAGAGTTGGCTGGGAATGGCATGGGCTCTC 987
 QY 228 HisGlyAspHisGlnArgPheSerThrPheAlaGlyRheLeuLeuPheGluThrLys 246
 DB 988 CATGGGGACCACCAACGCTTCTCCACCTTTGCAGGATTCTCTCTTTTGAAGACTAAG 1044

RESULT 17
 AAF94076
 ID AAF94076 standard; DNA; 810 BP.
 XX
 AC AAF94076:
 XX
 DT 23-MAY-2001 (first entry)
 XX
 DE Primer specific for DNA encoding secretory/membrane protein SEQ ID 510.
 KW Human; secretory protein; membrane protein; vaccine; gene therapy;
 KW rheumatoid arthritis; diabetes; PCR primer; ss.
 XX Synthetic.
 XX EP1067182-A2.
 XX
 PD 10-JAN-2001.
 XX
 PF 07-JUL-2000; 2000EP-0114090.
 XX
 PR 08-JUL-1999; 99JP-0194179.
 PR 11-JAN-2000; 2000JP-0118775.
 PR 02-MAY-2000; 2000JP-0183766.
 XX
 PA (HELI-) HELIX RES INST.

Ota T, Isogai T, Nishikawa T, Kawai Y, Sugiyama T, Hayashi K;
 WPI; 2001-093989/11.
 Nucleic acids encoding secretory proteins/membrane proteins, useful in
 gene therapy or as candidate target molecules in drug development -
 Claim 4; SEQ ID 510; 609pp + CD ROM; English.

This invention relates to nucleic acid sequences AAF93744 - AAF93916
 which encode human secretory or membrane proteins represented by
 AAF93917 - AAF88419. Included in the invention are primers
 AAF93917 - AAF94295 and AAF62232 - AAF62235 which are used to isolate the
 cDNA sequences of the invention. The invention also includes methods for
 the production of antibodies directed against the proteins, and cDNA
 sequences, which can be used in vaccines. The polynucleotide sequences
 can be used in gene therapy. The polynucleotide sequences and the
 proteins they encode may be used in the prevention, treatment and
 diagnosis of diseases associated with inappropriate secretory
 protein/membrane protein expression. The nucleic acids and complementary
 sequences may also be used as DNA probes in diagnostic assays
 (e.g. polymerase chain reactions (PCR)) to detect and quantitate the
 presence of similar nucleic acid sequences in samples. They may also be
 used to study the expression and function of secretory proteins/membrane
 polypeptides and their role in metabolism. The polypeptides may be used
 as antigens in the production of antibodies against them and in assays to
 identify modulators (agonists and antagonists) of expression and
 activity. The antibodies and antagonists may also be used as therapeutic
 agents to down regulate expression and activity. The antibodies may also
 be used as diagnostic agents for detecting the presence of the
 polypeptides in samples (e.g. by enzyme linked immunosorbant assay
 (ELISA)). Examples of diseases which may be treated include rheumatoid
 arthritis and diabetes.

Sequence 810 BP; 200 A; 201 C; 218 G; 188 T; 3 other;

Alignment Scores:

Pred. No.: 3,1e-91 Length: 810
 Score: 1259.00 Matches: 234
 Percent Similarity: 97.51% Conservative: 1
 Best Local Similarity: 97.10% Mismatches: 6
 Query Match: 92.10% Indels: 2
 DB: 22 Gaps: 0

US-10-036-041-2 (1-246) x AAF94076 (1-810)

QY 1 MetLeuTrpArgGlnLeuIleTyrTrpGlnLeuAlaLeuPheLeuProPheCys 20
 Db 89 ATGCTTTGGAGGAGCTCATCTATGGCACTGCTGGCTTTGTTTCTCCCTTTTTC 148
 QY 21 LeuCysGlnAspGluTyrMetGluSerProGlnThrGlyLeuProAspCysSer 40
 Db 149 CTGTGTCAGATGAATACATGGAGTCTCCACAACCGAGGACTACCCAGACTGCAGT 208
 QY 41 LysCysCysHisGlyAspTyrSerPheArgGlyTyrGlnGlyProGlyProGly 60
 Db 209 AAGTGTGTGTCAGACTACAGCTTTTCGAGGCTACCAAGGCCCTCTGGGCCACCGGC 268
 QY 61 ProGlyLeuProGlyAsnHisGlyAsnAsnGlyAsnGlyAlaThrGlyHisGlu 80
 Db 269 CTTCTCTGGCATTCAGGAACCATGGAAACATGGCAACATGGAGCCACTGGTCAATGAA 328
 QY 81 GlyAlaLysGlyGluLysGlyAspLysGlyAspLeuGlyProArgGlyGluArgGlyGln 100
 Db 329 GGAGCCAAAGTGAGAGGGCGACAAAGGTGACCTGGGGCTCGAGGGAGCGGGCGAG 388
 QY 101 HisGlyProLysGlyGluLysGlyTyrProGlyLeuProGlyLeuGlnIleAlaPhe 120
 Db 389 CATGGCCCCAAAGAGAGAGAGGGCTACCCGGGATTCACAGAACTTCAGATTGCATTC 448
 QY 121 MetAlaSerLeuAlaThrHisPheSerAsnGlnAsnSerGlyIleIlePheSerVal 140
 Db 449 ATGGCTTCTCTGGCAACCCACTTCAGCAATCAGAACAGTGGGATTCATTCAGCAGTGT 508
 QY 141 GluThrAsnIleGlyAsnPheAspValMetThrGlyArgPheGlyAlaProValSer 160
 Db 509 GAGACCAACATTCGAACTCTTTGATGTCATGACTGCTAGATTGGGGCCCCAGTATCA 568
 QY 161 GlyValTyrPhePheThrPheSerMetMetLysHisGluAspValGluGluValTyrVal 180
 Db 569 GGTGTGTATTTCTACCTTCAGCATGATGAAGCATGAGGATGTTGAGGAAGTGTATGTG 628
 QY 181 TyrLeuMetHisAsnGlyAsnThrValPheSerMetTyrSerTyrGluMetLysGlyLys 200
 Db 629 TACCTTATGCACATGGCAACAGCTCTTCAACATGTACAGCTATGAAATGAAGGGCAAA 688
 QY 201 SerAspThrSerSerAsnHisAlaValLeuLysLeuAlaLysGlyAspGluValTyrLeu 220
 Db 689 TCAGATACATCCAGCATCATCTGCTCTGAA-CTACCCAAANGGATGAGTTGGCTG 747
 QY 221 ArgMetClyAsnGlyAlaLeuHisGlyAspHisGlnArgPheSerThrPheAlaGlyPhe 240
 Db 748 CNAAT-GGCAATGGCGCTNTTTCATGGGGACCAACAGCTTCTTCACTTTTCAGGATTC 806
 QY 241 Leu 241
 Db 807 CTG 809
 RESULT 18
 AAI59230
 ID AAI59230 standard; cDNA; 1792 BP.
 XX
 AC AAI59230;
 XX
 DT 22-OCT-2001 (first entry)
 XX
 DE Human polynucleotide SEQ ID NO 1433.
 XX
 KW Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;

KW peripheral nervous system; neuropathy; central nervous system; CNS;
 KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
 KW amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
 KW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
 KW leukaemia; ss.
 XX Homo sapiens.
 OS
 XX
 PN WO200153312-A1.
 XX
 PD 26-JUL-2001.
 XX
 PF 26-DEC-2000; 2000WO-US34263.
 XX
 PR 21-JAN-2000; 2000US-0488725.
 PR 25-APR-2000; 2000US-0552317.
 PR 09-JUL-2000; 2000US-0598042.
 PR 19-JUL-2000; 2000US-0620312.
 PR 03-AUG-2000; 2000US-0653450.
 PR 14-SEP-2000; 2000US-0652191.
 PR 19-OCT-2000; 2000US-0693036.
 PR 29-NOV-2000; 2000US-0727344.
 XX
 PA (HYSE-) HYSEQ INC.
 XX
 PI Tang YT, Liu Z, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;
 PI Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J;
 PI Zhao QA, Zhou P, Goodrich R, Drmanac RT;
 XX
 DR WPI: 2001-442253/47.
 DR P-PSDB; AAM40074.
 XX
 XX Novel nucleic acids and polypeptides, useful for treating disorders
 PT such as central nervous system injuries -
 XX
 PS Claim 1; SEQ ID NO 1433; 10078pp; English.
 CC The invention relates to human nucleic acids (AAI57798-AAI61369) and
 CC the encoded polypeptides (AAM38642-AAI42213) with nootropic,
 CC immunosuppressant and cytostatic activity. The polynucleotides are useful
 CC in gene therapy. A composition containing a polypeptide or polynucleotide
 CC system, such as peripheral nervous injuries, peripheral neuropathy and
 CC localised neuropathies and central nervous system diseases, such as
 CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
 CC lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
 CC utilisation of the activities such as: Immune system suppression,
 CC Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
 CC and thrombolytic activity, cancer diagnosis and therapy, drug screening,
 CC assays for receptor activity, arthritis and inflammation, leukaemias and
 CC C.N.S disorders.
 CC Note: The sequence data for this patent did not form part of the printed
 CC specification.
 XX
 SQ Sequence 1792 BP; 541 A; 352 C; 393 G; 506 T; 0 other;

Alignment Scores:

Pred. No.: 5,02e-87 Length: 1792
 Score: 1211.00 Matches: 219
 Percent Similarity: 100.00% Conservative: 0
 Best Local Similarity: 100.00% Mismatches: 0
 Query Match: 88.59% Indels: 0
 DB: 22 Gaps: 0

US-10-036-041-2 (1-246) x AAI59230 (1-1792)

QY 28 GluSerProGlnThrGlyGlyLeuProAspCysSerLysCysHisGlyAspTyr 47
 Db 241 GAGTCTCCACAAACCGGAGGACTACCCAGACTGCAGTAGTAAAGTGTGTCATGAGACTAC 300
 QY 48 SerPheArgGlyTyrGlnGlyProGlyProGlyProGlyProGlyProGlyProGly 67
 Db 301 AGCTTTTCGAGGCTACCAAGGCCCTCTGGGCCACCGGCCCTCTGTCGATTCAGGAAC 360

QY 68 HisGlyAspAsnGlyAsnAsnGlyAlaThrGlyHisGluGlyAlaLysGlyGluLysGly 87
 DB 361 CATGGAAACATGGCAACATGGAGCCACTGGTCATGAAGGACCAAGGTGAGAGGGC 420
 QY 88 AspLysGlyAspLeuGlyProArgGlyGluArgGlyGlnHisGlyProLysGlyGluLys 107
 DB 421 GACAAAGGTGACCTGGGGCTCGAGGGAGCGGGCGGCGATGCGCCCAAGAGAGAAG 480
 QY 108 GlyTyrProGlyIleProGluLeuGlnIleAlaPheMetAlaSerLeuAlaThrHis 127
 DB 481 GGCTACCCGGGATTCACACAGAACTTCAGATTGCAATTCATGGCTTCTCTGGCAACCCAC 540
 QY 128 PheSerAsnGlnAsnSerGlyIleIlePheSerSerValGluThrAsnIleGlyAsnPhe 147
 DB 541 TTCAGCAATCAGAACAGTGGGATTATCTTCAGCAGTGTTCAGACCAACATTTGGAACCTTC 600
 QY 148 PheAspValMetThrGlyArgPheGlyAlaProValSerGlyValTyrPhePheThrPhe 167
 DB 601 TTTGATGTCATGACTGATAGATTGGGGCCCAAGTATCAGGTGTGTATTTCTTCACCTTC 660
 QY 168 SerMetMetLysHisGluAspValGluGluValTyrValTyrLeuMetHisAsnGlyAsn 187
 DB 661 AGCATGATGAAGCATGAGATGTTGAGGAAGTGTATGTGACCTTATGCACAATGGCAAC 720
 QY 188 ThrValPheSerMetTyrSerTyrGluMetLysGlyLysSerAspThrSerSerAsnHis 207
 DB 721 ACAGTCTTCAGCATGTACAGCTATGAATGAAGGGCAATCAGATACATCCACCATCAT 780
 QY 208 AlaValLeuLysLeuAlaLysGlyAspGluValTrpLeuArgMetGlyAsnGlyAlaLeu 227
 DB 781 GCTGTGCTGAAGTAGCCAAAGGGGATGAGGTTTGGCTGCGAATGGCAATGGCGCTCTC 840
 QY 228 HisGlyAspHisGlnArgPheSerThrPheAlaGlyPheLeuLeuPheGluThrLys 246
 DB 841 CATGGGACCAACACGCTTCTCCACCTTTGCAGGATTCCTGCTCTTTGAAACTAAG 897
 RESULT 19
 ID AAI199523
 ID AAI199523 standard; cDNA; 1620 BP.
 XX AC AAI199523;
 XX DT 07-JAN-2002 (first entry)
 XX DE Human polynucleotide SEQ ID NO 21.
 KW Cytostatic; immunosuppressive; nootropic; neuroprotective; antiviral;
 KW antiallergic; hepatotropic; antidiabetic; antiinflammatory; antiulcer;
 KW vulnerary; anticonvulsant; antibacterial; antifungal; antiparasitic;
 KW cardiant; gene therapy; cancer; immune disorder; cardiovascular disorder;
 KW neurological disease; infection; human; secreted protein; ss.
 OS Homo sapiens.
 XX WO200155173-A2.
 XX PD 02-AUG-2001.
 XX PF 17-JAN-2001; 2001WO-US01356.
 XX 31-JAN-2000; 2000US-0179065.
 PR 04-FEB-2000; 2000US-0180628.
 PR 24-FEB-2000; 2000US-0184664.
 PR 16-MAR-2000; 2000US-0186350.
 PR 17-MAR-2000; 2000US-0198974.
 PR 18-MAR-2000; 2000US-0190076.
 PR 18-APR-2000; 2000US-0198123.
 PR 19-MAY-2000; 2000US-0205515.
 PR 07-JUN-2000; 2000US-0209467.
 PR 28-JUN-2000; 2000US-0214886.
 PR 30-JUN-2000; 2000US-0215135.
 PR 07-JUL-2000; 2000US-0216647.
 PR 07-JUL-2000; 2000US-0216880.
 PR 11-JUL-2000; 2000US-0217487.
 PR 11-JUL-2000; 2000US-0217496.
 PR 14-JUL-2000; 2000US-0218290.
 PR 26-JUL-2000; 2000US-0220963.
 PR 26-JUL-2000; 2000US-0220964.
 PR 14-AUG-2000; 2000US-0224518.
 PR 14-AUG-2000; 2000US-0224519.
 PR 14-AUG-2000; 2000US-0225213.
 PR 14-AUG-2000; 2000US-0225214.
 PR 14-AUG-2000; 2000US-0225266.
 PR 14-AUG-2000; 2000US-0225267.
 PR 14-AUG-2000; 2000US-0225268.
 PR 14-AUG-2000; 2000US-0225270.
 PR 14-AUG-2000; 2000US-0225447.
 PR 14-AUG-2000; 2000US-0225757.
 PR 14-AUG-2000; 2000US-0225758.
 PR 14-AUG-2000; 2000US-0225759.
 PR 18-AUG-2000; 2000US-0226279.
 PR 22-AUG-2000; 2000US-0226681.
 PR 22-AUG-2000; 2000US-0226868.
 PR 22-AUG-2000; 2000US-0227182.
 PR 23-AUG-2000; 2000US-0227009.
 PR 30-AUG-2000; 2000US-0228924.
 PR 01-SEP-2000; 2000US-0229287.
 PR 01-SEP-2000; 2000US-0229343.
 PR 01-SEP-2000; 2000US-0229344.
 PR 01-SEP-2000; 2000US-0229345.
 PR 05-SEP-2000; 2000US-0229509.
 PR 05-SEP-2000; 2000US-0229513.
 PR 06-SEP-2000; 2000US-0230437.
 PR 06-SEP-2000; 2000US-0230438.
 PR 08-SEP-2000; 2000US-0231242.
 PR 08-SEP-2000; 2000US-0231243.
 PR 08-SEP-2000; 2000US-0231244.
 PR 08-SEP-2000; 2000US-0231413.
 PR 08-SEP-2000; 2000US-0231414.
 PR 08-SEP-2000; 2000US-0232080.
 PR 12-SEP-2000; 2000US-0232081.
 PR 14-SEP-2000; 2000US-0232397.
 PR 14-SEP-2000; 2000US-0232398.
 PR 14-SEP-2000; 2000US-0232399.
 PR 14-SEP-2000; 2000US-0232400.
 PR 14-SEP-2000; 2000US-0232401.
 PR 14-SEP-2000; 2000US-0233063.
 PR 14-SEP-2000; 2000US-0233064.
 PR 14-SEP-2000; 2000US-0233065.
 PR 21-SEP-2000; 2000US-0234223.
 PR 21-SEP-2000; 2000US-0234274.
 PR 25-SEP-2000; 2000US-0234997.
 PR 25-SEP-2000; 2000US-0234998.
 PR 26-SEP-2000; 2000US-0235484.
 PR 27-SEP-2000; 2000US-0235834.
 PR 27-SEP-2000; 2000US-0235836.
 PR 29-SEP-2000; 2000US-0236327.
 PR 29-SEP-2000; 2000US-0236367.
 PR 29-SEP-2000; 2000US-0236368.
 PR 29-SEP-2000; 2000US-0236369.
 PR 29-SEP-2000; 2000US-0236370.
 PR 02-OCT-2000; 2000US-0236802.
 PR 02-OCT-2000; 2000US-0237037.
 PR 02-OCT-2000; 2000US-0237038.
 PR 02-OCT-2000; 2000US-0237039.
 PR 02-OCT-2000; 2000US-0237040.
 PR 13-OCT-2000; 2000US-0239935.
 PR 13-OCT-2000; 2000US-0239937.
 PR 20-OCT-2000; 2000US-0240960.
 PR 20-OCT-2000; 2000US-0241221.
 PR 20-OCT-2000; 2000US-0241785.
 PR 20-OCT-2000; 2000US-0241786.
 PR 20-OCT-2000; 2000US-0241787.
 PR 20-OCT-2000; 2000US-0241808.

20-OCT-2000; 2000US-0241809.
 20-OCT-2000; 2000US-0241826.
 01-NOV-2000; 2000US-0244617.
 08-NOV-2000; 2000US-0246474.
 08-NOV-2000; 2000US-0246475.
 08-NOV-2000; 2000US-0246476.
 08-NOV-2000; 2000US-0246477.
 08-NOV-2000; 2000US-0246478.
 08-NOV-2000; 2000US-0246523.
 08-NOV-2000; 2000US-0246524.
 08-NOV-2000; 2000US-0246525.
 08-NOV-2000; 2000US-0246526.
 08-NOV-2000; 2000US-0246527.
 08-NOV-2000; 2000US-0246528.
 08-NOV-2000; 2000US-0246532.
 08-NOV-2000; 2000US-0246609.
 08-NOV-2000; 2000US-0246610.
 08-NOV-2000; 2000US-0246611.
 08-NOV-2000; 2000US-0246612.
 08-NOV-2000; 2000US-0246613.
 17-NOV-2000; 2000US-0249207.
 17-NOV-2000; 2000US-0249208.
 17-NOV-2000; 2000US-0249209.
 17-NOV-2000; 2000US-0249210.
 17-NOV-2000; 2000US-0249211.
 17-NOV-2000; 2000US-0249212.
 17-NOV-2000; 2000US-0249213.
 17-NOV-2000; 2000US-0249214.
 17-NOV-2000; 2000US-0249215.
 17-NOV-2000; 2000US-0249216.
 17-NOV-2000; 2000US-0249217.
 17-NOV-2000; 2000US-0249218.
 17-NOV-2000; 2000US-0249244.
 17-NOV-2000; 2000US-0249245.
 17-NOV-2000; 2000US-0249264.
 17-NOV-2000; 2000US-0249265.
 17-NOV-2000; 2000US-0249266.
 17-NOV-2000; 2000US-0249267.
 17-NOV-2000; 2000US-0249297.
 17-NOV-2000; 2000US-0249299.
 17-NOV-2000; 2000US-0249300.
 01-DEC-2000; 2000US-0250160.
 01-DEC-2000; 2000US-0250391.
 05-DEC-2000; 2000US-0251030.
 05-DEC-2000; 2000US-0251988.
 05-DEC-2000; 2000US-0256719.
 06-DEC-2000; 2000US-0251479.
 08-DEC-2000; 2000US-0251856.
 08-DEC-2000; 2000US-0251868.
 08-DEC-2000; 2000US-0251869.
 08-DEC-2000; 2000US-0251989.
 08-DEC-2000; 2000US-0251990.
 11-DEC-2000; 2000US-0254097.
 05-JAN-2001; 2001US-0259678.
 (HUMA-) HUMAN GENOME SCI INC.

Rosen CA, Barash SC, Ruben SM;
 WPI; 2001-451924/48.
 P-PSDB; AAM99925.

New nucleic acids and polypeptides, useful for treating, preventing or ameliorating human disorders and diseases -

Claim 1; SEQ ID NO 21; 465pp + Sequence Listing; English.

The invention relates to novel human polynucleotides (AAI99513-AAI99538) and the encoded proteins (AAM99915-AAM99934) which are useful for preventing, treating or ameliorating medical conditions e.g. by protein or gene therapy. The genes are isolated from a range of human tissues disclosed in the specification. The nucleic acids, proteins, antibodies and (ant)agonists are useful in the diagnosis, treatment and prevention of: (a) cancer, e.g. breast and ovarian cancer and other cancers of the adrenal gland, bone, bone marrow, breast, gastrointestinal tract, liver, lung, or urogenital; (b) immune disorders e.g. Addison's disease.

CC allergies, autoimmune haemolytic anaemia, autoimmune thyroiditis,
 CC diabetes mellitus, Crohn's disease, multiple sclerosis, rheumatoid
 CC arthritis and ulcerative colitis; (c) cardiovascular disorders such as
 CC myocardial ischaemia; (d) wound healing; (e) neurological diseases
 CC e.g. cerebral anoxia and epilepsy; and (f) infectious diseases such as
 CC viral, bacterial, fungal and parasitic infections.
 CC Note: The sequence data for this patent did not form part of the
 CC printed specification, but was obtained in electronic format directly
 CC from WIPO at ftp.wipo.int/pub/published_pct_sequences.
 XX

SQ Sequence 1620 BP; 485 A; 332 C; 360 G; 440 T; 3 other;

Alignment Scores:

Pred. No.: 7.73e-87 Length: 1620
 Score: 1208.00 Matches: 218
 Percent Similarity: 100.00% Conservatives: 1
 Best Local Similarity: 99.54% Mismatches: 0
 Query Match: 88.37% Indels: 0
 DB: 22 Gaps: 0

US-10-036-041-2 (1-246) x AAI99523 (1-1620)

Qy 28 GluSerProGlnThrGlyGlyLeuProAspCysSerLysCysHisGlyAspTyr 47
 Db 21 CAGTCTCCACAAACCGAGGACTACCCAGACTGAGTAAGTGTCTCATGAGACTAC 80
 Qy 48 SerPheArgGlyTyrGlnGlyProGlyProGlyProGlyProGlyProGlyProGly 67
 Db 81 AGCTTTTCGAGGCTTACCAAGGCCCTCCGGGCCACCGGCCCTCTGGCAATTCAGGAAC 140
 Qy 68 HisGlyAsnAsnGlyAsnAsnGlyAlaThrGlyHisGlyGlyGlyGlyGlyGlyGly 87
 Db 141 CATGGAACAATGGCAACAATGGAGGCACTGGTTCATGAGGAGGCAAGGTGAGAGGGC 200
 Qy 88 AspLysGlyAspLeuGlyProArgGlyGlyGlyGlyGlyGlyGlyGlyGlyGlyGly 107
 Db 201 GACAAAGGTGACCTGGGGCTTCAGGGGACGGGGGAGGAGGAGGAGGAGGAGGAGG 260
 Qy 108 GlyTyrProGlyIleProGlyLeuGlyLeuGlyLeuGlyLeuGlyLeuGlyLeuGly 127
 Db 261 GGCTACCCGGGGATCCACCAAGTTCAGATTGCAATTCATGCTTCTCTGGCAACCCAC 320
 Qy 128 PheSerAsnGlnAsnSerGlyIleIlePheSerSerValGluThrAsnIleGlyAsn 147
 Db 321 TTCAGCAATCAGAACAGTGGGATTATCTTCAGCAGTGTTCAGAGCAACATTCGAAACTTC 380
 Qy 148 PheAspValMetThrGlyArgPheGlyAlaProValSerGlyValTyrPheThrPhe 167
 Db 381 TTTGATGTCATGACTGGTAGATTGGGGCCAGTATCAGTGTGTATTTCTTCACCTTC 440
 Qy 168 SerMetMetLysHisGlyAspValGluGluValTyrValTyrLeuMetHisAsnGly 187
 Db 441 AGCATGATGAAGCATGAGGATGTTGAGGAAGTGTATGTGTACCTTATGCAATGCAAC 500
 Qy 188 ThrValPheSerMetTyrSerTyrGluMetLysGlyLysSerAspThrSerSerAsnHis 207
 Db 501 ACAGTCTTCAGCATGTACAGCTATGAATGAAGGCAATCAGATACATCAGCAATCAT 560
 Qy 208 AlaValLeuLysLeuAlaLysGlyAspGluValTyrPheLeuArgMetGlyAsnGlyAlaLeu 227
 Db 561 GCTGTCTGCTAGCTAGCCAAAGGGGATGAGGTTGGCTGGCAATGGCAATGGCTCTC 620
 Qy 228 HisGlyAspHisGlnArgPheSerThrPheAlaGlyPheLeuLeuPheGluThrLys 246
 Db 621 CATGGGGACCAACCAAGCTTCTCCACCTTTGAGGATTCCTGTCTTTGAACTAAG 677

RESULT 20

AAC64063
 ID AAC64063 standard; DNA; 738 BP.
 XX AAC64063;
 AC AAC64063;
 DT 19-FEB-2001 (first entry)

Human zacr3p3 degenerate DNA, SEQ ID NO:10.

Human zacr3p3; adipocyte complement related protein homologue; ACRP30; C1q domain; collagen-like domain; energy balance modulation; cellular metabolism; metabolic disorder; obesity; anorexia; antimicrobial agent; infection; platelet aggregation inhibition; adhesion; activation; vascular injury; antibacterial; antiviral; ds.

Homo sapiens.
Synthetic.

WO200063377-A1.

26-OCT-2000.

19-APR-2000; 2000WO-US10454.

20-APR-1999; 99US-0294943.

(ZYMO) ZYMOGENETICS INC.

Piddington CS, Bishop PD;
WPI; 2000-665243/64.

Novel zacr3p3 polypeptides used to treat or prevent bacterial or viral infections, for wound healing, improving blood flow, and to analyze energy efficiency in mammals -

Claim 10; Page 115; 123pp; English.

The invention relates to the human zacr3p3 protein (AAC29580) and to nucleic acids which encode it (AAC64058, AAC64063). Zacr3p3 is a homologue of adipocyte complement related protein (ACRP30) and contains a collagen-like domain comprising Gly-xaa-xaa or Gly-xaa-Pro repeats, and a C-terminal C1q domain comprising 10 beta-strands. The zacr3p3 gene is located on chromosome 5p12. The invention also relates to zacr3p3 fragments, fusion proteins containing zacr3p3 polypeptides, zacr3p3-specific antibodies, expression constructs and host cells comprising zacr3p3 nucleic acids, and methods of recombinant production of zacr3p3. Human zacr3p3, and its agonists and antagonists may be used in the study and modulation of cellular metabolism and energy balance in mammals, and may therefore be used to treat disorders such as obesity and anorexia, and conditions associated with these disorders. Due to its C1q like domain, zacr3p3 and zacr3p3-containing fusion proteins may be useful as antimicrobial agents, promoting lysis or phagocytosis of infectious organisms such as bacteria or viruses. Zacr3p3, its fragments, fusion proteins, antibodies and activity modulators may also be used to inhibit collagen-induced platelet aggregation, adhesion, or activation, and may therefore have potential for promoting blood flow within the vasculature of a mammal e.g., to treat injury to the vasculature or other collagenous tissue. Human zacr3p3 and its antibodies may additionally be used to study dimerisation and oligomerisation. The present sequence represents a degenerate DNA sequence encoding human zacr3p3.

Sequence 738 BP; 130 A; 74 C; 145 G; 99 T; 290 other;

Db	61	YTNWGTGCARGAYGARTAYATGGARMSNCCNCARCCNGGGNYTCCNCNGGAYTGYWSN	120
Qy	41	LysCysCysHisGlyAspTyrSerPheArgGlyTyrGlnGlyProProGlyProProGly	60
Db	121	AARTGTGTGCAYGGNGAYTAYSNNTYMGNGGNTAYCARGGNCNCNGGNCNCNGN	180
Qy	61	ProProGlyIleProGlyAsnHisGlyAsnAsnGlyAsnAsnGlyAlaThrGlyHisGlu	80
Db	181	CCNCCNGGNATHCCNGGNAAYCAYGNAAYAYAGGNAAYAYGGNGCNCNGNCAYGAR	240
Qy	81	GlyAlaLysGlyGluLysGlyAspLysGlyAspLeuGlyProArgGlyGluArgGlyGln	100
Db	241	GGNCNARCGNGARARGNGCAYARGGNGAYYTNGGNCNMGNGGNGARMGNGNCAR	300
Qy	101	HisGlyProLysGlyGluLysGlyTyrProGlyIleProProGluLeuGlnIleAlaPhe	120
Db	301	CAYGGNCCNAARGNGARARGNTAYCCNGGNATHCCNCCNGARYTNCARATHGCNTTY	360
Qy	121	MetAlaSerLeuAlaThrHisPheSerAsnGlnAsnSerGlyIleIlePheSerSerVal	140
Db	361	ATGGCNMSNYTNCNACNCAYTTYWSNAAYACARAAAYWSNGGNATHATHTTYWSNWSNGTN	420
Qy	141	GluThrAsnIleGlyAsnPhePheAspValMetThrGlyArgPheGlyAlaProValSer	160
Db	421	GARACNAAYATHGGNAAYTTYTYGAYGTNATGACNGGNGMNTTYGGNCCNCCNGTNWSN	480
Qy	161	GlyValTyrPhePheThrPheSerMetMetLysHisGluAspValGluValTyrVal	180
Db	481	GGNGTWTATYTTYACNTTYSNATGATGAARCAYGARGAYGTNGARGACTNTAYGTN	540
Qy	181	TyrLeuMetHisAsnGlyAsnThrValPheSerMetTyrSerTyrGluMetLysGlyLys	200
Db	541	TATYTATGTCAYAAAYCGNAAYACNGTNTTYWSNATGTAYWSNTAYGARATGAARGNAAR	600
Qy	201	SerAspThrSerSerAsnHisAlaValLeuLysLeuAlaLysGlyAspGluValTrpLeu	220
Db	601	WSNGAYACNWSNWSNAAYCAYCGCGTNTYTNAARYTNGCNAARGGNGAYGARGTNTGGYTN	660
Qy	221	ArgMetGlyAsnGlyAlaLeuHisGlyAspHisGlnArgPheSerThrPheAlaGlyPhe	240
Db	661	MGNATGGGNAAYGGNGCNYTNCAYGGNGAYCAYARMGNTTYWSNACNTTYCGNGNTTY	720
Qy	241	LeuLeuPheGluThrLys	246
Db	721	YTNNTTYTGARACNAAR	738
RESULT 21			
AAI61016/c			
ID AAI61016 standard; cDNA; 1799 BP.			
XX	AAI61016;		
XX	22-OCT-2001 (first entry)		
DE	Human polynucleotide SEQ ID NO 5005.		
KW	Human; neotrophic; immunosuppressant; cytostatic; gene therapy; cancer;		
KW	peripheral nervous system; neuropathy; central nervous system; CNS;		
KW	Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;		
KW	amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;		
KW	chemokinetic; thrombolytic; drug screening; arthritis; inflammation;		
XX	leukaemia; ss.		
OS	Homo sapiens.		
XX	WO200153312-Al.		
XX	26-JUL-2001.		
XX	26-DEC-2000; 2000NO-US34263.		
XX	21-JAN-2000; 2000US-0488725.		

PR 25-APR-2000; 2000US-0552317.
 PR 09-JUL-2000; 2000US-0598042.
 PR 19-JUL-2000; 2000US-0620312.
 PR 03-AUG-2000; 2000US-0653450.
 PR 14-SEP-2000; 2000US-0662191.
 PR 19-OCT-2000; 2000US-0693036.
 PR 29-NOV-2000; 2000US-0727344.
 XX (HYSE-) HYSEQ INC.
 XX
 PI Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;
 PI Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J;
 PI Zhao QA, Zhou P, Goodrich R, Drmanac RT;
 XX
 DR WPI: 2001-442253/47.
 DR P-PSDB; AAM41860.
 XX
 PT Novel nucleic acids and polypeptides, useful for treating disorders
 PT as central nervous system injuries -
 XX
 PS Claim 1; SEQ ID NO 5005; 10078pp; English.
 XX
 CC The invention relates to human nucleic acids (AAI57798-AAI61369) and
 CC the encoded polypeptides (AAM38642-AAM42213) with nootropic,
 CC immunosuppressant and cytostatic activity. The polynucleotides are useful
 CC in gene therapy. A composition containing a polypeptide or polynucleotide
 CC of the invention may be used to treat diseases of the peripheral nervous
 CC system, such as peripheral nervous injuries, peripheral neuropathy and
 CC localised neuropathies and central nervous system diseases, such as
 CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
 CC lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
 CC utilisation of the activities such as: Immune system suppression,
 CC Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
 CC and thrombolytic activity, cancer diagnosis and therapy, drug screening,
 CC assays for receptor activity, arthritis and inflammation, leukaemias and
 CC C.N.S disorders.
 CC Note: The sequence data for this patent did not form part of the printed
 CC specification.
 XX
 SQ Sequence 1799 BP; 531 A; 389 C; 344 G; 535 T; 0 other;

Alignment Scores:
 Pred. No.: 4,88e-59 Length: 1799
 Score: 858.50 Matches: 169
 Percent Similarity: 83.66% Conservative: 0
 Best Local Similarity: 83.66% Mismatches: 1
 Query Match: 62.80% Indels: 33
 DB: 22 Gaps: 1

US-10-036-041-2 (1-246) x AAI61016 (1-1799)
 QY 77 ThrGlyHisGluGlyAlaLysGlyGluLysGlyAspLysGlyAspLeuGlyProArgGly 96
 Db 1797 ACTGGTCATGAAGAGCCAAAGGTGAGAGGGCGACAAAGGTGACCTGGGGCTCGAGGG 1738
 QY 97 GluArgGlyGlnHisGlyProLysGlyGluLysGlyTyrProGlyIleProProGluLeu 116
 Db 1737 GAGCGGGGCAGCATGGCCCCAAGAGAGAGAGGGCTACCCGGGGATTCCACCAAGACT- 1679
 QY 116 ----- 116
 Db 1678 TCAGGTGGAGTGCAGTGGTGTGATCTGGCTCACTGCAGCTCCACCAAGGTTCAAGCG 1619
 QY 117 -----GlnIleAlaPheMetAlaSerLeu 124
 Db 1618 ATTCTTGGCTCAACCTCTGGAGTAGCTGGGATTACAGATTGCATTTCATGGCTTCTCTG 1559
 QY 125 AlaThrHisPheSerAsnGlnAsnSerGlyIleIlePheSerSerValGluThrAsnIle 144
 Db 1558 GCAACCCACTTCAGCAATTCAGAACAGTGGGATTATCTTCAGCAGTGTTCGAGACCAACATT 1499
 QY 145 GlyAsnPhePheAspValMetThrGlyArgPheGlyAlaProValSerGlyValThrPhe 164
 Db 1445 -----

Db 1498 GGAACACTTCTTTGATGTCATGACTGAGTAGATTGGGGCCCCCAGTATCAGGTGCTGATATTC 1439
 QY 165 PheThrPheSerMetMetLysHisGluAspValGluGluValTyrValTyrLeuMetHis 184
 Db 1438 TTCACCTTCAGCATGATGAACCATGAGGATGTTGAGGAAGTGTATGTGTACCTTATGCAC 1379
 QY 185 AsnGlyAsnThrValPheSerMetTyrSerTyrGluMetLysGlyLysSerAspThrSer 204
 Db 1378 AATGGCAACACAGTCTTCAGCATGTACAGCTATGAAATGAAGGCGAAATCAGATACATCC 1319
 QY 205 SerAsnHisAlaValLeuLysLeuAlaLysGlyAspGluValTyrLeuArgMetGlyAsn 224
 Db 1318 AGCAATCATGCTGCTGAGAGCTAGCCAAAGGGGATGAGGTTGGCTGCCGAATGGGCAAT 1259
 QY 225 GlyAlaLeuHisGlyAspHisGlnArgPheSerThrPheAlaGlyPheLeuPheGlu 244
 Db 1258 GGGCTCTCCATGGGACCAACGCTTCTCCACCTTTCAGGATTCCTGCTCTTTGAA 1199
 QY 245 ThrIys 246
 Db 1198 ACTAAG 1193
 RESULT 22
 ABK35221
 ID ABK35221 standard; cDNA; 1608 BP.
 XX
 AC ABK35221;
 XX
 DT 08-MAY-2002 (first entry)
 XX
 DE Human cDNA encoding secreted protein #359.
 XX
 KW Human; secreted protein; gene; ss; nutritional supplement; haemophilia;
 KW viral infection; bacterial infection; fungal infection; diabetes; asthma;
 KW autoimmune disorder; rheumatoid arthritis; multiple sclerosis; tumour;
 KW autoimmune thyroiditis; allergic reaction; neurodegenerative disease;
 KW Alzheimer's disease; Parkinson's disease; liver fibrosis; cancer; ulcer;
 KW coagulation disorder; inflammatory disorder; Crohn's disease; incision;
 KW tissue regeneration; wound healing; burn; haematopoiesis;
 KW myeloid cell deficiency; lymphoid cell deficiency.
 XX
 OS Homo sapiens.
 XX
 PN WO200177288-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 29-MAR-2001; 2001WO-US10224.
 XX
 PR 06-APR-2000; 2000US-195582P.
 XX
 PA (GEMY) GENETICS INST INC.
 XX
 PI Wong GG, Clark HF, Fechtel K, Agostino MJ, Howes SH, Resnick RJ;
 PI Gulukota K, Graham JR;
 XX
 DR WPI: 2002-179321/23.
 XX
 PT Five hundred and ninety two polynucleotides derived from a variety of
 PT human tissue sources which encode secreted proteins, useful for
 PT treating immune deficiencies and disorders such as autoimmune disorders
 PT
 PS Claim 1; Page 261-262; 372pp; English.
 XX
 CC The invention relates to 592 polynucleotides which have been derived from
 CC a variety of human tissue sources and which encode novel secreted
 CC proteins. The polynucleotides can be used as probes for the
 CC identification and isolation of full length cDNA and genomic DNA. The
 CC polynucleotides and proteins can also be used as nutritional supplements.
 CC The proteins are useful in the treatment of various immune deficiencies
 CC and disorders such as viral infections, bacterial infections, fungal
 CC infections, autoimmune disorders (e.g. rheumatoid arthritis, multiple

CC sclerosis, autoimmune thyroiditis and diabetes) and allergic reactions
 CC and conditions (e.g. asthma). They are also useful for treating
 CC neurodegenerative diseases (e.g. Alzheimer's disease, Parkinson's
 CC disease), liver fibrosis, coagulation disorders (e.g. haemophilia),
 CC inflammatory disorders (e.g. Crohn's disease) and tumours. They are also
 CC useful for tissue regeneration, for wound healing and in the treatment of
 CC burns, incisions and ulcers. The proteins are also useful for regulating
 CC haematopoiesis and for treating myeloid or lymphoid cell deficiencies.
 CC Sequences ABK34863-ABK35454 represent polynucleotides of the invention.

XX
 SQ Sequence 1608 BP: 487 A; 305 C; 339 G; 477 T; 0 other;

Alignment Scores:

Pred. No.: 2.43e-58 Length: 1608
 Score: 849.00 Matches: 159
 Percent Similarity: 100.00% Conservative: 0
 Best Local Similarity: 100.00% Mismatches: 0
 Query Match: 62.11% Indels: 0
 DB: 24 Gaps: 0

US-10-036-041-2 (1-246) x ABK35221 (1-1608)

QY 88 AspLysGlyAspLeuGlyProArgGlyGluArgGlyGlnHisGlyProLysGlyGluLys 107
 DB 2 GACAAAGGTGACCTGGGCGCTCGAGGGGAGCGGGGCGAGCATGGCCCCCAAGGAGAGAAG 61
 QY 108 GlyTyrProGlyLeuProGlyLeuGlnIleAlaPheMetAlaSerLeuAlaThrHis 127
 DB 62 GCTTACCGGGGATTCACCAAGAACTTCAGATTGATTCATGCTCTCTGCAACCCAC 121
 QY 128 PheSerAsnGlnAsnSerGlyIlePheSerValGluThrAsnIleGlyAsnPhe 147
 DB 122 TTCAGCAATCAGAACAGTGGGATTATCTTCAGCAGTGTGTGAGACCAACATTCGAAACTTC 181
 QY 148 PheAspValMetThrGlyArgPheGlyAlaProValSerGlyValTyrPheThrPhe 167
 DB 182 TTGTGATGCATGACGTGGTAGATTTCGGGCGCCAGTATCATGTTGTATTTCTTCACCTTC 241
 QY 168 SerMetMetLysHisGluAspValGluGluValTyrValTyrLeuMetHisAsnGlyAsn 187
 DB 242 ACATGATGATGACATGAGGATCTTGAGGAAGTGTATGTGTACCTTATGCAATGCAAC 301
 QY 188 ThrValPheSerMetTyrSerTyrGluMetLysGlyLysSerAspThrSerAsnHis 207
 DB 302 ACAGTCTTCAGCATGTACAGCTATGAAATGAAGGGCAAAATCAGATACATCCAGCAATCAT 361
 QY 208 AlaValLeuLysLeuAlaLysGlyAspGluValTyrLeuArgMetGlyAsnGlyAlaLeu 227
 DB 362 GCTGTGCTGAAGCTAGCCAAAGGGGATGAGGTTTGGCTGCGAATGGGCAATGGGCTCTC 421
 QY 228 HisGlyAspHisGlnArgPheSerThrPheAlaGlyPheLeuLeuPheGluThrLys 246
 DB 422 CATGGGGACCAACACCGCTTCACCTTTGCGAGGATTCCTGCTCTTTGAAACTAAG 478

RESULT 23

AAAC02874
 ID AAC02874 standard; cDNA; 471 BP.

XX AC AAC02874;

XX DT 06-OCT-2000 (first entry)

XX DE Human secreted protein 5' EST, SEQ ID NO: 2872.

XX KW Human; 5' EST; expressed sequence tag; secreted protein; cDNA isolation;
 XX KW gene therapy; chromosome mapping; ss.

XX OS Homo sapiens.

XX PN EP1033401-A2.

XX PD 06-SEP-2000.

XX

PF

21-FEB-2000; 2000EP-0200610.

XX

26-FEB-1999; 990US-0122487.

XX

(GEST) GENSET.

XX

Dumas Milne Edwards J, Duclert A, Giordano J;

XX

WPI; 2000-500381/45.

XX

P-PSDB; AAG02868.

XX

PT New nucleic acid that is a 5' expressed sequence tag (5' EST) for
 PT obtaining cDNAs and genomic DNAs that correspond to 5'ESTs and for
 PT diagnostic, forensic, gene therapy and chromosome mapping procedures -
 PS Claim 1; SEQ ID 2872; 71pp + CD-ROM; English.

XX

CC The present sequence is one of a large number of 5' ESTs derived from
 CC mRNAs encoding secreted proteins. An ORF has been identified within the
 CC sequence. The 5' ESTs were prepared from total human RNAs or polyA+ RNAs
 CC derived from 30 different tissues. EST sequences usually correspond
 CC mainly to the 3' untranslated region (UTR) of the mRNA because they are
 CC often obtained from oligo-dT primed cDNA libraries. Such ESTs are not
 CC well suited for isolating cDNA sequences derived from the 5' ends of
 CC mRNAs and even in those cases where longer cDNA sequences have been
 CC obtained, the full 5' UTR is rarely included. 5' ESTs are derived from
 CC mRNAs with intact 5' ends and can therefore be used to obtain full length
 CC cDNAs and genomic DNAs. 5' ESTs are also used in diagnostic, forensic,
 CC gene therapy and chromosome mapping procedures. They are used to obtain
 CC upstream regulatory sequences and to design expression and secretion
 CC vectors.

XX

SQ Sequence 471 BP: 107 A; 130 C; 134 G; 99 T; 1 other;

Alignment Scores:

Pred. No.: 8.56e-49 Length: 471
 Score: 721.00 Matches: 127
 Percent Similarity: 99.22% Conservative: 0
 Best Local Similarity: 99.22% Mismatches: 1
 Query Match: 52.74% Indels: 1
 DB: 21 Gaps: 0

US-10-036-041-2 (1-246) x AAC02874 (1-471)

QY 1 MetLeuTrpArgGlnLeuIleTyrTrpGlnLeuLeuAlaLeuPheLeuProPheCys 20
 DB 88 ATGCTTTGGAGGCGAGCTCATCTATTGGCAACTGCTGGCTTTGTTTCTCCCTTTTTC 147

QY 21 LeuCysGlnAspGluTyrMetGluSerProGlnThrClyLeuProProAspCysSer 40
 DB 148 CTGTGTCAAGATGAATACATGGAGTCTCCAAACCGGAGGACTACCCCGAGACTGCAGT 207

QY 41 LysCysCysHisGlyAspTyrSerPheArgGlyTyrGlnGlyProGlyProProGly 60
 DB 208 AAGTGTGTGTCATGGAGACTACACTTTCGAGGCTACCAAGCCCCCTGGCCACCGGGC 267

QY 61 ProProGlyIleProGlyAsnHisGlyAsnAsnGlyAsnAsnGlyAlaThrGlyHisGlu 80
 DB 268 CCTCTGGCATTCAGGAAACCATGGAAACATGGCAATGGAGCCACTGTCATGA 327

QY 81 GlyAlaLysGlyGluLysGlyAspLysGlyAspLeuGlyProArgGlyGluArgGlyGln 100
 DB 328 GGAGCCAAAGTGTAGAGGGCGACAAAGGTGACCTGGGGCTCGAGGGGAGCGGGGCGAG 387

QY 101 HisGlyProLysGlyGluLysGlyTyrProGlyIleProGlyLeuGlnIleAlaPhe 120
 DB 388 CATGGCCCCCAAGAGAGAGAGGGCTACCCGGGGATTCCACAGACTTCAGATTGCATTC 447

QY 121 MetAlaSerLeuAlaThrHisPhe 128
 DB 448 ATGCTTCTCTGGM-ACCCACTTC 470

RESULT 24

SQ Sequence 546 BP; 149 A; 129 C; 155 G; 108 T; 5 other;

Alignment Scores:

Pred. No.: 3,02e-32 Length: 546
Score: 513.50 Matches: 94
Percent Similarity: 55.29% Conservativity: 0
Best Local Similarity: 55.29% Mismatches: 3
Query Match: 37.56% Indels: 73
DB: 22 Gaps: 1

US-10-036-041-2 (1-246) x AAF93419 (1-546)

Qy 1 MetLeuTrpArgGlnLeuIleTyrTrpGlnLeuLeuAlaLeuPheLeuProPheCys 20
|||||
Db 37 ATGCTTTGGAGCAGCTCATNTATTTGGCAACTGCTGGCTTTGTTCTCCTCTTTGC 96
Qy 21 LeuCysGlnAspGluTyrMetGlu----- 28
|||||
Db 97 NTGTGTCAGAGTAATACATGAGGTGAGCGGAAGAACTAATAAAGTGTGGCAAGATA 156
Qy 28 ----- 28
Db 157 GTGCAAGCCACCAGACTGGCGGTAGCGGCTCCAGGAGGAGAAAGTGAGAGCGG 216
Qy 28 ----- 28
Db 217 AGCCATCTCTAAACTGGGACTGTGGATAATAACACTTNTACAGACCTAAATCCCTGAGA 276
Qy 28 ----- 28
Db 277 CCAGATGAGTACCCACCCGAGGTAGATGACCTAGCCAGATCACCACCATCTTGGGCG 336
Qy 29 ---SerProGlnThrGlyLeuProAspCysSerLysCysHisGlyAspTyr 47
|||||
Db 337 CAGTNTCCAAACCGGAGGACTACCCAGACTCAGTAAGTGTTCATGCGAGACTAC 396
Qy 48 SerPheArgGlyTyrGlnCysProGlyProGlyProGlyProGlyProGlyProGlyAsn 67
|||||
Db 397 AGCTTTGAGGTACCAAGGCCCTCGGCCACCGGCCCTCTGTCATTCAGGAAAC 456
Qy 68 HisGlyAsnAsnGlyAsnAsnGlyAlaThrGlyHisGlyAlaGlyGlyGlyGly 87
Db 457 CATGGAACAATGGCAACAATGGAGCCCACTGGTCAATGAAGGAGGCAAGGTGAGAAGGC 516
Qy 88 AspLysGlyAspLeuGlyProArgGlyGlu 97
|||||
Db 517 GACAAAGGTGACCTGGGCGCTCGAGGGGAG 546

RESULT 26

ABK3598
ID ABK3598 standard; DNA; 804 BP.

XX AC ABK35598;

XX DT 08-MAY-2002 (first entry)

XX DE Gene encoding novel human secreted or membrane-associated protein #17.

XX KW Human; secreted protein; membrane-associated protein; hypertension;
KW inflammatory disorder; neurological disorder; haematopoietic disorder;
KW skeletal developmental disorder; growth abnormality; autoimmune disorder;
KW neurodegenerative disorder; nervous system disorder; bacterial infection;
KW peripheral myelinopathy; viral infection; cancer; obesity; diabetes;
KW hypotension; sexual development disorder; blood disorder; gene; ds.

XX OS Homo sapiens.

XX XX WO200204600-A2.

XX XX 17-JAN-2002.

XX XX 12-JUL-2001; 2001WO-US21985.

XX PF

XX XX

PR 12-JUL-2000; 2000US-218033P.
PR 21-AUG-2000; 2000US-226517P.
XX (SMIK) SMITHKLINE BEECHAM CORP.
PA (SMIK) SMITHKLINE BEECHAM PLC.
PA (GLAX) GLAXO GROUP LTD.
XX
PI Agarwal P, Cogswell JP, Lai Y, Martensen SA, Rizvi SK, Strum JC;
PI Smith RF, Xiang Z, Xie Q;
XX
DR WPI: 2002-188468/24.
DR P-PSDB; AU484378.

XX
PT Novel secreted and membrane-associated polypeptides and polynucleotides
PT encoding the polypeptides, for preventing, treating and ameliorating
PT cancers, mental or sexual developmental disorders, and malignant tumours

XX
PS Claim 2; Page 110; 151pp; English.

XX
CC The present invention relates to the isolation of novel human secreted
CC or membrane-associated proteins and the genes encoding them. The
CC sequences of the invention are useful for treating, preventing and
CC ameliorating various diseases such as inflammatory disorders (e.g.
CC asthma), neurological disorders (e.g. dementia), haematopoietic
CC disorders, skeletal developmental disorders, growth abnormalities,
CC neurodegenerative disorders (e.g. Huntington's disease), nervous system
CC disorders, autoimmune disorders (e.g. rheumatoid arthritis),
CC peripheral myelinopathies, viral and bacterial infections,
CC alpha-mannosidosis, diabetes, cancers, malignant tumours, hyper- and
CC hypotension, obesity, bulimia, anorexia, manic depression, delirium,
CC mental retardation, Tourette's syndrome, schizophrenia, growth, mental
CC or sexual development disorders, and dysfunctions of the blood cascade
CC system including those leading to stroke. ABK35582-ABK35609 represent
CC the genes encoding the novel human secreted or membrane-associated
CC proteins of the invention.

XX SQ Sequence 804 BP; 130 A; 293 C; 268 G; 113 T; 0 other;

Alignment Scores:

Pred. No.: 4,37e-17 Length: 804
Score: 325.00 Matches: 82
Percent Similarity: 48.55% Conservativity: 35
Best Local Similarity: 34.02% Mismatches: 100
Query Match: 23.77% Indels: 24
DB: 24 Gaps: 8

US-10-036-041-2 (1-246) x ABK35598 (1-804)

Qy 21 LeuCysGlnAspGluTyrMetGluSerProGlnThrGlyLeuPro----- 36
|||||
Db 91 GTGTGGACCGCATGGGCCCGCTGGCTGGTCCGACGCGCGCTTCCGTGCC 150
Qy 37 -----ProAspCysSerLysCysHisGlyAspTyrSerPheArgGlyTyrGlnGly 54
|||||
Db 151 CCCTTCCCGCCAGCGCCCAAGGAGAGGTGGCGCGCGCGGAAAGCAGCCCTCGCGGGG 210
Qy 55 ProGlyProGlyProGlyProGlyProGlyProGlyProGlyProGlyProGlyProGly 74
|||||
Db 211 CCCCCTGGACCACTGTCAGAGGCGCCCGCCAGGAGAACCCGCGGAGGCGGCGGCGGCGG 270
Qy 75 GlyAlaThrGlyHisGluGlyAlaLysGlyGlyGlyGlyGlyGlyGlyGlyGlyGlyPro 94
|||||
Db 271 GGCCCTCCCGGT---CCAGGCGCTGGCGGGGCGCCCTGGACACACAGGTCCCAAGAGGCGCC 327
Qy 95 ArgGlyGluArgGlyGlnHisGlyProLysGlyGluLysGlyTyrProGly----- 111
|||||
Db 328 CCAGGAGAACCCGCGAGCGCCCGCGCGCGCTCCCGGT---CCAGGTCCGCGGCGG 384
Qy 112 -----IleProGluLeuGlnIleAlaPheMetAlaSerLeu 124
|||||
Db 385 GTGGGCGCGCTGCGGCTACGTGCCT-----CGCATTCCTTTCACGCGGCGCTG 435

QY 125 AlaThrHisPheSerAsnGlnAsnSerGlyIlePheSerSerValGluThrAsnIle 144
 Db CGCGGGCCCCAGAGGTTACGAGTG---CTGCGCTTCGACGAGCTGTGACCAACGTTG 492
 QY 145 GlyAsnPhePheAspValMetThrGlyArgPheGlyAlaProValSerGlyValThrPhe 164
 Db GGCACAGCGCTACGAGGACGACGCGGAGTGTACTGCCCCATGCCAGCGCTCTACTTC 552
 QY 165 PheThrPheSer---MetMetLysHisGluAspValGluGluValThrValThrLeuMet 183
 Db TCGCTTACCACTGCTCATGCGCGCGCGGACGACGACGACGATGTGGCCCACTCATG 612
 QY 184 HisAsnGlyAsnThrValPheSerMetTyrSerTyrGluMetLysGlyLysSerAspThr 203
 Db AAGAACGACAGGTCGCGGCCAGCCCATTTGTCAGGACGCGGACCAAGACTACGATAC 672
 QY 204 SerSerAsnHisAlaValLeuLysLeuAlaLysGlyAspGluValThrLeuArgMetGly 223
 Db GCCACCAACAGCGTCTTCTGACCTGGACGCGGCGGACGAGTCTTCATCAAGCTGGAC 732
 QY 224 AsnGlyAlaLeuHisGlyAspHis---GlnArgPheSerThrPheAlaGlyPheLeuLeu 242
 Db GCGGGAAGTGCACGCGGCGGACCAACACCAAGTACGACCTTCTCGGCTTCATATC 792
 QY 243 Phe 243
 Db 793 TAC 795
 RESULT 27
 AAZ61744
 ID AAZ61744 standard; cDNA; 1107 BP.
 XX AC AAZ61744;
 XX DT 27-MAR-2000 (first entry)
 XX DE cDNA encoding rat skin cell secreted protein, SEQ ID NO:217.
 KW Skin; dermal papilla; keratinocyte; neonatal foreskin fibroblast;
 KW embryonic skin cell; keratinocyte stem cell; transit amplifying cell;
 KW secreted; transmembrane; inflammation; cancer; neurological disease;
 KW angiogenesis; tumour vascularisation; growth disorder;
 KW developmental disorder; skin wound; hair follicle disorder;
 KW anti-inflammatory; cytostatic; neuroprotective; vulnery; ss.
 XX OS Rattus sp.
 XX PN W0955865-A1.
 XX PD 04-NOV-1999.
 XX PF 29-APR-1999; 99WO-NZ00051.
 XX PR 29-APR-1998; 98US-0069726.
 XX PR 09-NOV-1998; 98US-0188930.
 XX PA (GENE-) GENESIS RES & DEV CORP LTD.
 XX PI Strachan L, Sleeman M, Watson JD, Onrust R, Kumble A, Murison JG;
 XX WPI; 2000-072177/06.
 XX DR P-PSDB; AAY76039.
 XX PT Novel polynucleotides useful for the treatment of various conditions
 XX including wounds and cancer -
 XX Claim 1; Page 142-143; 235pp; English.
 XX The invention relates to novel nucleic acid sequences derived from rat
 XX dermal papilla, human keratinocytes and neonatal foreskin fibroblasts,
 XX and mouse embryonic skin, keratinocyte stem cells and transit amplifying
 XX cells. Polypeptides of the invention may be used to treat inflammation,
 XX cancer and neurological diseases. The proteins may be used to stimulate

CC the growth and motility of keratinocytes, to inhibit the growth of
 CC cancer cells, to modulate angiogenesis and tumour vascularisation, to
 CC modulate skin inflammation, to modulate epithelial cell growth and to
 CC inhibit binding of HIV-1 to leukocytes. The invention may also be used
 CC to treat growth and developmental defects, skin wounds and hair follicle
 CC disorders. Sequences AAZ61606-261832 represent cDNA sequences derived
 CC from several mouse, rat or human skin cell types. Sequences
 CC AAZ61606-261649, AAZ61725-261765, AAZ61802-261811 and AAZ61826 encode
 CC proteins with an N-terminal signal sequence, indicating that the proteins
 CC are secreted. Sequences AAZ61650-261668, AAZ61766-261780, AAZ61812-261817
 CC and AAZ61827-261829 encode proteins with one or more putative
 CC transmembrane domains.

Sequence 1107 BP; 273 A; 298 C; 328 G; 208 T; 0 other;

Alignment Scores: 3.28e-16 Length: 1107
 Pred. No.: 316.00 Matches: 86
 Score: 42.62% Conservative: 41
 Percent Similarity: 28.86% Mismatches: 89
 Best Local Similarity: 23.12% Indels: 82
 Query Match: 21 Gaps: 12
 DB:

US-10-036-041-2 (1-246) x AAZ61744 (1-1107)

QY 6 LeuIleTyrTrpGlnLeuLeuAlaLeuPheLeuLeuPheCysLeuCysGlnAspGlu 25
 Db 174 ATGATCTCTGGATGCTCTTGGCTGT---GCCCTTCG-----TGTGCTGTGAC 221
 QY 26 TyrMet-----GluSerProGlnThrGlyGlyLeuProProAspCys 39
 Db 222 CCAATGCTTGGTGCTTTCGTCGAGGAGTTCAGAGAGGTGGTCTCACTGCTGTC 281
 QY 40 SerLysCysCysHisGlyAspTyrSerPheArgGlyTyrGlnGlyProProGlyPro 59
 Db 282 AGT-----CTGCTGTGGTCCCAAGGCCCACT 308
 QY 60 GlyProGlyIleProGlyAsnHisGlyAsnGlyAsnGlyAlaThrGlyHis 79
 Db 309 GCGCTCCAGGACCAAGGATCTCCAGGAATGGTGGAGAGATGGTTTCTGCTAG 368
 QY 80 GluGlyAlaLysGlyGlyLysGlyAspGlyAsp----- 91
 Db 369 GATGCCCAAGACGCGGACGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 428
 QY 92 -----Leu 92
 Db 429 AGGACAGGCAACCGAGGAAACAAAGGCAAGGAGGAGGAGGAGGAGGAGGAGGAG 488
 QY 93 GlyProArgGlyGluArg-----GlyGln 100
 Db 489 GGTCTCGAGGACCAAGGGGTGAGTACCCCGGGAACATGGTATACCGGCAAG 548
 QY 101 HisGlyProLysGlyGlyLysGlyTyrProGlyIlePro----- 113
 Db 549 AAGGACCTAAGGCAAGAAAGGGAACCTGGGCTCCAGGCGCCCTAGCTAGCTGCG 608
 QY 114 ProGluLeuGlnIleAlaPheMetAlaSerLeuAlaThrHisPheSerAsnGlnAsnSer 133
 Db 609 AGCCGAGGCAAGTCGCGCTTTTCGGTGGCGGTAAACCAAGAGTTACCCAGCTGAG 668
 QY 134 GlyIleIlePheSerSerValGluThrAsnIleGlyAsnPhePheAspValMetThrGly 153
 Db 669 CCATCAAGTTGACAGATCTGATGATGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 728
 QY 154 ArgPheGlyAlaProValSerGlyValThrPhePheThrPheSerMetMet----- 170
 Db 729 AAGTTCGCTGCGAGGCTGCCAGGGATCTATTACTTACCTATGACATTCAGCTGCG 788
 QY 171 LysHisGluAspValGluGluValThrValThrLeuMetHisAsnGlyAsnThrValPhe 190
 Db 789 AAACAC-----CTGCGCATCGGCTAGTGACAAATGGCCAG-----TAC 827

Qy 191 SerMetTyrSerTyrGluMetLys---GlyLysSerAspThrSerSerAsnHisAlaVal 209
 Db 828 CGCATTCGGACTTTTGACCGCAACACCGGCAACCGAGTGGCTCGGCTCCACCATC 887
 Qy 210 LeuLysLeuAlaLysGlyAspGluValTrpLeuArgMet-----GlyAsnGly 225
 Db 888 CTACTCTCAAGGAGGTGATGAGTCTGGTTACAGATTTTCTACTCGGACGACGATGA 947
 Qy 226 AlaLeuHisGlyAspHisGlnArgPheSerThrPheAlaGlyPheLeuPhe 243
 Db 948 CTCTTCTACGACCCTTATTGGACCGACAGCCTGTTACCGGCTTCTCATCTAC 1001

RESULT 28
 AAC99677
 ID AAC99677 standard; cDNA; 1107 BP.
 XX AC AAC99677;
 XX DT 08-MAR-2001 (first entry)
 XX DE Skin cell cDNA, SEQ ID NO: 217.
 XX KW Rat; skin cell; cytostatic; antiinflammatory; anti-HIV;
 KW nontropic; neuroprotective; vulnerary; immunomodulatory; vaccine;
 KW keratinocyte growth stimulation; cancer; angiogenesis inhibition;
 KW inflammation; neurological disease; ss.
 XX OS Rattus sp.
 XX PN WO200069884-A2.
 XX PD 23-NOV-2000.
 XX PF 15-MAY-2000; 2000WO-NZ00075.
 XX PR 14-MAY-1999; 99US-0312283.
 XX PA (GENE-) GENESIS RES & DEV CORP LTD.
 XX PI Watson JD, Strachan L, Onrust R, Sleeman M, Kumble KD, Murison JG;
 XX WPI: 2001-007495/01.
 XX DR P-PSDB; AAB55958.

New isolated polynucleotide used in the identification of genetic disorders and encoding polypeptides used for treating inflammatory disease, cancer and neurological diseases -
 Claim 1; Page 186; 352pp; English.

The present polynucleotide encodes a polypeptide which is expressed in mammalian skin cells. The polypeptide is useful for stimulating keratinocyte growth and motility, inhibiting the growth of cancer cells, modulating angiogenesis, inhibiting angiogenesis and vascularisation of tumours, modulating skin inflammation, stimulating the growth of epithelial cells, inhibiting the binding of human immunodeficiency virus (HIV)-1 to leukocytes, and treating inflammatory disease, cancer and neurological diseases. The polynucleotide can be used as a marker, in the identification of genetic disorders, and for the design of oligonucleotides for examining expression patterns.

Sequence 1107 BP; 273 A; 298 C; 328 G; 208 T; 0 other;

Alignment Scores:
 Pred: No.: 3.28e-16 Length: 1107
 Score: 316.00 Matches: 86
 Percent Similarity: 42.62% Conservative: 41
 Best Local Similarity: 28.86% Mismatches: 89
 Query Match: 23.12% Indels: 82
 DB: 22 Gaps: 12

US-10-036-041-2 (1-246) x AAC99677 (1-1107)

Qy 6 LeuIleTyrTrpGlnLeuLeuAlaLeuPhePheLeuProPheCysLeuCysGlnAspGlu 25
 Db 174 ATGATCTCTGGATGCTCTTGGCTGT---GCCCTTCG-----TGTCTGCTGAC 221
 Qy 26 TyrMet-----GluSerProGlnThrGlyGlyLeuProProAspCys 39
 Db 222 CCATGTCTGCTGCTTGTCTCGCAGGACITCCAGAAAGGTGGTCTCACTGCTGTGC 281
 Qy 40 SerLysCysHisGlyAspTyrSerPheArgGlyTyrGlnGlyProProGlyProPro 59
 Db 282 AGT-----CTGCCGTGGTCCCAAGGCCACCT 308
 Qy 60 GlyProGlyIleProGlyAsnHisGlyAsnAsnGlyAsnAsnGlyAlaThrGlyHis 79
 Db 309 GGCCCTCCAGGACGACAGGATCTTCAGGAATGTTGGGAAGATGGTTTCTTCTGTAAG 368
 Qy 80 GluGlyAlaLysGlyGlyLysGlyAsp----- 91
 Db 369 GATGCCAAGACGCGCAGGACGAGCGGAGGACATGGAGAGAAGAGTCCACCTGC 428
 Qy 92 -----Leu 92
 Db 429 AGGACAGCAACCGAGGAAACAGGACCAAGGCAAGCTGGGCCATTTGGGAGCG 488
 Qy 93 GlyProArgGlyGluArg-----GlyGln 100
 Db 489 GGTCTCGAGGACCAAGGGGTGCTAGTGTACCCCGGAAACATGTTATACGGGCAAG 548
 Qy 101 HisGlyProLysGlyGlyLysGlyTyrProGlyIlePro----- 113
 Db 549 AAGGACCTAAGGCAAGAAAGGGAACCTGGGCTCCAGGCCCTGTAGTGGCGCACT 608
 Qy 114 ProGluLeuGlnIleAlaPheMetAlaSerLeuAlaThrHisPheSerAsnGlnAsnSer 133
 Db 609 AGCGAGCAAGTCGCGCTTTTCGGTGGCGTTAACCAAGAGTTACCCACGTGAGCGACTG 668
 Qy 134 GlyIleIlePheSerSerValGluThrAsnIleGlyAsnPhePheAspValMetThrGly 153
 Db 669 CCCATCAAGTTTGACAAGATTCGTGATGAATGAGGAGGCCACTACAATCATCCAGTGC 728
 Qy 154 ArgPheGlyAlaProValSerGlyValTyrPhePheThrPheSerMetMet----- 170
 Db 729 ANGTTCTGCTGCGAGCTGCCAGGATCTATTACTTACCTATGACATTCAGCTGGCCAAC 788
 Qy 171 LysHisGluAspValGluValTyrValTyrLeuMetHisAsnGlyAsnThrValPhe 190
 Db 789 AAACAC-----CTGGCCATCGGCTAGTGCACAAATGGCCAG-----TAC 827
 Qy 191 SerMetTyrSerTyrGluMetLys---GlyLysSerAspThrSerSerAsnHisAlaVal 209
 Db 828 CGCATTCGGACTTTTGACCGCAACACCGGCAACCGAGTGGCTCGGCTCCACCATC 887
 Qy 210 LeuLysLeuAlaLysGlyAspGluValTrpLeuArgMet-----GlyAsnGly 225
 Db 888 CTACTCTCAAGGAGGTGATGAGTCTGGTTACAGATTTTCTACTCGGACGACGATGA 947
 Qy 226 AlaLeuHisGlyAspHisGlnArgPheSerThrPheAlaGlyPheLeuPhe 243
 Db 948 CTCTTCTACGACCCTTATTGGACCGACAGCCTGTTACCGGCTTCTCATCTAC 1001

RESULT 29
 ABL34829
 ID ABL34829 standard; cDNA; 1107 BP.

XX AC ABL34829;
 XX DT 04-APR-2002 (first entry)
 XX DE Rat cDNA isolated from skin cells SEQ ID NO: 217.
 XX KW Human; rat; mouse; skin cell; skin wound; cancer; growth defect;
 KW developmental defect; inflammatory disease; dermatological; vulnerary;
 KW immunomodulator; anti-inflammatory; cytostatic; neuroprotective; gene;

KW SS.
 XX Rattus sp.
 XX WO200190357-A1.
 PN 29-NOV-2001.
 PD 24-MAY-2001; 2001WO-NZ00099.
 XX 24-MAY-2000; 2000US-206650P.
 PR 25-JUL-2000; 2000US-221232P.
 XX (GENE-) GENESIS RES & DEV CORP LTD.
 XX Watson JD, Strachan L, Sleeman M, Onrust R, Murison JG, Kumble KD;
 PI WPI; 2002-122020/16.
 DR New polynucleotides and polypeptides encoded by the polynucleotides
 PT isolated from skin cells, useful for treating skin wounds, cancers,
 PT growth and developmental defects, inflammatory diseases, or for
 PT modulating immune responses
 XX Claim 1; Page 161; 466pp; English.
 XX The present invention provides the protein and coding sequences of cDNAs
 CC isolated from human, murine and rat skin cell libraries. The sequences
 CC can be used in the development of therapeutic agents useful in the
 CC treatment of skin diseases, including skin wounds, cancer, growth
 CC defects, developmental defects and inflammatory diseases. The proteins
 CC have important roles in the induction of hair growth, cell proliferation
 CC and cell-cell interaction, in maintaining tissue integrity, in wound
 CC healing and in modulating immune responses. The present sequence is a
 CC cDNA of the invention.
 XX SQ Sequence 1107 BP; 273 A; 298 C; 328 G; 208 T; 0 other;
 Alignment Scores:
 Pred. No.: 3.28e-16 Length: 1107
 Score: 316.00 Matches: 86
 Percent Similarity: 42.62% Conservative: 41
 Best Local Similarity: 28.86% Mismatches: 89
 Query Match: 23.12% Indels: 82
 DB: 24 Gaps: 12
 US-10-036-041-2 (1-246) x ABL34829 (1-1107)
 Qy 6 LeuLeuTyrTrpGlnLeuLeuAlaLeuPheLeuProPheCysLeuCysGlnAspGlu 25
 Db 174 ATGATCTCTGATGCTCTTGCCCTGT---GCCCTTCG-----TGCTGCTGAC 221
 Qy 26 TyrMet-----GluserProGlnThrGlyLeuProProAspCys 39
 Db 222 CCAATGCTGTGGTCTGTCGAGGACTTCCAGAGGGTGGTCCCACTGCTGTGC 281
 Qy 40 SerLysCysCysHisGlyAspTyrSerPheArgGlyTyrGlnGlyProProGlyPro 59
 Db 282 AGT-----CTGCCTGTGTCCTCCAGGCCACCT 308
 Qy 60 GlyProProGlyLeuProGlyAsnHisGlyAsnGlnGlyAsnGlnGlyAlaThrGlyHis 79
 Db 309 GGCCTCCAGGACCAAGGATCTTCAGGAATGTTGGGAAGTGGTTTCTCTGTAAG 368
 Qy 80 GluGlyAlaLysGlyLysGlyAsp----- 91
 Db 369 GATGCCAAGACGGCCAGGACCGAGCCGAGGACAGTGGAGAGAAGTCCACCTGGC 428
 Qy 92 -----Leu 92
 Db 429 AGGACGACCAACCGAGGAACACAGGACCAAGGCAAGCTGGGGCCATTGGGACGCG 488
 Qy 93 GlyProArgGlyGluArg-----GlyGln 100

Db 489 GGTCTCGAGGACCCCAAGGGGCTCAGTGTTACCCCGGAACATGGTATATACCGGCAAG 548
 Qy 101 HisGlyProLysGlyGluLysGlyTyrProGlyIlePro-----113
 Db 549 AAGGGACCTAAGGGAAGAAAGGGGAACCTGGGCTCCCGAGCCCTCTAGCTGCGGCACT 608
 Qy 114 ProGluLeuGlnIleAlaPheMetAlaSerLeuAlaThrHisPheSerAsnGlnAsnSer 133
 Db 609 AGCCGAGCAAGTCGGCTTTTCGGTGGCGGTAAACCAAGAGTTACCCAGGTGAGGCACTG 668
 Qy 134 GlyIleIlePheSerSerValGluThrAsnIleGlyAsnPhePheAspValMetThrGly 153
 Db 669 CCATCAAGTTTGCACAAAGATTCTGATGAATGAGGAGGCCACTACAATGTCATCCAGTGC 728
 Qy 154 ArgPheGlyAlaProValSerGlyValTyrPhePheThrPheSerMetMet-----170
 Db 729 AAGTTCTGCTGCAGCGTCGCGGATCTATTACTTACCTATGACATTACGCTGCGCAAC 788
 Qy 171 LysHisGluAspValGluValTyrValTyrLeuMetHisAsnGlyAsnThrValPhe 190
 Db 789 AAACAC-----CTGCCATCGGCCCTAGTGCACAAATGGCAG-----TAC 827
 Qy 191 SerMetTyrSerTyrGluMetLys---GlyLysSerAspThrSerSerAsnHisAlaVal 209
 Db 828 CGCATTCGGACTTTTGACGCCAACACCGCAACACGACGCTGGCTCGGCTCCACCATC 887
 Qy 210 LeuLysLeuAlaLysGlyAspGluValTrpLeuArgMet-----GlyAsnGly 225
 Db 888 CTAGCTCTCAAGGAGGGTGATGAAGCTGGTTACAGATTTTCTACTCGAGCAGAATGGA 947
 Qy 226 AlaLeuHisGlyAspHisGlnArgPheSerThrPheAlaGlyPheLeuPhe 243
 Db 948 CTCCTTCTAGACCCCTATTGGACCGACAGCTGTTACCGGCTTCTCTATCTATC 1001
 RESULT 30
 AAD16350
 ID AAD16350 standard; DNA; 870 BP.
 XX AC AAD16350;
 XX DT 19-NOV-2001 (first entry)
 XX DE Human SBHACRP30a gene #1.
 XX KW Human; Alzheimer's disease; amyotrophic lateral sclerosis;
 KW ALS; Zollinger-Ellison syndrome; immune system disease; schizophrenia;
 KW inflammation; haematopoietic disease; anxiety; feeding disorder; aging;
 KW anorexia; depression; cardiovascular disease; sleep disorder; seizure;
 KW memory alteration; migraine; stroke; asthma; neuropathy; hypoglycaemia;
 KW sexual disorder; growth abnormality; infection; autoimmune disease;
 KW rheumatoid arthritis; cataractogenesis; angiogenesis; atherosclerosis;
 KW cerebral ischaemia; cirrhosis; Huntington's disease; Hodgson's disease;
 KW hypercholesterolaemia; headache; amnesia; cardiac arrhythmia; obesity;
 KW diabetes mellitus; glomerulonephritis; renovascular hypertension;
 KW cancer; vaccine; gene therapy; SBHACRP30a gene; ds.
 XX OS Homo sapiens.
 XX FH Key Location/Qualifiers
 XX CDS 1..870
 XX FT /*tag= a
 XX FT /product= "Human SBHACRP30a protein #1"
 XX FT /transl_except= (pos:235..243, aa:Ala-Leu)
 XX WO200160850-A1.
 XX PD 23-AUG-2001.
 XX PF 14-FEB-2001; 2001WO-US04703.
 XX PR 14-FEB-2000; 2000US-0182172.
 XX PR 29-FEB-2000; 2000US-0186084.

PR 18-APR-2000; 2000US-0198583.
 PR 04-OCT-2000; 2000US-0237963.
 XX (SMK) SMITHKLINE BEECHAM CORP.
 PA (SMK) SMITHKLINE BEECHAM PLC.
 XX
 PI Agarwal P, Kabnick KS, Murdoch PR, Rizvi SK, Smith RF, Xiang Z;
 XX WPI; 2001-536566/59.
 DR P-PSDB; AAE09443.
 XX
 PT New secreted and membrane associated polypeptides for treating
 PT Alzheimer's disease, psoriasis, cancer, enterocolitis, sleep and sexual
 PT disorders, stroke, and asthma
 XX
 PS Claim 2; Page 41; 94pp; English.
 CC The present sequence is a gene encoding human SBHCRP30a protein,
 CC a secreted protein of the invention.
 CC The invention relates to secreted and membrane associated polypeptides
 CC and nucleic acid molecules encoding such polypeptides. Sequences of the
 CC invention are useful for treating diseases such as Alzheimer's disease,
 CC amyotrophic lateral sclerosis (ALS), Zollinger-Ellison syndrome, diseases
 CC of the immune system, haematopoietic disease, inflammation, anxiety,
 CC schizophrenia, feeding disorders, anorexia, depression, social, sexual
 CC and memory alteration and altered immune response, sleep disorder, learning
 CC cancer, stroke, asthma, neuropathy, aging, sexual disorders, treatment
 CC of transsexuals, growth abnormalities, obesity, infections, autoimmune
 CC diseases (e.g. rheumatoid arthritis), cataractogenesis, angiogenesis,
 CC disorders associated with healthy maintenance of gastric mucosa and
 CC repair of acute and chronic mucosal lesion, lung carcinoma, cerebral
 CC ischaemia, atherosclerosis, cirrhosis, Huntington's disease, headache,
 CC amnesia, multiple sclerosis, Hodgson's disease, dilated cardiomyopathy,
 CC congestive heart failure, cardiac arrhythmias, hypercholesterolaemia,
 CC viral and non-viral hepatitis, type I and type II diabetes mellitus,
 CC glomerulonephritis, renovascular hypertension, hypoglycaemia, periodic
 CC paralyses, tendinitis and malignant hyperthermia. Polypeptides of the
 CC invention are used to identify membrane bound and soluble receptors.
 CC They are also useful as vaccines for inducing an immunological response
 CC in a mammal. Polynucleotides of the invention are used in gene therapy.
 CC They are also valuable for chromosome localisation studies and tissue
 CC expression studies.
 XX

SQ Sequence 870 BP; 239 A; 200 C; 237 G; 194 T; 0 other;

Alignment Scores:
 Pred. No.: 2.98e-16 Length: 870
 Score: 315.00 Matches: 86
 Percent Similarity: 41.26% Conservative: 32
 Best Local Similarity: 30.07% Mismatches: 96
 Query Match: 23.04% Indels: 72
 DB: 22 Gaps: 9

US-10-036-041-2 (1-246) x AAD16350 (1-870)

Qy 14 LeuPhePheCysLeuPheCysGlnAspGluTyrMetGluSerProGlnThrGly 33
 Db 13 CTCATGTTACAAAGTTTCCCATTTGTCAGTGGACACCCCGGGGTAATCAGTTGAAA 72
 Qy 34 GlyLeuProProAspCysSerLysCysCysHisGlyAspTyrSerPheArgGlyTyrGln 53
 Db 73 GGAGAGAACTACTCCCGCCAGGTATATCTGC-----AGCATCTCGCTTGCCT 120
 Qy 54 GlyProGlyProGlyProGlyProGlyProGlyProGlyProGlyProGlyProGlyProGly 73
 Db 121 GGACCTCCAGGCCCCCGGAGCAAAATGTTCCCTCCCGCCCGCCCGGCGGCGCTT 180
 Qy 74 AsnGlyAlaThrGlyHisGluGlyAlaLysGlyGlyLysGlyAsp----- 88
 Db 181 CCAGGAGAGATGTTAGACCGCGCAGGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGT 240
 Qy 88 ----- 88

Search completed: March 13, 2003, 18:19:54
 Job time : 280 secs

Db 241 TTGAGAGTAAGACTGGAGCCGCTAGGTCTTCCGCTGTAGAGAAAGGGAGCACCAGAGAGACT 300
 Qy 89 -----LysGlyAspLeuGlyProArgGlyGluAlaGlyGlnHisGlyPro----- 103
 Db 301 GCGAAGAAGGACCCATAGGACGAGGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 360
 Qy 104 -----LysGlyGluLysGlyTyrProGlyLysProPro----- 114
 Db 361 CCTGGACCAAGGAG 420
 Qy 115 -----GluLeuGlnIleAlaPheMetAlaSerLeuAlaThrHisPheSerAsn 130
 Db 421 TGTGAAGCATCGTCTCAATCCGCTTTCTTGTGGCATCACACACAGCTACCCAGAA 480
 Qy 131 GlnAsnSerGlyIlePheSerValGluThrAsnIleGlyAsnPhePheAspVal 150
 Db 481 GAAAGACTACCTATTATTTAAACAGGTCTCTTCAACGAGGAGAGAGAGAGAGAGAGAGAG 540
 Qy 151 MetThrGlyArgPheGlyAlaProValSerGlyValTyrPhePheThrPheSerMetMet 170
 Db 541 GCCACAGGAGAGTTCATCTGTCTTCCAGGAGATCTATTACTTTCTTATGATATCACA 600
 Qy 171 -----LysHisGluAspValGluGluValTyrValTyrLeuMetHisAsnGlyAsn 187
 Db 601 TTGGCTAATAAGCAT-----CTGGCAATCGGACTGGTACACAGTGG--- 642
 Qy 188 ThrValPheSerMetTyrSerTyrGluMetLys-----GlyLysSer 201
 Db 643 -----CAATACCGGATAAAGACTTCGACGCCCAACACAGGAAACCAT 684
 Qy 202 AspThrSerSerAsnHisAlaValLeuLysLeuAlaLysGlyAspGluValTrpLeuArg 221
 Db 685 GATGTGGCTTCGGGTCCACACTCATCTATCTGCAGCCAGAGAGAGAGAGAGAGAGAGAG 744
 Qy 222 Met-----GlyAsnGlyAlaLeuHisGlyAspHisGlnArgPheSerThrPhe 237
 Db 745 ATTTCTTCACAGACAGAGATGGCTTCTTCAGACCCAGGTTGGCAGACAGAGCTATTTC 804
 Qy 238 AlaGlyPheLeuPhePhe 243
 Db 805 TCCGGGTTTCTCTTATAC 822

CC The present sequence is one of a large number of 5' ESTs derived from
CC mRNAs encoding secreted proteins. An ORF has been identified within the
CC sequence. The 5' ESTs were prepared from total human RNAs or polyA+
CC derived from 30 different tissues. EST sequences usually correspond
CC mainly to the 3' untranslated region (UTR) of the mRNA because they are
CC often obtained from oligo-dT primed cDNA libraries. Such ESTs are not
CC well suited for isolating cDNA sequences derived from the 5' ends of
CC mRNAs and even in those cases where longer cDNA sequences have been
CC obtained, the full 5' UTR is rarely included. 5' ESTs are derived from
CC mRNAs with intact 5' ends and can therefore be used to obtain full length
CC cDNAs and genomic DNAs. 5' ESTs are also used in diagnostic, forensic,
CC gene therapy and chromosome mapping procedures. They are used to obtain
CC upstream regulatory sequences and to design expression and secretion
CC vectors.

XX
SQ Sequence 471 BP; 107 A; 130 C; 134 G; 99 T; 1 other;
Query Match 26.4%; Score 452; DB 21; Length 471;
Best Local Similarity 99.6%; Pred. No. 4.4e-121;
Matches 452; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
QY 1 GGCATCTGCCCGAGGAGACACCGCTCTCGAGCTCTGCTCTTCTCAGGAGACTCTGA 60
DB 12 GGCATCTGCCCGAGGAGACACCGCTCTCGAGCTCTGCTCTTCTCAGGAGACTCTGA 71
QY 61 GGCTCTGTTGAGATCATGCTTTGGAGGAGCTCATCTATTGGCACTGCTGGCTTTGTT 120
DB 72 GGCTCTGTTGAGATCATGCTTTGGAGGAGCTCATCTATTGGCACTGCTGGCTTTGTT 131
QY 121 TTTCTCTCTCTTTTGGCTGTCTGAAGATGAATACATGAGTCTCCACAAACCGGAGGACT 180
DB 132 TTTCTCTCTCTTTTGGCTGTCTGAAGATGAATACATGAGTCTCCACAAACCGGAGGACT 191
QY 181 ACCCCAGACTGCAGTAAGTGTCTCATGAGACTACAGCTTTTCAGGCTACCAAGGCC 240
DB 192 ACCCCAGACTGCAGTAAGTGTCTCATGAGACTACAGCTTTTCAGGCTACCAAGGCC 251
QY 241 CCCTGGGCGCCAGGCTCTCTGCAATTCAGGAACCATGGAACATGGAACATGGA 300
DB 252 CCCTGGGCGCCAGGCTCTCTGCAATTCAGGAACCATGGAACATGGAACATGGA 311
QY 301 AGCCACTGCTCATGAGGAGCAACAGGTGAGAGGGCGCACAAAGTACCTGGGCGCTCG 360
DB 312 AGCCACTGCTCATGAGGAGCAACAGGTGAGAGGGCGCACAAAGTACCTGGGCGCTCG 371
QY 361 AGGGAGCGGGGCGAGCATGGCCCCAAAGGAGAGAGAGGCTACCCGGGGATTCCACCAGA 420
DB 372 AGGGAGCGGGGCGAGCATGGCCCCAAAGGAGAGAGAGGCTACCCGGGGATTCCACCAGA 431
QY 421 ACTTCAGATTGCATCATGGCTTCTCTGGCAACC 454
DB 432 ACTTCAGATTGCATCATGGCTTCTCTGGMAACC 465

AA339551 standard; DNA; 472 BP.
AA339551;
AA339551;
21-JUN-1999 (first entry)
Human secreted protein 5' EST SEQ ID NO 149.
Human; secreted protein; EST: expressed sequence tag; diagnosis;
forensic; gene therapy; chromosome mapping; signal peptide;
upstream regulatory sequence; cytokine activity; cell proliferation;
differentiation; haematopoiesis regulation; tissue growth regulation;
proliferative hormone regulation; chemotactic; chemokinetic; haemostatic;
thrombolytic; anti-inflammatory; tumour inhibition; ds.
no sapiens.

PN W0906551-A2.
XX
PD 11-FEB-1999.
XX
PF 31-JUL-1998; 98WO-IB01235.
XX
PR 01-AUG-1997; 97US-0905133.
XX
PA (GEST) GENSET.
PI Duclert A, Dumas Milne Edwards J, Lacroix B;
XX WPI; 1999-153781/13.
DR P-PSDB; AAY11485.
XX
PT New nucleic acids encoding human secreted - proteins obtained from
PT cDNA libraries prepared from substantia nigra, cerebellum, surrenals
PT and fetal brain tissue
XX
PS Claim 1; Page 263; 434pp; English.
XX
CC AAX39440 to AAX39597 represent 5' expressed sequence tags (ESTs) for
CC human secreted proteins, and encode the proteins given in AAY11374 to
CC AAY11531, respectively. The proteins given represent the signal peptide
CC and an N-terminal fragment of a secreted protein. The nucleic acid
CC sequences can be used for producing secreted human gene products. They
CC can also be used to develop products for diagnosis and therapy. The
CC proteins obtained may have cytokine activity, cell
CC proliferation/differentiation activity, haematopoiesis regulating
CC activity, tissue growth regulating activity, reproductive hormone
CC regulating activity, chemotactic/chemokinetic activity, haemostatic and
CC thrombolytic activity, receptor/ligand activity, anti-inflammatory
CC activity, tumour inhibition activity or other activities. The products
CC can be used in forensic, gene therapy and chromosome mapping procedures.
CC The sequences can also be used for obtaining corresponding promoter
CC sequences. The nucleic acids encoding the signal peptide can be used for
CC directing extracellular secretion of a polypeptide or the insertion of a
CC polypeptide into a membrane, or importing a polypeptide into a cell.
XX
SQ Sequence 472 BP; 108 A; 130 C; 134 G; 99 T; 1 other;

Query Match 26.4%; Score 452; DB 20; Length 472;
Best Local Similarity 99.6%; Pred. No. 4.4e-121;
Matches 452; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
QY 1 GGCATCTGCCCGAGGAGACACCGCTCTCGAGCTCTGCTCTTCTCAGGAGACTCTGA 60
DB 13 GGCATCTGCCCGAGGAGACACCGCTCTCGAGCTCTGCTCTTCTCAGGAGACTCTGA 72
QY 61 GGCTCTGTTGAGATCATGCTTTGGAGGAGCTCATCTATTGGCACTGCTGGCTTTGTT 120
DB 73 GGCTCTGTTGAGATCATGCTTTGGAGGAGCTCATCTATTGGCACTGCTGGCTTTGTT 132
QY 121 TTTCTCTCTCTTTTGGCTGTCTGAAGATGAATACATGAGTCTCCACAAACCGGAGGACT 180
DB 133 TTTCTCTCTCTTTTGGCTGTCTGAAGATGAATACATGAGTCTCCACAAACCGGAGGACT 192
QY 181 ACCCCAGACTGCAGTAAGTGTCTCATGAGACTACAGCTTTTCAGGCTACCAAGGCC 240
DB 193 ACCCCAGACTGCAGTAAGTGTCTCATGAGACTACAGCTTTTCAGGCTACCAAGGCC 252
QY 241 CCCTGGGCGCCAGGCTCTCTGCAATTCAGGAACCATGGAACATGGAACATGGA 300
DB 253 CCCTGGGCGCCAGGCTCTCTGCAATTCAGGAACCATGGAACATGGAACATGGA 312
QY 301 AGCCACTGCTCATGAGGAGCAACAGGTGAGAGGGCGCACAAAGTACCTGGGCGCTCG 360
DB 313 AGCCACTGCTCATGAGGAGCAACAGGTGAGAGGGCGCACAAAGTACCTGGGCGCTCG 372
QY 361 AGGGAGCGGGGCGAGCATGGCCCCAAAGGAGAGAGAGGCTACCCGGGGATTCCACCAGA 420
DB 373 AGGGAGCGGGGCGAGCATGGCCCCAAAGGAGAGAGAGGCTACCCGGGGATTCCACCAGA 432

421 ACTTCAGATGTCATTCAGCTTCTCTGCAACC 454
 |||||
 433 ACTTCAGATGTCATTCAGCTTCTCTGCAACC 466

RESULT: 26

ABV56781
 ID ABV56781 standard; cDNA; 472 BP.

ABV56781;

17-SEP-2002 (first entry)

Human prostate expression marker cDNA 56772.

Human; prostate cancer; cytostatic; carcinogen; pharmacodynamic marker;
 pharmacogenomic marker; gene; ss.

Homo sapiens.

WO200160860-A2.

23-AUG-2001.

20-FEB-2001; 2001WO-US05171.

17-FEB-2000; 2000US-183319P.

16-MAR-2000; 2000US-189862P.

25-MAY-2000; 2000US-207454P.

09-JUN-2000; 2000US-211314P.

18-JUL-2000; 2000US-219007P.

13-DEC-2000; 2000US-255281P.

(MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.

Schlegel R, Endege WO, Monahan JE;

WPI; 2001-662795/76.

Novel isolated nucleic acid molecule associated with cancerous state of
 prostate cells and correlating with presence of prostate cancer, useful
 for detecting presence of prostate cancer, stage of prostate cancer -

Claim 1; Page 10943; 11750pp; English.

The invention relates to an isolated nucleic acid molecule (I) comprising
 a nucleotide sequence given in Tables 1-9 (ABV00010-ABV62213) of the
 specification or its complement. (I) is useful for:

- (a) assessing whether a patient is afflicted with prostate cancer;
 - (b) monitoring the progression of prostate cancer in a patient;
 - (c) assessing the efficacy of a test compound to inhibit prostate
 cancer in a patient;
 - (d) assessing the efficacy of a therapy for inhibiting prostate cancer
 in a patient;
 - (e) selecting a composition for inhibiting prostate cancer in a patient;
 - (f) assessing the prostate cell carcinogenic potential of a compound;
 - (g) determining whether prostate cancer has metastasized in a patient;
 - (h) assessing the aggressiveness or indolence of prostate cancer in a
 patient;
- (I) is also useful as a pharmacodynamic or pharmacogenomic marker.

Sequence 472 BP; 141 A; 105 C; 92 G; 134 T; 0 other;

Query Match 20.2%; Score 345.6; DB 23; Length 472;
 Best Local Similarity 87.7%; Pred. No. 4.4e-90;
 Matches 400; Conservative 0; Mismatches 54; Indels 2; Gaps 2;

587 AAGCATGAGGATGTGAGGAAGTGTATGTACCTTATGCAATGG-CAACACAGT-CT 644

|||
 17 AACCATGAGGATGTGAGGAAGTGTATGTACCTTATGCAATGGCCACACAGTCT 76

|||||
 645 TCACATGTACAGTATGAATGAAGGCAATCAGATACATCCAGCATCTGTGTC 704

|||||
 |||||

Db 77 TCAGCATGTCAGTTATATAAGGAGGCAATCAAACTCTCCACCATCTCTCTGTGC 136
 Qy 705 TGAAGTACGCAAGGGGATGAGTTTGGCTGGCAATGGCAATGGCTCTCCATGGG 764
 |||
 Db 137 TAAACCTACCAAGGGGATAAGTTGGCTGCAAAATGGCAATGGCTCTCTATGGG 196
 Qy 765 ACCACCAAGCTTCTCCACCTTTGCAGGATTCCTGCTCTTTGAAACTAAGTAATATATG 824
 |||||
 Db 197 ACCACCAAGCTTCTCCACTTTTGAGGATCCCTGCTTTTGAACCTAATAATATTG 256
 Qy 825 ACTAGATAGTCCACTTTTGGGGAAGACTTGTAGCTGAGCTGATTGTTACGATCTGAGG 884
 |||||
 Db 257 ACTAAATCCCTCCATTTTGGGAAACTTGTACCTGACCTGATTGTTCCAATCTGAGG 316
 Qy 885 AACATTAAGTTGAGGGTTTACATTTGCTGATTCAAAAAATTAATGTTGCAATGTTGT 944
 |||||
 Db 317 AACATTAAGTTGAGGGTTTACTTTGCTGTATAAAAAATTTATGGTTGCAATGTTGT 376
 Qy 945 TCACGTACAGGTACACCAATAATTTGGAACAATTCAGGGGCTCAGAGAATCAACACCA 1004
 |||||
 Db 377 TCACCTACAGGCACACCAATAATTTGGAACAATTCAGGGGCTCAGAGAATCAACACCA 436
 Qy 1005 AAATAGTCTTCTCAGATGACCTTGACTAATATATCTC 1040
 |||||
 Db 437 AAATAGTCTTCTCAGATGACCTTGACTAATATATCTC 472

RESULT: 27

AAF93419

ID AAF93419 standard; cDNA; 546 BP.

AC AAF93419;

XX 21-MAY-2001 (first entry)

XX cDNA encoding SRT protein isolated from prostate tissue SEQ ID 240.

XX Human; SRT; gene therapy; gene mapping; tissue typing; ss.

XX Homo sapiens.

XX WO200107611-A2.

XX 01-FEB-2001.

XX 21-JUL-2000; 2000WO-US200006.

XX 26-JUL-1999; 99US-0145701.

XX (GETH) GENENTECH INC.

XX Baker KP, Goddard A, Wood WI;

XX WPI; 2001-112729/12.

XX New isolated nucleic acid molecule encoding a SRT polypeptide is useful
 for production of recombinant SRT polypeptides, gene mapping,
 diagnosing genetic disorders and for gene therapy

XX Claim 2; Fig 240; 663pp; English.

XX Sequences AAF93180 - AAF93743 represent polynucleotide sequences encoding
 human SRT proteins. The cDNA sequences are isolated from various
 different human tissue cDNA libraries. The invention relates to a method
 for detecting cDNA encoding an SRT protein, a vector containing cDNA
 encoding SRT, a host cell transformed with the vector, an isolated SRT
 polypeptide, and an antibody which binds to SRT. The polynucleotide
 sequence can be used in gene therapy and is useful in the recombinant
 production of SRT polypeptides, as a hybridisation probe to screen
 libraries to isolate cDNAs with sequence identity to SRT polypeptides, to
 map the gene encoding the SRT polypeptides and analysing genetic
 disorders, tissue typing and disease tissue detection. The SRT
 polynucleotide sequences can be used in polymerase chain reaction,

